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ABSTRACT OF DISSERTATION
Antigen presentation in central nervous system antitumor immunity
by
Jay Bowman-Kirigin
Doctor of Philosophy in Biology and Biomedical Sciences
Immunology
Washington University in St. Louis, 2022
Gavin Dunn, Principal Investigator and Co-Chairperson
David DeNardo, Co-Chairperson

Glioblastoma multiforme (GBM) patients face limited treatment options and poor
outcomes. The median survival is less than two years, and there are no FDA approved
immune therapies. Although GBM itself is an immune-suppressive, heterogeneous tumor,
the lack of FDA approved immune therapies might be in part because the cancer immunity
cycle is less well understood for GBM than for other tumor types. My studies focused on
developing mouse models of malignant glioma that more faithfully recapitulate human
GBM from an immunologic perspective, and on defining the role of the conventional
dendritic cell 1 subset (cDC1) and lymphatic drainage in central nervous system (CNS)
antitumor immunity.

While genetically engineered mouse models of glioma have been described, they are for
various reasons unsuitable to study the immune system’s reaction against the tumor, due
to their use of outbred mice, immunologically immature mice, human oncogenes to drive

xii

transformation, or highly inflammatory initiation events. Furthermore, the most commonly
deleted tumor suppressors in GBM are underrepresented in existing models. Thus, we
engineered the tumor suppressor genes p16INK4a and p19ARF (INK4a/ARF; CDKN2A/B in
humans) and phosphate and tensin homolog (PTEN) to be loxP-flanked on a pure
C57BL/6 background. We used lentiviral transduction of Cre and the murine oncogene
platelet derived growth factor beta (PDGFβ) to conditionally delete these tumor
suppressors and transform target cells in brains of immunologically mature mice, which
resulted in brain tumor formation.
With the standard treatment, GBM invariably recurs, with 20%-30% of cases
hypermutated. It is often the loss of mutS homolog 6 (MSH6), a mismatch repair protein,
that confers resistance to temozolomide (standard-treatment) and leads to treatmentinduced hypermutations. We developed the tools to model this phenomenon in a
preclinically. We isolated astrocytes from the B6 INK4a/ARFfl/fl x PTENfl/fl mice and
transformed them with the Cre/mPDGFβ lentivirus constructs. We used CRISPR to delete
the mismatch repair protein MSH6 in these ex-vivo transformed astrocytes. We
characterized their resistance to temozolomide and successfully induced hypermutation
with long term temozolomide treatment and inhibition.
Within the immunologically distinct location of the CNS the type of antigen presenting cell
(APC) responsible for priming T cell responses against brain tumors remains undefined.
In other non-CNS tumors, the conventional dendritic cell 1 (cDC1) subset cross-presents
tumor-derived and cell-associated tumor antigen to generate antitumor CD8+ and CD4+
T cell responses. However, the homeostatic brain parenchyma is largely devoid of
cDC1—their steady state location is restricted to the choroid plexus and the dura. Using
xiii

orthotopic, syngeneic transplant models of murine glioblastoma, we investigated the roles
of cDC1 and other antigen presenting cells in antitumor immunity of the CNS. We used
the cDC1-deficient interferon regulatory factory 8-deficient (IRF8+32-/-) mice to determine
that cDC1 are required to mediated αPD-L1 induced survival benefit as well as to
generate neoantigen-specific CD8+ T cell responses against the brain tumors.
Furthermore, using a fluorescent tracking system, we observed that dendritic cells
(including the cDC1 subset) isolated from the tumor, the lymphatic vessel-containing
dura, and the cervical lymph nodes harbored tumor-derived antigen. We extended these
findings to humans. We identified several subsets of conventional dendritic cells,
including the CD141+ cDC1 equivalent, in the immune cell infiltrate of a variety of human
brain tumor types (including GBM), as well as in the tumor-adjacent dura. We determined
tumor-infiltrating dendritic cells, including the CD141+ subset (equivalent to the mouse
cDC1), contained the tumor-specific fluorescent metabolite of 5-aminolevulinic acid (5ALA), protoporphyrin IX (PPIX), which is used for fluorescence guided resection of
malignant glioma. The PPIX signal was absent in both tumor-infiltrating T cells and
equivalent dendritic cell subsets isolated from intraoperatively harvested peripheral blood,
which indicates that this phenomenon was specific to antigen presenting cells that had
infiltrated the tumor. To our knowledge, this is the first observation in humans of antigen
presenting cells ingesting tumor-derived material.
Together, these data provide evidence that cDC1 play a significant role in CNS antitumor
immunity in mice and humans. Collectively, these studies have yielded improved tools to
study the immunity cycle in GBM and have shed light on some of the elements regarding
the nature and mechanism of antigen presentation in CNS antitumor immunity.

xiv

CHAPTER ONE
Introduction to glioblastoma, cancer immunology, and CNS immunity
1.1 Glioblastoma patients face a poor prognosis
Glioblastoma GBM is the most common primary malignancy of the central nervous
system (CNS), with about 13,000 new cases per year 1. Patients stricken with this disease
have universally poor outcomes. With the standard treatment, the median survival is 1520 months

2, 3

. Despite immense resources dedicated toward investigating better

therapies to improve disease outcomes, the standard therapy has remained largely the
same since 2005, and is based on a landmark New England Journal of Medicine paper
in which the authors described improved outcomes based on addition of temozolomide
therapy to gross total resection and radiotherapy

2

. Unfortunately for patients,

temozolomide treatment only provides benefit for the subset of patients with low
methylguanine-methyltransferase expression in their tumors 4, which occurs in just onethird to one-half of cases 5, 6.
Following initial treatment and gross total resection of the tumor, GBM invariably occurs,
with a five-year survival of just 6.8% 1. One of the major challenges for treating GBM is
that despite maximal resection, the malignant cells always extend beyond the margin of
the tumor to distant parts of the brain, where they seed themselves to drive recurrence.
Evidence for this phenomenon was demonstrated by GBM cases which recurred despite
efforts to resect tumors with an immense margin of healthy brain tissue surrounding the
tumor. This included GBM recurrence despite complete hemispherectomies performed in

1

the 1920s by Walter Dandy attempting to treat GBM 7. The severity of this disease
combined with the absence of treatments which lead to long term survival warrant further
investigation into different treatment types.

1.2 Immune editing
The ability of the immune system to restrain cancer had been an idea of varying popularity
but was definitively demonstrated in a landmark study by Shankaran and colleagues (of
Robert Schreiber’s lab) in which they described how immunocompromised Rag2-deficient
hosts, which lack T cells and B cells, grew greater numbers of spontaneous tumors than
their wild-type counterparts. They further described that carcinogen-induced tumors from
immune deficient animals were rejected when transplanted in immune competent
syngeneic hosts, whereas carcinogen-induced tumors that originated from immune
competent counterparts were less immunogenic and grew progressively when
transplanted into immune competent hosts 8. These findings demonstrated the principle
that tumors which originated from immune competent hosts had already been “edited” by
the immune system, which consisted of removing more immunogenic cells and leaving
behind less immunogenic cells so that the resultant tumor was less immunogenic. In
contrast, “un-edited” tumors that originated from immune deficient mice had never been
exposed the immune system to eliminate the more immunogenic targets, which made
these “un-edited” tumors able to be rejected when transplanted into wild-type immune
competent hosts. By demonstrating these findings, the paper showed conclusively that
the immune system restrained tumor growth and settled this question regarding whether
the immune system could recognize and respond to malignancies.

2

It is now widely accepted that tumors that present clinically exist because they have
escaped control of the immune system 9. The immunoediting model is based on the
following premise: malignant cells harbor mutations that result in the expression of
mutated proteins, which can be seen as “foreign” by the immune system since the
immune system was not tolerized against these “new” antigens, termed “neoantigens.”
As a tumor grows, it gives rise to mutant proteins. Tumor-infiltrating conventional dendritic
cells can phagocytize and capture these mutant proteins, activate, migrate to a draining
lymph node, and present the processed mutant proteins to prime naïve T cells against
the neoantigens contained within the mutant protein. Once primed and clonally expanded,
these neoantigen-specific effector T cells home from lymph node to tumor, where
malignant cancer cells may present peptides derived from their own mutated proteins on
major histocompatibility complex I (MHCI). In the tumor, malignant can be destroyed by
neoantigen-specific effector CD8+ T cells as any foreign invader would be. Moreover, the
immune response is further bolstered by effector CD4+ T cells, which can secrete
cytokines in response to neoantigens presented on major histocompatibility complex II
(MHCII) by professional antigen presenting cells. These stimulated CD4+ T cells can
subsequently orchestrate and direct the immune response against the tumor.
Occasionally, malignant cells arise that can evade complete destruction by surveilling
immune cells, and persist in equilibrium with the immune system, but still lack the capacity
to escape completely beyond the immune system’s control. The immune system and the
cancer cells persist in this tug of war, unbeknownst to the host, until selective pressure
from the immune system eliminates the more immunogenic tumor cells. Due to this
selective pressure, the remaining less immunogenic malignant cells grow out. At this

3

point, wherein the malignant cells have completely escaped beyond the control of the
immune system, the tumor becomes clinically apparent 9-12. While this process has been
described for mouse fibrosarcoma and a variety of other tumor types, it remains unknown
how exactly this process occurs with glioblastoma.

1.3 Brief history of cancer immunology, with particular focus on
dendritic cells
The idea that the immune system could potentially be an aid in cancer eradication is not
new but has experienced periods varying popularity. The idea of using the immune
system to defeat cancer dates to the use of Coley’s toxins in the 1890s. Dr. Coley
documented several observations in which sarcoma or carcinoma patients became
infected with “accidental erysipelas” (presumably from group A streptococcus) following
surgery to resect their tumors. In some of these instances, the postoperative erysipelas
infection was followed by tumor regression 13. Dr. Coley began to experiment with the use
streptococcus inoculations in his own patients with limited success (some of his patients
unfortunately died due to the bacterial infections themselves). In this treatment, Dr. Coley
used streptococcal bacterial toxins as an adjuvant to non-specifically activate the immune
system, which led to tumor regression in some of his patients who were lucky enough to
have a tumor that could be recognized and rejected by the immune system, and who
were also fortunate enough not to die from the streptococcus infection itself. Despite
these observations, the actual mechanism of tumor regression was poorly understood at
the time. Moreover, despite his success, he was doubted by his contemporaries, which
may have delayed the commonplace acceptance of similar ideas.

4

The 1908 Nobel Prize in Physiology or Medicine was awarded to Paul Erlich and Élie
Metchnikoff for their discovery of immune surveillance with their observation that foreign
substances would in certain instances be phagocytosed and neutralized when implanted
into a host organism. Erlich believed that this defense system was also present within the
blood and further postulated that the immune system could recognize and protect against
cancer. Five decades later in 1959, Lloyd Old and colleagues began to shed more light
upon the relationship between cancer and the immune system. In their experiments, they
set out “to alter the growth and lethality of various experimental tumors by agents known
to possess the common property of stimulating the phagocytic capacity of the
reticuloendothelial system.” Specifically, they described how immunization with the
Bacillus Calmette-Guérin vaccine could lead to regression of transplantable sarcoma
model by activating the immune system

14

. In further experiments in 1962, Old and

colleagues determined that carcinogen induced tumors possessed antigens—recipient
mice could be inoculated with low levels of carcinogen-induced cancer cells, and then
would later resist much larger inoculations of those same cells, which would ordinarily
result in tumor outgrowth when transplanted into a naïve host 15. Around the same time,
as described in a widely regarded review written by Dunn and colleagues, these
discoveries regarding cancer immunity were threaded together to form the hypothesis of
“cancer immunosurveillance” that had been partially postulated by Sir Macfarlane Burnet
and Lewis Thomas. In this hypothesis, one of the evolutionary tasks of the immune
system was to detect and respond to neoplasms 10, 16, 17.
Despite these important observations that the immune system could seemingly detect,
respond to, and selectively amplify immune responses against malignancy, the
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mechanism by which the immune system carried out this detection and selective
amplification remained a mystery. It was believed that there was a missing “accessory
cell” that connected innate immunity, which non-selectively phagocytized invaders to form
the first line of defense, to adaptive immunity, which amplified humoral or cellular
responses against a specific threat or antigen.
In what later panned out to be a remarkably important discovery in 1973 (but perhaps
unappreciated at the time), Ralph Steinman and Zanvil Cohn first isolated conventional
dendritic cells (cDC) from lymphoid organs of mice. They characterized these cells based
on their abundant dendrites and distinguished them from other cells based on their low
baseline phagocytic activity, restriction to lymphoid organs, and low frequency (~1% of
the total cells in all lymphoid organs measured). While they simply described basic
features of this new cell type without characterizing its relevance to the immune system,
Steinman presciently quipped that this new cell type might retain “antigens on its cell
surface through the mediation of specific antibody”

18

. Although the significance of this

newly discovered dendritic cell was unknown at the time, further experiments in 1980 by
Michel Nussenzweig (in collaboration with Steinman and Cohn) showed that in contrast
to purified macrophages, a second and much more common antigen presenting cell,
purified dendritic cells could stimulate cytotoxic CD8+ T cells to activate and proliferate 19.
These discoveries suggested that dendritic cells might possess some unique capacity to
function as the bridge between innate and adaptive immunity by performing the role of
the sentinel “accessory cell.” In a nutshell, this meant they could bring antigens that they
had phagocytized in the periphery into contact with T cells harbored by lymphoid organs

6

in order to drive amplification of T cells that could in turn recognize antigens derived from
the invading pathogens in order to respond to and eradicate the pathogen.
These discoveries also augured that cDC might be critical to the early detection of
neoplasms through their sentinel-like immune surveillance functions and ability to initiate
an adaptive immune response, however mice that were deficient in cDC (or particular
cDC subsets) would be needed to prove this in vivo. Decades later in 2008, experiments
by Kai Hildner of Kenneth Murphy’s lab punctuated that point and definitively established
a role for dendritic cells in immune surveillance against cancer. They developed a mouse
in which the conventional dendritic cell 1 subset (cDC1) failed to develop by targeting and
selectively deleting the gene for Basic Leucine Zipper ATF-Like Transcription Factor 3
(BATF3), a transcription factor required for cDC1 development. They used this mouse to
establish that cDC1 were critical to mount an effective antitumor immune response in
vivo. They employed a regressor fibrosarcoma tumor developed in Bob Schreiber’s lab.
Under ordinary conditions, wild-type mice spontaneously reject this tumor. In contrast, the
tumor grows progressively in Rag2-/- mice, which lack T cells and B cells. Hildner and
colleagues established that cDC1 were also required for tumor rejection by demonstrating
that the tumor also grew progressively in their cDC1-deficient BATF3-/- mouse 20.
The role of dendritic cells (mostly cDC1, but also cDC2 in select studies) in tumor
immunology has been expanded and defined further. The importance of cDC for
antitumor immunity has been demonstrated in a variety of tumor types. Several functions
of cDC have been well described, including the ability of cDC to phagocytize tumorassociated material and traffic that material to lymph nodes 21-24, to cross present antigen
(cDC1 specifically) to prime CD8+ T cells and drive tumor rejection 25, as well as to present

7

cell-associated antigen (cDC1 specifically) to prime CD4+ T cells

26

. Moreover,

experiments have demonstrated additional important roles of cDC1 in antitumor immunity,
including: the requirement of cDC1 for type 1 interferon signaling 27, 28, the additional role
of cDC1 in antitumor immunity independent of cross presentation
cDC1 in establishing the immune microenvironment

30

29

, the requirement of

, and their susceptibility to

subversion from the tumor by manner of cDC1-exclusion as a mechanism of tumor
escape 30, 31. Despite these discoveries establishing the importance of cDC1 in antitumor
immunity more broadly, the role of the cDC1 in CNS antitumor immunity remains
unknown. cDC have been understudied in the CNS likely for variety of reasons, perhaps
because they are absent in the steady state brain parenchyma, because the CNS lacks
conventional lymphatics, and/or because the CNS immune response is unique, all of
which will be discussed below.

1.4 CNS immune privilege dogma
Historically, the CNS has been widely regarded as an immune privileged anatomic
location, meaning that foreign tissues transplanted there would not stimulate an immune
response that led to rejection of the transplanted tissue by the host’s immune system, in
contrast to other regions outside the CNS, where transplanted foreign tissues would be
attacked. This understanding was largely based on experiments which demonstrated that
immune responses were delayed or weakened in the brain parenchyma compared to an
equivalent perturbation in the periphery.
Examples of this include experiments by Shirai in 1921 in which he observed that a
xenografted rat fibrosarcoma grew well in the mouse brain, but was rejected when
implanted subcutaneously or intramuscularly into mice
8

32

. In 1923 Murphy and Strum

added a twist to these findings by showing that while xenografted fibrosarcoma cells grew
well when transplanted into a mouse brain, that co-transplantation of the same xenograft
fibrosarcoma cells into both the mouse’s spleen and brain stimulated rejection of the
transplanted fibrosarcoma from the brain 33. In 1948 Medwar extended the principle that
immune responses in the brain could occur under specific circumstances in an elegant
set of experiments in which he demonstrated that rabbit skin allografted into a recipient
rabbit’s brain parenchyma only rejected if that rabbit had been simultaneously allografted
elsewhere on the body

34

. The observations with xenograft fibrosarcoma and allogeneic

skin that (1) peripheral immunization was required to stimulate a brain parenchymal
immune response, and (2) that immune responses primed solely in the brain parenchyma
were weak or absent compared to an immune response primed by the same stimulus in
the periphery, have been repeated using bacteria (Bacillus Calmette–Guérin) 35, influenza
viruses 36, and adenovirus vectors 37, as summarized nicely by Galea et al 38. Interestingly,
these observations of attenuated immunity resulting from a stimulus being implanted into
the brain parenchyma required the stimulus to be introduced solely and specifically to the
brain parenchyma—when xenografted tumors, BCG vaccine, or influenza were
introduced to the ventricles, they all elicited strong immune responses in the brain
36

33, 35,

. Furthermore, when H-2 incompatible neocortical allograft tissue was transplanted into

cerebral ventricles of mice alone, rejection occurred without external stimulus and was
further hastened by simultaneous transplant of allograft tissue into the skin

39

. Similarly,

neural tissue that was either xenografted or derived from the same species but differed
at both major and minor histocompatibility loci was likewise rejected when transplanted
into the third ventricles of mice or rats

40

. Rejection of engrafted tissue from the brain

9

parenchyma may be context dependent as well: experiments in the early 1990s showed
data that seemed to contradict previous observations. Finsen and colleagues were able
to document certain instances in which mouse neural tissue xenografted into the
hippocampus of rat brains stimulated inflammation including extravasation of T cells,
macrophages, and IgG into the xenografted tissue, which was followed by rejection in
most cases when they extended the observation period and looked beyond the day 35
timepoint 41.
These experiments, taken at face value, might lead one to conclude that the brain
parenchyma is an immunologically privileged anatomic location in which only absent or
weakened immune responses can occur. However, upon closer inspection, these
observations offer a more nuanced view of CNS immunology and collectively show that
given the correct initiating event, the CNS immune response has potential to be
immensely potent. In many of these experiments, other than the initiating inflammatory
stimuli of transplanting the tissue or pathogen into the brain parenchyma, there lacked a
constant source of inflammation that propagated enough to drive recruitment of immune
cells into the brain parenchyma. Moreover, the inability of the CNS immune system to
spontaneously reject tumors from the brain is not a universal phenomenon as suggested
by Shirai’s 1921 fibrosarcoma brain tumor experiments

32

. We have made several

observations to the contrary and indeed our field of work would not exist if this were the
case. Furthermore, several conditions involving the immune system in the CNS, such as
demyelinating disease, infectious encephalitis, and the previously documented immune
responses against CNS tumors illustrate the potential for potent immune responses within
the CNS under the right conditions.

10

1.5 The blood brain barrier
The uniquely regulated and generally impermissive blood-brain barrier (BBB) has posed
a second roadblock to disputing the belief firmly held by some that the brain is hermetically
sealed from the immune system. As summarized by Engelhardt et al. 42, the blood brain
barrier is formed by specialized endothelial cells conjoined by tight junctions that form a
much tighter barrier compared to endothelial cells in systemic circulation 43. Additionally,
the BBB endothelial cells themselves have low pinocytotic activity

44

so as to limit

transcellular or paracellular efflux from the blood into the brain parenchyma. There is a
second boundary, as reviewed by Abbot et al.

45

, which is formed by astrocyte foot

processes and pericytes that comprise the glia limitans and which surrounds cerebral
vasculature. This further restricts entry of substances from the blood to the brain
parenchyma. However, the integrity of the blood brain barrier is not uniform—
circumventricular regions of the brain lack a functional blood brain barrier 46, and perhaps
more importantly, the blood brain barrier suffers dysregulation and loss of integrity during
inflammatory conditions

44, 45

and in the setting of brain tumors. In an elegant set of

experiments, Don Long used electron micrographs of brain tumor tissue sections to
demonstrate that brain tumors are vascularized by endothelial cells with dysmorphic cellcell junctions. He identified that expected fusions between endothelial cells were often
absent, with large spaces opening in place of junctions. Secondly, he observed an
absence of the glia limitans, which would ordinarily be formed by pericytes and astrocyte
foot processes. These breaches in the endothelial barrier allowed for passage of tracers
or other substances from the blood in his experiments 47, and could presumably serve as
a conduit for immune cells, which will be discussed below. Moreover, Elegant
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experiments by Rong Wang and colleagues demonstrated that subpopulations of
endothelial cells isolated from glioma tumors harbored the same mutations as the tumor,
which suggests that stem-like cells originating from the tumors themselves can
differentiate into endothelial cells allowing for additional blood flow into the tumor 48.
While the blood brain barrier restricts passage of most cells and solutes from blood to
brain in the steady state, inflammation itself and the dysregulated vasculature associated
with brain tumors can drive open the barrier in specific places, allowing surveilling immune
cells to enter. The consequence of this is that brain tumors are not sequestered from the
immune system, and the logical conclusion is that there are abundant opportunities for
interaction between the immune system and the brain tumor itself. Moreover, evidence
exists for steady state immune surveillance of the brain, which will be discussed below.

1.6 Immune surveillance and antigen presentation in the CNS
While the brain is not immune privileged in the sense that the immune response is
completely absent from the brain, it is appropriate to state that the immune response is
different from other regions of the body. The innate immune cell type response for immune
surveillance and antigen presentation in the CNS remains an unsettled debate. The only
steady state leukocyte in the brain parenchyma is the microglia

49

. A specialized

macrophage called the border associated macrophage exists along the basement
membranes of blood vessels

49

. Even though these two cell types can present antigen,

they are not known to be able to migrate outside the CNS to lymph nodes, a role ordinarily
carried out by conventional dendritic cells. While conventional dendritic cells do possess
the machinery necessary to be able to capture antigen and migrate to lymph nodes to
stimulate T cell responses, the steady state brain parenchyma is relatively devoid of them.
12

Early studies performed in 1981 which investigated various rat tissues for the presence
of the recently discovered dendritic cell found that with one exception, all the tissues they
investigated, including heart, liver, thyroid, pancreas, skin, kidney, ureter, and bladder
harbored dendritic cells. The striking exception to their observations was the brain

50

.

However, studies fifteen years later determined that the CNS was not truly devoid of
dendritic cells, and rather that their location was restricted to the choroid plexus, which
supplies CSF to the ventricles, and the meninges, which comprises the fibrous sheath
covering the brain

51

. However despite the observations demonstrating that the brain

parenchyma is devoid of dendritic cells in the steady state, dendritic cells have been
shown to infiltrate the brain parenchyma in considerable numbers once inflammation
begins

51

. it is further conceivable that a dysregulated blood-brain barrier as is the case

in glioma would permit entry of surveilling dendritic cells regardless of inflammation
status. Needless to say, despite these previous observations regarding various antigen
presenting cell subset characteristics and behavior, the type of antigen presenting cell
that conducts immune surveillance and primes T cell responses in the brain remains an
open question.
Evidence does exist for steady state antigen sampling in the brain. Harris and colleagues
of Zsuzsanna Fabry’s group showed that sampling of brain-derived antigens does indeed
occur in a set of remarkably clever experiments 52. They engineered a mouse to express
the MHCI and MHCII restricted ovalbumin epitopes selectively in oligodendrocytes (a
CNS-restricted cell type which functions to myelinate neurons), or in gut epithelial cells.
They found that adoptively transferred OTI CD8+ T cells, which recognize the MHCIrestricted ovalbumin epitope, divided equivalently in the spleens of either the
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oligodendrocyte-OVA or gut epithelium-OVA mice, which showed that antigen sampling
in the steady state occurred equally when that antigen either was confined to the gut or
to the CNS. They determined that while antigen sampling occurred as evidenced by the
division of OTI cells following their adoptive transfer into the oligodendrocyte-OVA mice,
that the OTI cells did not physically enter the brain parenchyma in the steady state, and
additionally that the mice bore no evidence of disease. Notably, this phenomenon was
largely restricted to OTI cells. In contrast, OTII CD4+ T cells, which recognize the MHCII
epitope in ovalbumin, did not divide when adoptively transferred, although the
oligodendrocytes did express full length ovalbumin, which included the ovalbumin specific
MHCII antigen. While neither of these adoptively transferred transgenic T cells entered
the brain parenchyma in the steady state, the opposite happened in the inflamed state.
They found that OTI cells did enter the brain parenchyma in the inflamed condition of
experimental autoimmune encephalitis (EAE), however the presence of OTO cells did not
exacerbate disease to a greater degree than in the EAE-only group which had no
additional adoptively transferred OT-I CD8+ T cells. These data collectively show that
even in the steady state, immune surveillance in the form of afferent immunity still takes
place in the CNS. While this set of experiments did provide strong supporting evidence
that steady state antigen sampling does indeed exist for CNS-derived antigens, it stopped
short of determining which cell type was responsible for initiating this surveillance.
Interestingly, Zozulya and colleagues (also of Fabry’s group) found that monocyte-derived
dendritic cells (cultured by treating hematopoietic stem cells with GM-CSF (sometimes
additionally with IL-4)) could cross a brain-endothelial cell monolayer in vitro

53

. The

endothelial tight junctions became reorganized when dendritic cells crossed, and the

14

transcytosis could be inhibited by blocking matrix metalloproteases that were expressed
by dendritic cells. This process occurred without affecting endothelial barrier integrity,
which they assessed by measuring electrical resistance across the endothelial
monolayer. This experiment provided evidence that this type of dendritic cell possesses
the machinery necessary to cross the blood-brain barrier, and suggests that dendritic cells
could be the cell type responsible for steady state antigen sampling, although this paper
stopped short of describing this phenomenon in vivo, Furthermore, the authors did not
use true conventional dendritic cells which are grown using Flt3L culture instead of GMCSF, and more closely represent the dendritic cells which arise in vivo.
A third interesting study by Fabry’s group led by Karman and colleagues showed that
injection of a traceable fluorescent ovalbumin antigen into the brain parenchyma of mice
led to recruitment of dendritic cells, which processed the ovalbumin

54

. They further

identified that intracerebrally injected monocyte-derived dendritic cells migrated to
cervical lymph nodes in the neck and could stimulate a systemic immune response, which
caused T cells to home back to the brain. They also described that antigen-specific T cell
homing to the brain required dendritic cells to be injected intracerebrally and could not be
re-created by peripherally injecting antigen-loaded dendritic cells. Collectively, these data
highlighted the role of dendritic cells in initiating an immune response in the CNS, but
their studies used exogenously derived monocyte-derived dendritic cells for most
experiments, therefore they didn’t fully answer how endogenous antigen presentation
takes place by the dendritic cells that arise naturally in vivo.
Perhaps the most intriguing study regarding which cell type is responsible for CNS
antigen presentation was conducted by Mundt and colleagues, of Burkhard Becher’s
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group. In an elegant set of experiments, they used temporal and conditional deletion of
MHCII from different antigen presenting cell types known to exist in the brain in either the
steady state or inflamed state and measured the effect of their perturbations on EAE

55

.

They deleted MHCII from microglia by crossing the microglial-specific Sall1CreERT2 mouse
to an MHCIIfl/fl mouse. They identified that MHCII on microglia was dispensable for EAE.
They administered tamoxifen at different time points to a Cx3xr1CreERT2 mouse (expressed
in all brain APCs) which had been crossed to a MHCIIfl/fl mouse. Constant tamoxifen
treatment deleted MHCII from all brain APCs (microglia, border associated macrophages,
and cDC). One-time early administration of tamoxifen deleted MHCII from only long-lived
microglia and border associated macrophages, which turn over slowly. However, onetime treatment permitted MHCII expression to be restored on conventional dendritic cells,
which are replaced quickly by HSCs. Only the early one-time treatment regimen, in which
MHCII expression was restored in cDC, resulted in disease. In contrast, long term
treatment, which deletes MHCII from all APC subsets (microglia, macrophages, cDC)
prevented disease. This suggests that that border associated macrophages (in addition
to microglia), but not cDC, were dispensable for disease progression. This clever set of
experiments provided strong evidence that conventional dendritic cells are required for
disease progression in EAE and that they may be the type of APC responsible for immune
surveillance and T cell priming in the CNS, at least in this disease model of autoimmunity.
Finally, in a shrewd set of experiments by David Giles and colleagues of Benjamin Segal’s
lab, they demonstrated in an EAE model that cDC accumulated in considerable numbers
in the CNS and possessed superior ability to prime MOG-specific CD4+ T cells (which
recognize the antigen used to trigger EAE) compared to endogenously arising Ly6C+
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monocyte-derived dendritic cells (moDC) (not to be confused with GM-CSF cultured
monocyte-derived dendritic cells). They also showed that cDC were more proinflammatory than moDC (from LPS stimulation, cDC made more IL-12p40 compared to
moDC, and moDC made more of the immune-suppressive cytokine IL-10 compared to
cDC), and that depletion of cDC using a ZBTB46-DTR mouse, which depletes all
conventional dendritic cells, resulted in attenuated disease severity compared to wildtype mice 56.
While the steady state brain is relatively devoid of conventional dendritic cells, these
studies showed that homeostatic CNS antigen sampling still takes place, that cultured
dendritic cells possess the ability to cross the endothelial portion of the blood brain barrier
in vitro, that dendritic cells process antigen injected into the brain, and that when
exogenously introduced into the brain, exogenously cultured monocyte-derived dendritic
cells can migrate to cervical lymph nodes. Moreover, by using multiple different
experimental approaches, researchers have also demonstrated that conventional
dendritic cells are required for disease progression in EAE. These studies drive home the
point that the brain is far from immune privileged, and that CNS immune surveillance likely
occurs at all times. These studies are also highly suggestive that dendritic cells play a
role in immune surveillance against CNS tumors.

1.7 CNS lymphatic drainage
Two unique features of the CNS, which have also contributed to the CNS immune
privilege dogma, are the lack of conventional lymphatic tissues within the brain
parenchyma and the absence of secondary lymphoid tissue in close anatomic proximity
to the CNS. Without definitively describing the presence of dura lymphatics, investigators
17

have known for quite some time that there exist mechanisms to clear debris and solutes
from the brain, and secondly that the cervical lymph nodes in the neck likely hold
importance in lymphatic drainage and priming an immune response in the CNS in
autoimmune conditions.
Of historical note, CNS-associated lymphatics are first known to be described by Italian
physician and anatomist Paolo Mascagni (1755-1815). In 1787, he published a book that
described the lymphatic vessels of the human body, which included descriptions of
meningeal lymphatic vessels. This book was published in Latin, and not translated until
recently

57

1919)

who described the absence of meningeal lymphatic vessels, contrary to

. His work was also later overshadowed by anatomist Gustaf Retzius (1842-

Mascagni’s work

57

. Perhaps these two reasons—the lack of translation of Mascagni’s

work, and the contrary descriptions by later anatomists, might be partly responsible for
why dura lymphatics were overlooked until much more recently. Moreover, later
anatomists quipped that Mascagni “was probably so impressed with the lymphatic system
that he saw lymph vessels even where they did not exist — in the brain” 57, 58. In the 20th
century, studies have produced evidence of dura lymphatics in a variety of species
ranging from dogs to rats to humans as described by Sandrone et al. 57, but they did not
completely describe the drainage route, nor did they describe the precise anatomic
structures of lymphatic vessels associated with the CNS, although the logical conclusion
was that some sort of CNS lymphatic drainage mechanism likely existed.
Some of these early studies which stopped short of completely describing CNS
lymphatics consisted of injecting tracers into various anatomic locations in the CNS. In
1992 Zhang and colleagues showed drainage of that intracranially injected carbon
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particles which had entered the subarachnoid space superficial to the vertex of the
hemispheres drained along paravascular pathways to the cribriform plate, and into the
superficial cervical lymph nodes 59. In 1993 Kida and colleagues described that India ink
injected into the cisterna magna caused deep cervical lymph nodes to be “selectively
blackened within 30 min” followed 6 hours later by selective blackening of lumbar paraaortic lymph nodes. They also described that intracerebrally injected carbon particles
accumulated around arterial structures and localized to “discrete channels which passed
through the cribriform plate and into lymphatics in the nasal submucosa.” 60 While these
studies partially described routes by which debris was cleared and implicated some sort
of lymphatic system which carries out this process, they stopped short of describing the
complete structure, and importantly, how the immune system was involved.
Some of the first experiments to test hypotheses regarding the immune involvement of
the cervical lymph nodes in CNS immunology where those involving EAE models. In the
late 1990s Phillips and colleagues showed that cervical lymphadenectomy reduced
disease severity in EAE in Lewis Rats, which was one of the first studies establish a
connection between cervical lymph nodes and the CNS immune response 61. In the late
2000s further studies extended these results: Furtado and colleagues demonstrated that
activated myelin basic protein-specific CD4+ T cells first appeared in the cervical lymph
nodes before appearing in the brain, and that lymphadenectomy reduced disease burden
in a mouse spontaneous EAE model

62

. In a similar study of chronic relapsing EAE,

Furtado and colleagues resected the superficial cervical, the deep cervical, and the
lumbar lymph nodes, and determined that resecting these particular lymph nodes could
ameliorate disease compared to sham treated mice. They also demonstrated that reactive
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T cells against the immunizing peptide first appeared in the superficial cervical lymph
nodes, and that epitope spreading to other EAE antigens occurred in the deep cervical
lymph nodes, the lumbar lymph nodes, and the spleen

63

. While these studies provided

strong circumstantial evidence that regions of the brain likely were equipped with
lymphatic drainage, and that the cervical lymph nodes in the neck were a key player, they
did not definitively demonstrate the presence of lymphatic vessels in or around the
anatomic structures surrounding the brain, nor did they precisely describe how antigen
presenting cells migrate from brain parenchyma to the cervical lymph nodes.
In two landmark studies published in 2015, Louveau and colleagues (from Jonathan
Kipnis’s group), along with Aspleund and colleagues (from Kari Alitalo’s group) described
bona fide lymphatic vessels harbored by the dura which drained solutes and
macromolecules from the CNS to the deep cervical lymph nodes, as well as to the
superficial cervical lymph nodes

64, 65

. The general lymphatic drainage route model that

they described was of dura lymphatics traversing along the venous sinuses (also
harbored by the dura) as they exit the skull and enter the neck, with lymphatic vessels
hugging the venous sinuses along the entire path, eventually converging on deep cervical
lymph nodes that lie upon the internal jugular vein the neck. Louveau and colleagues
specifically described that when Evan’s Blue Dye was injected into the ventricles of mice,
the deep cervical lymph nodes contained Evan’s Blue within 30 minutes of ventricular
injection. They also reported that the superficial cervical lymph nodes contained Evan’s
Blue at later time points following ventricular injection. Complimenting those findings,
Aspleund and colleagues reported that molecular tracers injected into the brain
parenchyma drain to the deep cervical lymph nodes, and that this process could be
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inhibited by ligating the lymphatic vessels that run along the internal jugular vein in the
neck. Interestingly, the Aspleund and colleagues did not observe lymphatic drainage from
the CNS to occur in the superficial cervical lymph nodes, however this might have been
because they were using a different tracer or were injecting the tracer into a different
anatomic location within the brain.
In 2018 Da Mesquita and colleagues (also from Kipnis’s group) extended their earlier
findings and determined that ablation of meningeal lymphatics diminished solute
clearance and accelerated Alzheimer’s disease in mice compared to control mice, and
conversely, that improving dura lymphatic function by administering VEGF-C increased
antigen clearance from ventricles and alleviated cognitive deficits compared to control
mice

66

. In another study by Louveau and colleagues which further described the role of

dura lymphatics, they demonstrated that ablation of dura lymphatics reduced disease
burden in EAE and also prevented CCR7-dependent trafficking to the cervical lymph
nodes of both cisterna magna-injected, as well as dura-associated T cells. They also
demonstrated that ablation of lymphatics along the cribriform plate prevented T cells from
migrating specifically to the superficial cervical lymph nodes compared to control mice 67.
Most importantly, dura lymphatics have been described in humans and non-human
primates in studies using MRI. In a shrewd set of experiments. Absinta and colleagues
described lymphatic vessels by discerning differential MRI signal between two different
contrast agents: one that easily extravasates across a permeable capillary endothelial
barrier, and one that does not and remains in the blood

68

. This allowed them to discern

between blood vessels and other vessels that collect waste products (i.e., lymphatic
vessels). They found that the contrast agent which easily diffused across capillaries
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became concentrated in two distinct lumens traversing along each side of the superior
sagittal sinus, whereas the blood-confined contrast agent that remained in the blood
vessels was restricted to the superior sagittal sinus. The anatomic location and structure
of these lymphatic vessels in the CNS mirrored that which had been demonstrated to
exist in mice: lymphatic vessels traverse along the superior sagittal sinus and exist in
close proximity to the cribriform plate across many different mammalian species.
Finally, of particular relevance to our work, studies have demonstrated dura lymphatics
to be important for CNS antitumor immunity. In a landmark study just recently published
in 2020, Song and colleagues (from Akiko Iwasaki’s lab) showed in a preclinical model of
glioblastoma that expansion of dura lymphatics using VEGF-C agonism provoked a more
potent antitumor immune response by strengthening CD8+ T cell responses against the
tumor, and additionally extended survival compared to control mice with unexpanded dura
lymphatics. Importantly, the researchers determined that the benefit of VEGF-C agonism
could be abrogated by ligating the lymphatic vessels that drain from the CNS to the deep
cervical lymph node 69.
While brain tumors present clinically because they have escaped beyond the control of
the immune system, it seems unlikely that this process arose because of the failure of
immune surveillance to detect and respond to malignant cells that arose in the first place.
Experiments which have demonstrated active CNS immune surveillance and potent
immune responses suggest instead that the immune system exerts selective pressure on
the tumor from its nascence, eliminating more immunogenic malignant cells early on,
which leaves behind less immunogenic malignant cells which can then escape beyond
control of the immune system to form the clinically apparent brain tumor. These studies
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which collectively demonstrate potent CNS immune responses under varying
circumstances and conditions suggest that the CNS immune response could potentially
be augmented in a clever way to develop more effective therapies against glioblastoma.

1.8 GBM itself is immune-suppressive and heterogeneous
Beyond the unique nature CNS immune surveillance, several factors underlie the
challenge with harnessing the immune system to treat GBM, among them are that GBM
itself is generally an immune-suppressive tumor. A wide variety of immunologic defects
has been associated with GBM, including systemic effects, and defects within the tumor
itself. These factors pose unique challenges toward developing immune therapies against
GBM and warrant further discussion.
GBM has been demonstrated to cause severe lymphopenia in a large fraction of patients.
In a recent study, Pakawat Chongsathidkiet and colleagues of Peter Fecci’s group
explored this phenomenon. They identified that a significant fraction of treatment naïve
GBM patients present with lymphopenia and decreased average blood CD4+ and CD8+
T cell concentrations, as well as decreased average splenic volume compared to healthy
controls. They determined that lymphopenia results from sequestration of T cells in the
bone marrow, mediated by loss of S1P receptor on the T cells. S1P receptor normally
functions as a chemokine receptor that recently primed T cells use to egress from the
lymph node in which they were primed into the blood 70, where S1P ligand concentrations
are the highest. They also demonstrated in a preclinical model that artificially increasing
the SP1 receptor concentration on host cells using a S1P receptor knock-in mouse could
improve survival in the brain tumor setting when combined with 41BB agonism, compared
to S1P knock-in alone, or wild-type mice treated with 41BB agonist. Lastly, they identified
23

that the effect of lymphopenia was specific to having a malignancy of the brain using
preclinical models—the same tumor injected peripherally did not cause the same degree
of lymphopenia

71, 72

. This study identified potential causes of systemic lymphopenia in

GBM patients. The implications are important to consider when assessing possible
immune therapies for GBM.
Beyond causing systemic lymphopenia, GBM suppress the immune system locally as
well using a variety of mechanisms. One mechanism is the production of indoleamine 2,3
dioxygenase 1 (IDO1) by the tumor. IDO1 enzymatically catabolizes tryptophan as part
of the first (and rate limiting step) of kynurenine synthesis. In turn, kynurenine has
immune-suppressive effects. While only being expressed at low levels in steady state
brain parenchyma, IDO1 can be induced by inflammatory conditions
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, and strikingly,

IDO1 is expressed by expressed by 90% of IDH1-wt GBM tumors. Moreover, IDO
expression can be induced in GBM cell lines with baseline undetectable IDO1 by
exposing those cell lines to pro-inflammatory cytokines
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. The downstream tryptophan

metabolite kynurenine, upregulated by IDO1 production, has been shown to cause
selective apoptosis of murine TH1 but not TH2 thymocytes in vitro
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, deletion of specific

thymocyte subsets in vivo 75, and conversion of TH17 cells into T regulatory cells 76, all of
which could polarize the immune response into one ineffective against tumors. Pivotal
studies by Derek Wainwright have additionally defined the role of IDO1 in GBM in vivo
using preclinical models. Wainwright and colleagues first showed that whereas IDO1
expression caused recruitment of the immune-suppressive T-regulatory cell (Treg) to the
tumor, suppression of IDO1 in brain tumors led to decreased infiltration of Treg cells into
the tumor, and increased survival compared to control mice. Furthermore, they
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demonstrated that this beneficial effect of IDO1-suppression in the tumor was immunemediated and required the presence T cells in order to occur. They demonstrated that the
survival benefit of IDO1 suppression was lost in Rag1-/- mice, which lack T and B cells 77.
In follow up studies, they identified that drug inhibition of IDO1 in mice augmented the
effects of checkpoint blockade and improved survival in a T cell-mediated process, and
that this effect was somewhat inhibited by temozolomide administration. They also
showed that paradoxically, a small amount of systemic IDO1 expression was required for
maximal response to checkpoint blockade, and that inhibiting IDO1 in the tumor, rather
than systemically deleting IDO1 in the host, provided greatest benefit 78, 79.
In addition to IDO expression, GBM tumors have high levels of immune-suppressive
cytokines. GBM cells themselves can produce TGF-β

80-82

, and the tumor

microenvironment is known to have high levels of IL-10, although IL-10 is unlikely
produced by the tumor cells themselves 82, and is instead produced by tumor-associated
CD68 expressing macrophages/microglia

83, 84

. TGF-β and IL-10 normally produced by

Treg cells to inhibit the B7-1,B7-2-CD28 APC-T cell co-stimulation pathway, to polarize the
immune system away from TH1 responses, and to limit IL-2 production and subsequent
T cell proliferation 85, which would ordinarily strengthen antitumor immunity.
Beyond the immune-suppressive mechanisms by the tumor discussed above, GBM
tumors have high levels of PD-L1 expression, which normally functions to suppress the
immune system. In a survey of glioblastoma tumor samples, Anna Berghoff and
colleagues (of Wolfgang Wick’s group) identified that 88% of primary GBM specimens,
and 72% of recurrent specimens have high levels of PD-L1 expression, and that 73% of
tumors had sparse to moderate tumor infiltrating lymphocyte (TIL) density 86. Notably, the
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presence of TIL or PD-L1 expression did not appear to correlate with outcome. In a clever
study, Andrew Parsa, and colleagues of Russell Pieper’s lab, discovered a previously
unknown connection between tumor suppressor loss and upregulated PD-L1 expression.
They identified that deletion of phosphate and tensin homolog (PTEN; a tumor suppressor
lost or deleted in 41% of GBMs 6) caused increased PD-L1 expression in tumor cells and
reduced the cytotoxic activity of tumor antigen-specific CD8+ T cells
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. Moreover, the

microenvironment of GBM can induce PD-L1 expression on monocytes/macrophages as
well. Bloch and colleagues (of Andrew Parsa’s group, after he had started his own lab)
discovered that glioma conditioned media could induce PD-L1 expression on monocytes
isolated from healthy donor peripheral blood mononuclear cells. This included both
conditioned media from gliomas resected from patients, as well as conditioned media
from glioma cell lines, although they did not identify the soluble factor responsible for this
process. They noted that IL-10 induced PD-L1 expression on the monocytes, but to a
lesser degree than caused by tumor-conditioned media itself, which suggests that another
factor was likely responsible 88.
In addition to upregulation of these immune-suppressive factors described above, GBMs
are infiltrated by the immunosuppressive myeloid derived suppressor cells (MDSCs)89.
Moreover, GBM patients tend to have high levels of circulating levels of MDSCs
compared to healthy controls

90

. An excellent review by Dmitry Gabrilovich and Srinivas

Nagaraj summarizes the characteristics and function of MDSCs

91

, which will be briefly

described. Although MDSCs share similar markers to neutrophils and monocytes when
examined by flow cytometry, MDSCs have unique immune-suppressive functions and
have a more immature phenotype compared to their mature myeloid counterparts. They
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exert their immunosuppressive effects primarily through secretion of arginase, and their
production of nitric oxide and reactive oxygen species. Among the consequences of
depleted arginine and increased ROS are suppressed T cell activation and division 91.
Beyond the above-mentioned mechanisms of immune suppression, GBM is a
heterogeneous tumor 92, 93, which itself is an immune-suppressive mechanism. Mutations
are often not commonly shared between different regions of the tumor—determining the
mutations present in the tumor requires sampling the whole tumor. For instance,
EGFRvIII, a common oncogene in GBM, has been demonstrated to be expressed only
by a fraction of the tumor cells within EGFRvIII-positive GBM specimens 93, 94. There are
several implications of this: first, there are more elements a prospective treatment would
need to target. For instance, a T cell (or any drug inhibitor) which might be effective
against one tumor cell, or against a subclone, might not be effective at all against a
different cell or subclone within the same tumor. Second, increased intratumoral
heterogeneity itself has been demonstrated to reduce tumor immunogenicity. In a clever
set of experiments, Yochai Wolf and colleagues of Yarenda Samuels’s lab demonstrated
that the B2905 melanoma cell line could be transformed into a more heterogeneous, less
immunogenic, more aggressive tumor when subjected to UVB irradiation before
implantation into immune competent wild-type mice, but that single cell clones isolated
from that same heterogeneous tumor cell line rejected when implanted into wild-type mice
95

. Moreover, they determined that the growth differences between the parental, UVB-

irradiated, or single-cell clone tumors were diminished when those cell clines were
injected into immune-compromised NSG mice. These findings demonstrated that
intratumoral heterogeneity itself is a mechanism of immune evasion. As such, the high
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degree of intratumoral heterogeneity within GBM will pose additional challenges to any
immune therapy—clever and potentially combinatorial methods of treatment will be
required to overcome this.
These studies collectively show that multiple causes contribute to the immune system’s
failure at eradicating GBM. There are immune-suppressive effects GBM that act locally,
such as IDO1 depletion of tryptophan/production of kynurenine, PD-L1 expression,
MDSC induced depletion of arginine and production of ROS, and production of the
immune-suppressive cytokines IL-10 and TGFβ. There are also immune-suppressive
effects of GBM that act globally, including tumor-induced lymphopenia, and increased
peripheral circulating MDSCs. Intratumoral heterogeneity poses additional hurdles.
These factors collectively indicate that the immunosuppressive mechanisms of GBM are
complicated and multi-factorial. Anyone hoping to develop successful immune therapy
should take care to select an immune therapy that not only bolsters the immune system,
but which also successfully addresses and inhibits the immune-suppressive factors
present in GBM.

1.9 Background on immunotherapy and its current role in GBM
Immunotherapy has led to success in the treatment of once-thought incurable advancedstage cancers. Beyond Coley’s toxins of the late 19th century, the idea of bolstering the
immune system as a means of cancer treatment largely remained an unturned stone.
This changed in the 1980s, when Steve Rosenberg successfully used recombinant IL-2,
the essential growth factor required for T cell division, to exogenously expand a patient’s
own T cells and then transplant them back into the patient to drive antitumor immunity
and treat advanced melanoma. The identification of the potential utility of bolstering T cell
28

responses to combat cancer by using recombinant IL-2 played a large role “in the
introduction of immunotherapy into the mainstream of cancer treatment” as reported by
Dr. Rosenberg himself 96.
Beyond establishing that T cells were important, pivotal work was done to establish
various regulatory cell surface proteins that modulated the activity of T cells. CTLA-4 was
first identified as an inhibitory protein expressed by activated T cells and T regulatory
cells. In a pivotal study in 1995, Matthew Krummel and Jim Allison discovered that CTLA4 had opposing effects compared to CD28 on T cell stimulation, and that crosslinking
CTLA-4 with CD28 and the T cell receptor could almost completely suppress T cell
proliferation and IL-2 secretion, compared with crosslinking CD28 and the T cell receptor
alone
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. The potent inhibitory effects of CTLA-4 on lymphoproliferation were further

demonstrated by Tivol and colleagues in (of Arlene Sharpe’s lab) in parallel. They
generated CTLA-4 knockout mice and demonstrated that compared to wild-type mice,
CTLA-4-/- mice rapidly developed “lymphoproliferative disease with multiorgan
lymphocytic infiltration and tissue destruction.”
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In further work by the Allison lab that

established the link between CTLA-4 modulation and antitumor immunity, Dana Leach
along with Matthew Krummel used CTLA-4 blocking antibodies to drive rejection of a
variety of experimental tumors in mice, including with therapeutic (not just prophylactic)
antibody administration of the CTLA-4 blocking antibody 99.
Around the same time, Yasumasha Ishida and colleagues (out of Tasuku Honjo’s lab)
used subtractive hybridization to identify PD-1 as a gene that was commonly expressed
between a murine T cell hybridoma and a murine hematopoietic progenitor cell line when
they underwent apoptosis
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. In further studies, Agata and colleagues (also of Honjo’s
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lab) identified PD-1 as a cell surface protein that was upregulated on T cells as a result
of activation, and established the role of PD-1 as a negative feedback loop of T cell
activation, rather than a signaling mechanism for apoptosis

101

. Hiroyuki Nishimura of

Honjo’s lab extended the role of PD-1 and did similar experiments to those which
established that CTLA-4 controlled autoimmunity. They established that compared to
wild-type mice, PD-1-/- mice suffered severe autoimmunity in the form of dilated
cardiomyopathy, which was abrogated by crossing a PD-1-/- mouse with the immunedeficient Rag2-/- mouse 102. Yosiko Iwai (of Nagahiro Minato’s lab) established the link of
PD-1 to cancer immunology by blocking PD-L1/PD-1 signaling to drive rejection of
experimental tumors in mice, much as Leach had done with CTLA-4 blockade a few years
before 103.
These discoveries demonstrated the concept that immune checkpoint molecules could
be inhibited to unleash the immune system and restrain cancer growth. While CTLA-4
blockade is less commonly used clinically due to its severe autoimmune side effects, it
has shown success, along with PD-1/PD-L1 blockade in treating melanoma and nonsmall cell lung carcinoma (NSCLC)
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. These treatments have also showed promise in

treating melanoma or NSCLC-originating metastases to the brain 105-108.
Despite these advances for immunotherapy with select cancer types, immunotherapy has
been somewhat of a white whale for GBM. With the exception of a very small number
cases, including that of select cases of hypermutated GBM 109, 110, PD-1/PD-L1 blockade
is not an effective therapy to treat GBM. Two phase III clinical trials testing PD-1/PD-L1
blockade in unmethylated methyl guanine methyl transferase (MGMT) GBM (Checkmate
498 Trial, NCT02617589), and the same target in methylated MGMT GBM (Checkmate
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548 Trial, NCT02667587) failed to demonstrate benefit from PD-1/PD-L1 blockade in
treating GBM 111.
However, there have been specific settings in which checkpoint blockade has shown
some benefit to the broadest group of GBM patients: that is, when administered as a
neoadjuvant (before surgery). In a phase II trial that compared neoadjuvant to adjuvant
(or post-surgery) pembrolizumab (anti PD-1) to treat GBM, researchers demonstrated
survival benefit from pembrolizumab administered as a neoadjuvant compared to
adjuvant pembrolizumab alone. They also identified that neoadjuvant treatment led to
increased CD8+ T cell infiltrate, increased interferon gamma signature, and decreased
cell-division signature within the tumor at the time of tumor resection, compared to postsurgery pembrolizumab adjuvant alone

112

. The limited success of checkpoint blockade

as a neoadjuvant rather than as an adjuvant therapy (administered after tumor resection)
demonstrated that pre-operatively boosting T cell function could be therapeutically
beneficial. The authors of the neoadjuvant study suggest that neoadjuvant treatment
leads to positioning already primed, functional CD8+ T cells within the tumor at the time
of surgery, which leads to more complete destruction of residual tumor. In contrast, postsurgery adjuvant therapy alone allows for dysfunctional T cells to exert greater effects at
the time of resection, which might result in less effective killing of residual tumor cells, as
suggested by the lack of clinical benefit when checkpoint blockade is delayed until after
surgery. However, the mechanism of neoadjuvant therapy underlying the benefit has not
been fully characterized.
In addition to trials that tested checkpoint blockade to treat GBM, there are a few
examples of clinical trials that tested the benefit from targeting neoantigens themselves
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to treat GBM. EGFRvIII is one of the most common neoantigens in GBM. It is expressed
at varying levels (measured by mRNA expression) in 10-20% of GBM patients 6. It
consists of a deletion of exons 2 through 7 of EGFR 6 and results in a junctional protein
that harbors an immunogenic antigen. This antigen can generate an antibody response
113

, which makes it an attractive target for chimeric antigen receptor (CAR) T cells. The

antigen also contains MHCI and MHCII binding peptides capable of generating a T cell
response

114, 115

. The Rindopepimut vaccine against EGFRvIII in GBM patients showed

early promise in a phase II trial
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, but failed at the phase III stage
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. Preliminary

therapies using chimeric antigen receptor T cells (CAR-T) against EGFRvIII
demonstrated evidence of EGFRvIII antigen loss by the tumor
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have

, which suggests

immune editing may have taken place. Notwithstanding these results, CAR-T cells did not
perform better than the standard of care in these clinical trials 120.
There have also been efforts to develop a dendritic cell vaccine. The DC-Vax trial from
Northwest Biotherapeutics trial has entered phase III, with results incoming, however
early data suggests that this vaccine formulation doesn’t perform radically better than
standard of care. The vaccine consists of harvesting CD14+ monocytes from the patient,
differentiating them into dendritic cells using a combination of GM-CSF and IL-4, maturing
them with TNF-α, IL-1β, and IL-6, exposing them to tumor lysate, and injecting them
subcutaneously into the GBM patient 121. The phase III trial currently in progress reports
a median survival of 23.1 months and a group of long-term survivors in their intent to treat
cohort compared to the placebo group, but the trial is still underway 122.
Despite these challenges, there is ample evidence that immune responses are indeed
present (albeit deranged) within GBM. The promising results associated with the
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neoadjuvant trial suggest that the key to unlocking effective immune therapies might
require thinking outside the box and employing a multi-pronged combinatorial approach
which utilizes various treatments and targets different aspects of the immune system as
well as the tumor itself.

1.10 Conclusion
GBM is a complex tumor located within a unique immunologic environment where the
immune response differs compared to other regions of the body. This anatomic location
uniquely has a lack of parenchyma lymphatics, absence of proximal lymph nodes, lack of
infiltrating immune cells at baseline, and a restrictive endothelial cell barrier. GBM also
poses the additional challenge of being an immune-suppressive, heterogeneous tumor.
Despite this, considerable evidence exists that immune responses in the CNS have
potential to be strong (as evidenced by demyelinating disease and encephalitis). It is also
clear that despite their apparent absence in the steady state brain, conventional dendritic
cells almost certainly play a key role in immune responses in the brain based on the
studies discussed above, however the role of dendritic cells in CNS antitumor immunity
is not well described. Although no silver bullet yet exists to treat GBM, and successful
treatment of GBM will require addressing the hurdles of immune suppression and tumor
heterogeneity, our hope is that investigating the cancer immunity cycle in GBM as it
occurs endogenously, with particular focus on dendritic cells, lymphatic drainage, and
antigen presentation might offer insight and clues into developing better treatments.
Herein, I will discuss the body of work I performed during my PhD studies that
encompasses developing immunologically faithful and better representative preclinical
models of GBM, and finally, I will describe how we think dendritic cells, lymphatic
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drainage, and antigen presentation work in preclinical models of GBM. Finally, I will
discuss the relevance of conventional dendritic cells to GBM in humans and share the
discoveries we have made in clinical samples.
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CHAPTER TWO
Immunologically faithful autochthonous genetically
engineered mouse models of malignant glioma
2.1 Introduction
Autochthonous genetically engineered mouse models (GEMMs) of cancer are a powerful
tool to recapitulate malignancy in a manner that more faithfully represents human cancer
than other preclinical mouse models of cancer. These models typically function by
leveraging a nearly silent initiation event to cause one or a few cells in a specific tissue to
transform into malignant cells which coevolve with the immune system for their entire
lifespan to give rise to the tumor. In contrast, orthotopic models require transplanting a
bolus of malignant cells into the brain, many of which probably fail to engraft and die,
which itself is likely an inflammatory event.
Glioblastoma is a low to moderate mutational burden tumor, with 50-100 somatic
mutations 6, and tumors typically do not respond to checkpoint blockade except in rare
cases
123

111

. In contrast, orthotopic glioma models harbor thousands of somatic mutations

. Two out of the three of the most commonly used models (GL261 and CT2A) are

carcinogen-induced and all three (those two as well SMA650) can be successfully treated
by checkpoint blockade alone 124, 125 or by combined checkpoint blockade and vaccination
in the more aggressive model CT2A

126

. In contrast to orthotopic models, GEMMs allow

for precise targeting of genes to cause transformation, which has potential to result in a
lower mutational burden tumor that has a mutational landscape more like human GBM
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and as such has a greater chance of more faithfully recapitulating the tumor-immune
system interactions than orthotopic preclinical models.
There are a variety of methods to cause the genetic mutations required for GEMM glioma
models. Typically, GEMMs are engineered such that the host organism is permissive to
a transforming event that will cause the target cells or tissue to have gain of function of
oncogenes, and loss of growth restraint by tumor suppressors, both of which are required
to engender malignant potential in the transformed target cells 127. In contrast to GEMMs
in which germline mutations of tumor suppressor genes drive non-specific tumor
formation, or alternatively GEMMs in which mice that harbor tissue-specific Cre are
crossed to mice with loxP-flanked tumor suppressors to drive tissue-specific tumor
formation, viral delivery of the transforming agent has the added benefit of allowing for
precise spatial and temporal control of tumor formation. The usual method is to deliver an
oncogene, as well as Cre, which excises loxP-flanked tumor suppressors in target cells if
the mouse is genetically engineered as such.
The agents of delivery typically used for GBM GEMMs are retrovirus, adenovirus, the
RCAS-tVA system, and Lentivirus. Retrovirus allows for stable integration of transferred
genes, however it only infects actively dividing cells 128. Although retrovirus has been used
successfully to induce GBM in preclinical models 129, we chose not to bias our GBM model
toward only originating from actively dividing precursors, as the cell of origin for GBM is
not entirely settled 130.
Adenovirus has been used in preclinical models of glioma

131

, and can transduce both

actively dividing and non-dividing cells 132, although the virus’s genes do not integrate into
the target cell’s genome and expression of the virally delivered genes is transient 133, 134.
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This means that any potential oncogene delivered by the adenovirus would be lost shortly
after initiation of transformation and continuous expression of the oncogenes required to
drive transformation of target cells would not be possible. Thus, adenovirus can only
usefully delete loxP-flanked genes given that this scenario only requires transient Cre
expression. Adenovirus-driven GEMMs require the mouse to be engineered such that
Cre both causes tumor suppressor deletion and oncogene gain of function. As such, in
addition to requiring loxP-flanked tumor suppressors, the mouse must also be engineered
with a transgene insert consisting of loxP-stop-loxP-oncogene or a similar construct such
that Cre expression also causes oncogene gain of function. The consequence of this is
that the transformation-driving oncogene is hard to substitute easily and doesn’t allow for
the flexibility provided by other virally-driven GEMMs.
The RCAS/tv-a glioma model system uses expression of the TVA retroviral receptor
under control of a specific promoter (typically under different promoters to target
astrocytes, neural stem cells, or oligodendrocyte precursor cells), which binds the RCAS
virus to permit entry into the target cell to drive transformation

135-137

. The promoter-

specific tv-a mouse is typically crossed to a mouse with the desired loxP-flanked tumor
suppressors. In this system, the RCAS retrovirus transduces only cells which express the
TVA receptor to deliver the oncogene and Cre. This means targeting is precise to a
specific target cell type, however the drawbacks of this system are that it restricts the cell
of transformation to only those cells which express the desired tv-a promoter. The second
drawback is that to achieve sufficient viral titers to transduce target cells, DF-1 chicken
fibroblasts that produce the RCAS virus must be physically implanted into the brains of
the tv-a mouse

136

. Injecting a foreign cell type into a mouse brain has potential to be
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highly inflammatory and might provoke an outsize immune response that subjects the
tumor to more immune editing early in its lifecycle or other such undesired consequences
more so than in other GEMMs, which in contrast only require implanting the virus itself.
Lentivirus has also been used successfully for GEMM glioma models 138, 139. We selected
lentivirus because it offers flexibility to substitute oncogenes easily, because it can infect
dividing and non-dividing cells (especially relevant given the unknown cell of origin in
GBM), because it stably integrates (and thus would drive continuous oncogene
expression), and because it does not require xenografting foreign cells into the brains of
recipient mice to achieve viral titers sufficient for transformation.
While similar genetically engineered autochthonous models of glioma have been used
before, to our knowledge, these systems have used outbred mice, immune compromised
mice, human oncogenes to drive tumor formation, or highly immunogenic initiation events.
These factors make the other models less than ideal for studying the pure interaction
between tumor and the immune system. With outbred mice, the investigator can never
conclude with certainty that an observed immune reaction is due to the presence of a
tumor-derived neoantigen, whether it’s due to the mixing of different genetic backgrounds,
or whether it’s due to unique genetic differences with immunologic consequences that
may arise by nature of the strain being outbred. With GEMMs that use immune
compromised mice, any antitumor immune response is attenuated or absent, and
certainly does not simulate how antitumor immunity could occur in humans.
We modeled our GEMM glioma to target two of the most commonly lost tumor
suppressors in GBM. We engineered mice with INK4a/ARFfl/fl and PTENfl/fl mutations on
a pure C57BL/6 background. These tumor suppressors are mutated or lost in 60% and
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34% of GBM cases respectively 6. We selected murine platelet derived growth factor beta
(PDGFβ) as our transforming oncogene as, PDGFβ aberrancy is observed in 13% of
GBM tumors 6, and has led to transformation in previous models when the human PDGFβ
construct was used 129, 139, 140. Our model is appropriate for immunologic studies because
it faithfully recapitulates the mutations expressed in a larger proportion of GBM tumors,
uses inbred mice, uses lentivirus instead of retrovirus, and employs murine PDGFβ
instead of human PDGFβ used in previous models (to which the mouse is not
immunologically tolerant). These unique features make our model more suitable for
studying antitumor immunity in GBM

2.2 Results
2.2.1 GEMM glioma concept: lentivirus specifically and precisely alters target cells
For tumor induction, we selected the Lenti-LucOS lentiviral backbones created by the
Tyler Jacks Lab. These have used in a preclinical model of mouse fibrosarcoma 141, and
hence would likely be suitable for target cell transformation in our model. Under the control
of a ubiquitin promoter, the lentivirus normally drives expression of luciferase fused with
the H-2Kb restricted antigens SIINFEKL and SIYRYYGL, as well as the I-Ad antigen from
ovalbumin (termed “OS” cassette). In a second open reading frame, the lentivirus drives
expression of Cre under the control of a PGK promoter. We substituted luciferase in the
construct with murine PDGFβ followed by a stop codon to prevent expression of the
antigens in the downstream OS cassette (termed Lenti-PDGFβ). The ubiquitin-driven and
PGK-driven open reading frames (ORFs) in this lentivirus backbone make the lentivirus
suitable for expression of lentivirally delivered genes in most target cells given their
ubiquitous expression.
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We engineered mice to individually possess INK4a/ARFfl/fl or PTENfl/fl mutations on pure
C57BL/6 backgrounds, intercrossed them, and bred them to homozygosity at both alleles
for the loxP mutations flanking these genes. These mutations permit selective deletion of
INK4a/ARF and PTEN in target cells that express Cre. The underlying concept behind
the model is to use lentivirus to transform target cells by simultaneously forcing PDGFβ
oncogene overexpression and inducing Cre production required to delete the abovementioned tumor suppressors. These collective mutation events lead to transformation of
target cells (Figure 2-1A) such that they have potential to form tumors (Figure 2-1B).
2.2.2 Lenti-PDGFβ lentivirus drives gene deletion and PDGFβ overexpression
We assessed the function of the Lenti-PDGFβ lentivirus in vitro. To do so, we measured
PDGFβ expression and Cre-mediated deletion of loxP-flanked genes in target cells by a
variety of methods. We first tested Cre function using Cre-reporter line. To generate the
Cre-reporter line, we transduced 3T3 cells with the pMSCV-loxP-dsRed-loxP-eGFPPuro-WPRE retrovirus 142. At baseline, these cells fluoresce red. Cre expression mediates
excision of the loxP-flanked dsRed gene responsible for red fluorescence, and eGFP
expression commences (Figure 2-1C). When the 3T3 Cre-reporter cells were
untransduced by a Cre expressing lentivirus, they fluoresced red. In contrast, when
transduced with Lenti-PDGFβ, they expressed GFP just 24 hours post-transduction
(Figure 2-1D). When observed at later time points, RFP expression extinguished in target
cells, and they only expressed GFP (data not shown).
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Figure 2-1. Autochthonous tumor model. Α. Overview of lentiviral transforming event in autochthonous
tumor model. B. Concept of tumor growth in vivo. C. 3T3 Cre-reporter line. D. Fluorescent microscopy of
3T3 Cre-reporter cells transduced with Lenti-PDGFβ.
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To determine the ability of the lentiviral constructs to drive PDGFβ expression in target
cells, we extracted mRNA from 3T3 Cre-reporter cells described above that had been
untransduced with additional constructs, transduced with Lenti-Cre empty (carries Cre
only), Lenti-PDGFβ, or Lenti-PDGFβ-ΟS, (which also expresses ovalbumin MHCI and
MHCII antigens, as well as SIY antigen). Compared to untransduced or to Lenti-Cre
empty transduced controls, Lenti-PDGFβ and Lenti-PDGFβ-OS transduced cells
expressed high levels of murine PDGFβ mRNA (Figure 2-2A).
To determine the ability of the Lenti-PDGFβ lentivirus to drive deletion of loxP-flanked
tumor suppressors in INK4a/ARFfl/fl x PTENfl/fl target cells, we isolated astrocytes from
this mouse strain and transduced them with lentivirus. We extracted their DNA and
performed PCR to determine whether the INK4a/ARF genes had been deleted.
Compared to wild-type tail or INK4a/ARFfl/fl x PTENfl/fl tail DNA, INK4a/ARFfl/fl x PTENfl/fl
astrocytes that had been transduced with Lenti-PDGFβ harbored deletion of INK4a/ARF
genes measured by PCR (Figure 2-2B). We performed a similar test of genetic deletion
in murine embryonic fibroblasts (MEFs) that had been isolated from the founder PTENfl/fl
mouse line. Compared to untransduced PTENfl/fl-MEFs, those transduced by LentiPDGFβ lost expression of PTEN as measured by western blot (Figure 2-2C).
To determine the capacity of Lenti-PDGFβ to drive secretion of PDGF-ΒΒ from cells which
carried the backbone lentiviral sequence, we transiently transfected 293Ts with LentiPDGFβ and measured PDGF-BB concentrations in the conditioned growth media, as well
as in the total cell lysates. Compared to Lenti-Cre empty or untransfected 293Ts, those
transfected by Lenti-PDGFβ or Lenti-PDGFβ-OS secreted high levels of PDGF-BB into
the growth media at 24 and 48-hours post-transfection and expressed high levels of
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intracellular PDGF-BB as well (Figure 2-2D). Collectively, these data demonstrate that
the lentivirus possesses functional Cre, drives excision of loxP-flanked tumor suppressors
in target cells, forces murine PDGFβ overexpression, and has the capacity to cause
murine PDGF-BB secretion, all of which would be required to transform target cells in
vivo.
2.2.3 Lenti-PDGFβ lentivirus drives brain tumor formation in vivo
Having assessed that Lenti-PDGFβ lentivirus functioned as hypothesized in vitro, we next
assessed the ability of the lentivirus to cause brain tumor formation in vivo. We
hypothesized that tumor formation would require both tumor suppressor deletion and
oncogene and gain of function, and that tumor suppressor deletion alone would be
insufficient. To test this hypothesis, we injected either highly concentrated Lenti-Cre
empty lentivirus (expresses Cre only), or highly concentrated Lenti-PDGFβ lentivirus
(expresses Cre and mPDGFβ) into the striata of INK4a/ARFfl/fl x PTENfl/fl mice. Compared
to Lenti-Cre empty lentivirus injected mice, those injected with Lenti-PDGFβ lentivirus
formed malignant glioma brain tumors and had a median survival of 140 days. In contrast,
100 percent those with Lenti-Cre empty survived for the entire observation period (Figure
2-2E). Histology of the tumors revealed hallmarks of malignancy: anaplasia and mitotic
figures, however, the tumors possessed histological features of gliosarcoma (Figure 22F). Out of nine tumors measured examined by histology, 8 were gliosarcomas and 1
was an oligodendroglioma. Gliosarcomas stained strongly for type III collagen and were
negative for glial fibrillary acidic protein (GFAP), a marker of cells of astrocytic origin (data
not shown).
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Figure 2-2. Lentivirus function and brain tumor induction in autochthonous tumor model. Α. Murine
PDGFβ mRNA expression in 3T3 Cre-reporter cells transduced with various lentivirus constructs. B.
Genomic loss of INK4a/ARF or C. Loss of PTEN protein expression following transduction by Lenti-PDGF.
D. Lentivirus-driven PDGF-BB secretion. E. Survival curve following intracranial lentiviral injection and
subsequent brain tumor formation. F. Histology of autochthonous Lenti-PDGFβ-induced brain tumor.
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Notably, several of the mice in each of the cohorts intracranially injected with LentiPDGFβ lentivirus also had neck masses, which appeared to harbor malignant cells after
they were cultured ex-vivo. We also observed an interesting phenomenon in some of the
mice that did not suffer brain tumors, particular to later cohorts: they became sick with
ascites and died. When dissected, these mice did not have brain tumors, but notably
appeared to have liver cirrhosis upon gross inspection. Collectively, the data show that
while Lenti-PDGFβ could drive brain tumor formation, the histology was not that of
glioblastoma multiforme, and instead had histologic characteristics of gliosarcoma.
Having determined that the Lenti-PDGFβ lentivirus led to gliosarcoma formation when
injected into the striatum, we selected a different lentivirus backbone with different open
reading frame promoters to selectively target glial cells. We chose three different
lentiviruses to drive expression in different types of target cells, provided by the
Washington University Hope Center. In these lentiviral backbones, ORF expression is
driven by the GFAP promoter to target astrocytes and their progenitors, the myelin basic
protein (MBP) promoter to target oligodendrocytes and their progenitors
promoter to broadly target cells in throughout the white matter

143

143

, or the CMV

, including astrocytes

and oligodendrocytes. We cloned Cre-P2A-mPDGFβ into each of these lentivirus
backbones and verified their function in vitro as we had done before with the other
lentiviral constructs. We determined that the three Cre-PDGFβ lentivirus constructs,
driven by either MBP, GFAP, or CMV, could drive genomic deletion of INK4a/ARF, loss
of PTEN protein expression, and mPDGFβ overexpression by qPCR. Having verified their
function in vitro, we injected concentrated lentivirus into the brains of INK4a/ARFfl/fl X
PTENfl/fl mice with the assistance of the Hope Center. We also targeted a different region
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of the brain—the subventricular zone, which has higher concentrations of neural stem
cells (including astrocyte and oligodendrocyte progenitors)

144

, which we envisioned

would be more permissive to transformation and which has been targeted to efficiently
generate glioblastoma in other GEMMs

135, 145-147

. We targeted the subventricular zone

with four different lentivirus constructs: CMV-Cre empty, CMV-Cre-PDGFβ, GFAP-CrePDGFβ, and MBP-Cre-PDGFβ. We injected four mice per construct and monitored their
health continuously. Notably, none of the mice developed brain tumors, but nearly all of
them developed the same ascites as the mice injected with the Lenti-PDGFβ constructs
in previous experiments. They also had cirrhotic appearing livers when dissected. This
suggests that both types of lentivirus constructs used had peripheral effects.

2.3 Conclusion and Discussion
In summary, we have created a genetically engineered mouse model of malignant glioma
that relies on both loss of function of tumor suppressors and gain of function of oncogenes
to completely drive transformation. Notably, our model has features that make it more
appropriate for immunologic study. First, the mice we used were both immunologically
competent and inbred. To our knowledge, most genetically engineered mouse models of
glioma use outbred mice. Secondly, to our knowledge our model is the first to use murine
PDGFβ—models that report using PDGFβ as the oncogene to drive transformation have
used human PDGFβ, to which the mouse immune system is not tolerant.
Although these features make this model more suitable for immunologic study and did
lead to brain tumor formation in some instances, unfortunately the histology was not that
of glioblastoma, and instead was that of gliosarcoma. Notably, gliosarcoma is one of the
rare malignant tumors of the CNS that is known to metastasize extraneurally
46
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. The

metastatic neck masses we observed in some of the mice are additional features beyond
histology that suggest our model was that of gliosarcoma. The next and easiest logical
step would be to use different oncogenes to drive tumor formation. EGFR is mutated in
57% of GBM, whereas PDGF signaling is overexpressed in 10% of GBMs 6. Moreover,
EGFRvIII, the most common EGFR modification, is highly expressed in 11% of GBMs,
and expressed above background in 19% of GBMs 6. Thus, EGFRvIII could be cloned
into both the Lenti-LucOS backbone, as well as the MBP/GFAP/CMV promoter lentiviral
backbones. Once its function was verified, this virus could be injected intracranially into
mice in an attempt to develop a glioblastoma GEMM.
As an attempt to generate a tumor that had histologic characteristics of glioblastoma
rather than gliosarcoma, we targeted specific cell types using lentivirus with ORFs driven
by the GFAP and MBP promoters, which are specific to glial cells. Unfortunately, no
tumors were observed following injection of any of these lentiviruses. When the mice died,
they had ascites and appeared to have liver cirrhosis. The absence of tumor formation
could be due to injecting lower titers of lentivirus, a different concentration method (we
used the Hope Center for the second generation of lentiviruses, whereas we used the
University of Iowa Viral Vector Core for the original Lenti-PDGFβ lentivirus constructs), or
potentially insufficient expression of PDGFβ by the second-generation lentiviral
backbones.
Notably, PTENfl/fl mice have been used in models of steatohepatitis and hepatocellular
carcinoma 149. Given our observations of cirrhotic livers in multiple experiments, we may
have inadvertently introduced the virus into systemic circulation, which could have been
sequestered by the liver, wherein any Cre expression whatsoever would cause deletion
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of tumor suppressors there, bringing about disruptive genetic changes that had potential
to alter cell behavior and change the normal function and morphology of the liver.
In summary, we have generated a new GEMM of malignant glioma. We were able to
induce successful tumor formation with the Lenti-PDGFβ lentivirus, but not with the Hope
Center-originating CMV/GFAP/MBP promoter-driven lentiviruses which we used in an
effort generate tumors with GBM histology. The model will require additional work to
become a fully competent GEMM of GBM.
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CHAPTER THREE
Ex-vivo derived models of recurrent hypermutated glioma
3.1 Introduction
The standard treatment for glioblastoma is maximal safe resection, followed by
radiotherapy and temozolomide 2, the latter of which unfortunately is only effective in the
roughly one-third to one-half of patients whose tumors express low levels of the DNA
repair protein methylguanine methyltransferase (MGMT)

5, 6, 150, 151

. MGMT ordinarily

functions to repair methylation damage to DNA, and as such acts to immediately reverse
temozolomide-induced DNA damage under normal conditions

152

. In GBM, low MGMT

expression is often due to MGMT promoter methylation, which silences MGMT gene
transcription. GBM invariably recurs, and of recurrent cases, approximately 20-30% are
hypermutated

153, 154

. GBM itself usually presents as a low to modest mutational burden

tumor and harbors a median of 2.2 coding mutations per megabase, which amounts to
fewer than 100 total mutations across the entire tumor 6. We hypothesize that additional
mutations, which might ordinarily be a marker of poor prognosis, could serve as additional
targets for the immune system.
GBM is not responsive to PD-1/PD-L1 checkpoint blockade under normal circumstances.
This was determined by two phase III clinical trials which demonstrated that GBM patients
with tumors that had either unmethylated (Checkmate 498 Trial, NCT02617589) or
methylated MGMT promoters (Checkmate 548 Trial, NCT02667587) experienced no
survival benefit from adjuvant PD-1/PD-L1 treatment
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111

. However, there are certain

cases in which checkpoint blockade could potentially be an effective tool to treat GBM,
distinct from the neoadjuvant setting, which demonstrated survival benefit in a phase II
clinical trial as discussed previously

112

. Although the relationship between mutational

burden and responsiveness to checkpoint blockade therapy is highly complex, there are
several promising case reports in which patients with patients with hypermutated GBM
experienced demonstrable benefit from checkpoint blockade therapy 109, 110.
Genomic hypermutation in GBM is often conferred by mutations or deficiencies in the
mismatch repair pathway 155, 156. Ordinarily, MGMT is one of the proteins responsible for
repairing the DNA damage caused by temozolomide 152, which exerts its cytotoxic activity
by methylating the guanine bases in DNA to cause mispairings and subsequent DNA
damage. Because the action of temozolomide would be immediately reversed by MGMT
under normal conditions, temozolomide treatment requires low tumor MGMT expression
to be an effective therapy 5, 6, 150, 151.
In addition to low MGMT expression, there is a second requirement for temozolomide
sensitivity: intact mismatch repair machinery

152

. Ordinarily, when temozolomide

methylates the guanine bases in DNA, MGMT reverses this damage. If this first DNA
repair step fails (presumably due to low MGMT expression), the methylated guanine is
mis-paired with thymine instead of cytosine during replication. When this happens, the
mutS homolog 2/mutS homolog 6 (MSH2/MSH6) heterodimer complex recognizes the
mis-paired guanine-thymine pairing, and the MSH2/MSH6 complex recruits the additional
components of the mismatch repair pathway, mutL homolog 1 (MLH1) and post-meiotic
segregation 1 homolog 2, mismatch repair system component (PMS2), to orchestrate
removal of the mis-paired thymine and replacement by cytosine, repairing the damage
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157

. When this step happens without reversing the original methylation of guanine that

resulted from temozolomide exposure (a function which would normally be performed by
MGMT), the cell again mis-pairs methyl-guanine with thymine instead of its correct pair,
cytosine. A repeated repair attempt follows, and fails, and the cell can become trapped in
a futile cycle of repeated and failed repair attempts because it can’t repair the original
damage caused by temozolomide. This can lead to cell cycle arrest and temozolomide
induced cell death 152, 157.
In contrast to this scenario, when any one of the mismatch repair proteins is defective or
missing (often MSH6 in GBM), the cell cannot detect the temozolomide-caused DNA
damage, proceeds forward through cell division, and incorporates the mispairings into the
daughter cells’ genomes. These temozolomide-induced mutations accumulate over
successive cell divisions, and lead to the state of hypermutation within the tumor

155, 156

.

In addition to hypermutation, a second consequence of defective mismatch repair is loss
of sensitivity to temozolomide—in this setting, DNA damage, no longer detected by the
cell, does not activate the mismatch repair machinery to attempt the repair the
mispairings, which would normally result in restraining cell division and causing cell death
158

. Instead, it’s as if cells carry on dividing as though they have no damage to their DNA,

because they cannot sense the presence of mispairings without functional MSH6.
The standard of care for all GBM includes temozolomide treatment. This is because the
correlation between MGMT promoter methylation and MGMT expression is imperfect—
some tumors with unmethylated MGMT promoters suggestive of high MGMT expression
might still actually have low MGMT expression for other unknown reasons independent
of MGMT promoter methylation status. Therefore, because of the dearth of available
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treatment options, and possibility that temozolomide might still provide clinical benefit to
patients with tumors that have unmethylated MGMT promoters, temozolomide is still
administered to every GBM patient as part of the standard treatment

152

. This alkylating

treatment which damages DNA thus leads to 20-30% of cases recurring as hypermutated
tumors for the reasons described above 153, 154.
The relationship between mutational burden and responsiveness to checkpoint blockade
is not entirely straightforward. Indeed, a landmark phase II trial by Le and colleagues
demonstrated that patients with mismatch repair-deficient colorectal cancer, which has a
higher mutational burden than most tumors, had more favorable survival when treated
with anti PD-1 therapy when compared to the mismatch repair-proficient patient cohort
159

. In a follow up second landmark study, Le and colleagues extended their findings to

other tumor types and demonstrated that mismatch repair-deficiency (which would result
in higher mutational burden than the same tumor with intact mismatch repair machinery)
increased likelihood of response to and PD-1 therapy across twelve solid tumor types 160.
Additionally, GBM patients with hypermutated tumors have experienced some benefit
after checkpoint blockade treatment in isolated cases. One such documented case was
a patient with a germline DNA polymerase epsilon (POLε) mutation (L424V) which
conferred loss of function of the proofreading exonuclease region in POLε, which
replicates and proofreads the leading strand of DNA. This patient presented with
multifocal brain tumors and had a germline POLε L424V mutation. His tumors harbored
roughly 10000 non-synonymous mutations. He was treated with checkpoint blockade and
experienced a robust T cell infiltrate into the tumor post-treatment as well as an objective
radiographic response

109

. The second report of benefit from checkpoint blockade in the
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setting of GBM occurred in a sibling pair who presented with pediatric recurrent
hypermutated GBM (over 20000 mutations in each tumor) and biallelic mutations in the
mismatch repair gene PMS2. They were treated with anti PD-1 therapy and experienced
demonstrable benefit as well, well outliving the median survival of children with their
condition 110.
Preclinical models have also demonstrated increased responsiveness to checkpoint
blockade as a function of mutational burden. In a clever study, Germano and colleagues
recently reported that deletion of the mismatch repair protein MLH1 followed by
temozolomide treatment conferred hypermutation, increased abundance of neoantigens,
and conferred checkpoint sensitivity in the in the normally checkpoint-insensitive CT26
colorectal cancer preclinical mouse model

161

. Although this finding is promising, this

study would be unrealistic for CNS tumors—the parental CT26 line contained 152
mutations per megabase, whereas basally, GBM presents with 1 to 4 mutations per
megabase 6. An appropriate model should account for the low mutational burden of the
primary tumor.
Moreover, although these findings might give reason for hope regarding the potential for
checkpoint blockade to effectively treat hypermutated GBM, there is reason for some
doubt that this treatment strategy will perform as a silver bullet. In a recent pivotal study,
Wolf and colleagues reported that patients with melanoma that harbored greater
intratumoral heterogeneity (defined as number of subclones clones comprising the tumor)
had worse survival compared to patients with melanoma that harbored less intratumoral
heterogeneity

95

. They devised a clever mechanism to increase the intratumoral

heterogeneity in a preclinical model of melanoma—they subjected the B2905 mouse
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melanoma cell line to UVB irradiation to increase both mutational burden and intratumoral
heterogeneity. The UVB-irradiated cells had more subclones by their analysis and formed
more aggressive tumors than un-irradiated less heterogenous controls. Notably, single
cell clones isolated from the UVB-irradiated B2905 cell line grew less aggressively or
were rejected altogether when transplanted into mice compared to either the un-irradiated
tumors or the UVB-irradiated tumors. Interestingly, they determined that growth
differences were eliminated between the parental line, the UVB-irradiated line, and singlecells clones derived from the UVB-irradiated line when these lines were transplanted into
immune-deficient NSG mice instead of wild-type mice used for prior experiments. This
demonstrated that the growth differences were immune-mediated. They also determined
that responsiveness to checkpoint blockade could be predicted in patient cohorts by
overlaying the intratumoral heterogeneity score over the response data: patients with high
intratumoral heterogeneity were less likely to respond to checkpoint blockade, and
patients with low intratumor heterogeneity were more likely to respond to checkpoint
blockade.
Unfortunately, most patients with GBM have remarkably heterogeneous tumors 92, 93, 162.
Mutations are often not shared between different tumor regions. For instance, EGFRvIII,
a common oncogene within GBM, has been shown to be expressed only by a fraction of
the tumor cells within EGFRvIII-positive GBM

93, 94

. Additionally, there is evidence that

patients with hypermutated GBM also harbor heterogeneous tumors. This was
demonstrated by a landmark study conducted by our lab in collaboration with the Malachi
Griffith lab, in which MD/PhD student Max Schaettler and PhD student Megan Richters
sequenced different tumor regions of GBM tumors and compared the mutations between
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different tumor regions originating from the same tumor. They found that similar to GBM
tumors with a normal mutational burden across all regions, high mutational burden GBM
tumors harbored mostly private mutations in the disparate tumor regions that were not
shared with other regions originating from the same tumor 162.
However, given the isolated case reports demonstrating success of checkpoint blockade
in treating hypermutated GBM, as well as the positive correlation between mutational
burden and checkpoint blockade responsiveness in other tumor types, we strongly felt
that studying the relationship between tumor mutational burden and responsiveness to
checkpoint blockade in GBM using preclinical models was warranted. We set out to
develop an isogenic preclinical model of GBM to investigate the relationship between
mutational burden, intratumoral heterogeneity, and checkpoint blockade sensitivity in
malignant glioma so that the 20%-30% of patients with hypermutated GBM might be
afforded more effective treatment options.
To generate a model of recurrent, hypermutated GBM, we isolated astrocytes from the
INK4a/ARF-/- x PTEN-/- mice and transformed them with Lenti-PDGFβ lentivirus to both
delete INK4a/ARF and PTEN and to overexpress murine PDGFβ. We next used CRISPR
to bi-allelically delete MSH6, a commonly lost or mutated mismatch repair gene in
hypermutated GBM

155

. We treated these cell lines with temozolomide to simulate the

standard therapy and induce increased tumor mutational burden in the MSH6-/- parental
transformed Lenti-PDGFβ-INK4a/ARF-/- x PTEN-/- astrocyte line. We additionally modeled
DNA polymerase epsilon mutations as drivers of hypermutation.
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3.2 Results
3.2.1 Lenti-PDGFβ transforms INK4a/ARFfl/fl x PTENfl/fl mouse astrocytes
Before developing our isogenic model of hypermutation, we first set out to develop a
parental isogenic transformed astrocyte-derived malignant glioma cell line with a low
baseline mutational burden. We utilized both the mice and the lentiviral constructs from
our autochthonous glioma GEMM. We began by isolating astrocytes from INK4a/ARFfl/fl
x PTENfl/fl P0 pups, grouped them into male or female cohorts, and transduced them with
Cre +/- mPDGFβ expressing lentivirus constructs (Figure 3-1A). We generated three
different INK4a/ARF-/- x PTEN-/- astrocyte lines: Lenti-Cre empty, to solely delete the loxPflanked tumor suppressors, Lenti-PDGFβ to do the same plus additionally enforce murine
PDGFβ overexpression, or Lenti-PDGFβ-OS to do the aforementioned plus additionally
overexpress the OS cassette, which contains the MHCI/H-2Kb-restricted antigens
SIINFEKL (from ovalbumin) and SIY, as well as the MHCII/I-Ad antigen from ovalbumin.
We had previously verified that the lentivirus constructs expressed functional Cre and
drove PDGFβ overexpression measured by qPCR and protein expression (see Chapter
2). To determine if the transformed INK4a/ARF-/- x PTEN-/- astrocytes retained
characteristics of astrocytes, we performed immunofluorescence for GFAP, a commonly
used astrocyte marker. Compared to either 3T3 mouse fibroblasts, or the GL261 mouse
glioma line, INK4a/ARF-/- x PTEN-/- astrocytes that had been transduced with LentiPDGFβ lentivirus expressed GFAP by immunofluorescence (Figure 3-1B), which
suggests we both successfully isolated astrocytes, and that they retained characteristics
of their astrocyte lineage following tumor suppressor deletion and oncogene
overexpression.
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To determine if the transduced astrocytes were transformed into malignant cells, and
whether they possessed the intrinsic ability to spontaneously generate an immune
response, we transplanted them subcutaneously into flanks of immune competent wildtype C57BL/6 mice. We tested three different INK4a/ARF-/- x PTEN-/- astrocyte lines: first,
a negative control which lacked oncogene overexpression (and was presumably
untransformed), which was transduced with Lenti-Cre empty. Second: Lenti-PDGFβtransduced, and third, Lenti-PDGFβ-OS-transduced. After transplantation, we monitored
for tumor growth. As expected, the Lenti-Cre empty line did not form tumors. The LentiPDGFβ-OS ovalbumin/SIY antigen-expressing line formed small tumors, which soon after
regressed. The Lenti-PDGFβ line grew progressively (Figure 3-1C). Collectively, these
data show that to be transformed into malignant cells, INK4a/ARFfl/fl x PTENfl/fl astrocytes
required both (a) deletion of tumor suppressors and (b) oncogene overexpression, and
additionally, that expression of the immunogenic OS cassette was sufficient to drive tumor
rejection.
We next examined for evidence of a CD8+ T cell response in mice that had been
transplanted with the astrocyte lines. With lines that formed tumors and grew
progressively, we carried the growth curve until a later timepoint to fully measure tumor
growth potential, and thus we did not include the progressively growing Lenti-PDGFβ
cohort in this experiment. We isolated the lymph nodes adjacent to the injection site as
well as the spleens from mice that had been transplanted with either the Lenti-Cre empty
line (which never formed tumors), or the Lenti-PDGFβ-OS line, which formed small
tumors that regressed. We performed an interferon-γ release assay (ELISPOT) on CD8+
T cells isolated from either the draining lymph node or the spleen.
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Figure 3-1. Astrocytes are transformed and conditionally immunogenic. A. Schematic of INK4a/ARFfl/fl
x PTENfl/fl astrocyte isolation and experimental design. B. Immunofluorescence of GFAP and DAPI in
transformed astrocytes, GL261 glioma cells, and 3T3 mouse fibroblast cells. C. Growth curves of flank
tumors from transplantation of transformed astrocytes. D. ELISPOT IFNγ release assay of CD8+ T cells
isolated from spleens or dLNs of Lenti-Cre Empty astrocyte line injected mice, or Lenti-PDGFβ-OS
astrocyte line injected mice that had rejected tumors. Statistics by student’s t-test. * p <0.05.
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In contrast to both splenic and lymph node CD8+ T cells which were isolated from mice
subcutaneously transplanted with Lenti-Cre astrocytes, CD8+ T cells isolated from the
same organs of mice transplanted with Lenti-PDGFβ-OS astrocytes released IFNγ above
background in response to stimulation with SIINFEKL peptide and naïve antigen
presenting cells (Figure 3-1D).
Collectively, these data show that when transformed INK4a/ARF-/- x PTEN-/- astrocytes
expressed the immunogenic antigens carried by the OS cassette, that mice transplanted
with such astrocytes spontaneously generate a CD8+ T cell response against those
antigens.
3.2.2 CRISPR disrupts MSH6 gene to confer loss of MSH6 protein expression
To generate hypermutated tumors from Lenti-PDGFβ INK4a/ARF-/- x PTEN-/- transformed
astrocytes, we targeted two different pathways: first, MSH6 of the mismatch repair
pathway, and second, the exonuclease region of DNA polymerase epsilon, which
proofreads as DNA polymerase epsilon performs replication of the leading strand. To
target MSH6, we used CRISPR to disrupt the first exon of MSH6 in Lenti-PDGFβtransduced INK4a/ARF-/- x PTEN-/- astrocytes. We isolated single cell clones, and used
Sanger sequencing combined with the TIDE computer program to deconvolute the
Sanger sequence and assess for biallelic MSH6 disruptions 163. We screened single cell
clones that grew well in culture and selected three clones which were predicted by TIDE
to have biallelic disruption of MSH6. We performed a western blot for MSH6 and
determined that compared to 293T cells which overexpressed murine MSH6, or to Cas9empty transfected transformed astrocytes, that the three single-cell clones targeted with
Cas9-MSH6 did not express detectable protein levels of MSH6 (Figure 3-2A).
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3.2.3 Lenti-PDGFβ transformed astrocytes resist temozolomide at baseline
We hypothesized that deletion of MSH6 from the transformed astrocytes would confer
resistance to temozolomide, which has been well documented in GBM 158. We utilized a
propidium iodide assay to assess cell cycle, and from the information gleaned, to identify
cell populations which harbored temozolomide resistance. Cell cycle can be quantitatively
analyzed by propidium iodide

164

, which intercalates into DNA and fluoresces

165

.

Temozolomide treatment methylates the O6 atom on guanine bases, which causes the
now-methylated guanine to be mis-paired with thiamine instead of its normal partner,
cytosine

166

. In attempting to reverse this mis-pairing, cells upregulate mismatch repair

machinery, and in doing so, can be trapped in a futile state of repair if MGMT is not present
to repair and reverse the guanine methylation originally caused by temozolomide 166. The
result is that many cells are unable to complete cell division following their G2 phase. This
leads to greater numbers of cells trapped in the 4N (and even 8N) state as their DNA
continues to double without successful completion of cell division. This is quantifiable by
flow cytometry as 4N and 8N cells will uptake either twice as much or four times as much
PI because of the increased amount of DNA in each cell, and as a result, will fluoresce
more brightly in a quantitatively detectable manner 164.
We treated GL261 murine glioma cells with escalating doses of temozolomide and
determined that cells treated with increased levels of temozolomide harbored more cells
in the 4N and 8N state in a dose-dependent manner (Figure 3-2B). In contrast, LentiPDGFβ INK4a/ARF-/- x PTEN-/- transformed astrocytes treated with temozolomide did not
have more cells attributed to the 4N or 8N peaks (Figure 3-2C). Collectively, these data
show that while GL261 murine glioma cells demonstrated sensitivity to temozolomide,
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that the transformed astrocytes we generated were temozolomide resistant, despite
having intact MSH6, which should permit temozolomide sensitivity when functional.
3.2.4 MGMT expression confers temozolomide resistance in transformed astrocytes
Temozolomide resistance is conferred by a variety of factors, including high MGMT
expression in patient tumors 152. When expressed by cells, MGMT reverses the guanine
methylation damage caused by temozolomide

6

. Thus, we hypothesized that the

transformed astrocytes might express high levels of MGMT at baseline, and hence would
be resistant to temozolomide treatment. We performed a western blot on parental MSH6WT transformed astrocytes, as well as on the three MSH6-/- clones, along with GL261,
which we hypothesized would have low MGMT expression due to baseline temozolomide
sensitivity. All transformed astrocytes, including the MSH6-/- clones, expressed detectable
levels of MGMT (Figure 3-2D). In contrast, GL261 did not express detectable levels
MGMT (Figure 3-2D). Notably, the three MSH6-/- clones expressed lower levels of MGMT
than the parental MSH6-WT transformed astrocytes. Collectively, these data indicate
MGMT expression as a potential mechanism that the transformed astrocytes might
employ to resist temozolomide treatment as measured by propidium iodide nuclear
analysis.
MGMT expression can be inhibited by the small molecule O6 benzyl guanine (O6BG) 167.
Because of this, treatment of cell lines with O6BG can sensitize them to temozolomide.
We subjected the MSH6-WT as well as the MSH6-/- astrocytes to dual treatment with both
temozolomide and O6BG and performed the propidium iodide nuclear analysis assay.
The results were indeterminate and did not allow us to confirm that MSH6 deletion
conferred temozolomide resistance with proper MGMT inhibition. Thus, we performed an
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orthogonal growth curve experiment to assess temozolomide sensitivity. From previous
experiments in our lab, we had determined that treatment of GL261 glioma cells with
500µM temozolomide completely arrested growth of GL261 in vitro. We subjected the
transformed astrocytes to the same concentration of temozolomide, with or without O6BG,
along with O6BG alone. At baseline, either temozolomide or O6BG treatments alone
slightly restrained growth of MSH6-WT transformed astrocytes. However, both inhibitors
combined restrained growth considerably in this cell line, leading to a 6.25-fold decrease
in cell count at the end of the experiment (Figure 3-2E). In contrast, the three MSH6-/clones displayed varying levels of decreased temozolomide sensitivity. Clone 1 was
slightly sensitive to temozolomide, whereas clones 2 and 3 were not (Figure 3-2E).
Treatment with O6BG alone restrained growth slightly in clones 1 and 3. When treated
with both temozolomide and O6BG, all 3 clones grew more slowly. However, in contrast
to the parental MSH6-WT line, which was growth-restricted over 6-fold from O6BG +
temozolomide treatment, the three MSH6-/- lines were growth-restricted by 2 to 4-fold from
O6BG + temozolomide treatment (Figure 3-2E). Collectively, these data show that MSH6
deletion confers some amount of resistance to temozolomide/O6BG-indued growth
inhibition when compared to their MSH6-WT counterpart but suggests that high
concentrations of temozolomide and MGMT inhibition can still somewhat restrain growth
even in MSH6-deficient cells.
Given our previous findings that the Lenti-PDGFβ INK4a/ARF-/- x PTEN-/- transformed
astrocytes expressed GFAP and formed tumors when transplanted into the flanks of wildtype mice, we hypothesized that they would also form brain tumors. When transplanted
into the brain, the only tumors that resulted were extracranial, subcutaneous masses
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outside of the skull (Figure 3-2F), with no tumor within the brain parenchyma. This
observation suggests that the transformed cells, which originated from astrocytes,
harbored growth traits that engendered them with tropism for subcutaneous, rather than
intracranial anatomic locations. A possible explanation for the possibility of tumors
forming extracranially despite being transplanted intracranially is that in addition to
harboring tropism for subcutaneous regions, some malignant cells might have refluxed
from the stab wound or were left behind by the needle upon withdrawal, leaving malignant
cells outside of the skull to form tumors in subcutaneous spaces.
3.2.5 MSH6 deletion or DNA polymerase epsilon disruption confers hypermutation
Although the Lenti-PDGFβ INK4a/ARF-/- x PTEN-/- transformed astrocytes did not form
intracranial tumors, and instead formed extracranial subcutaneous tumors, we still
subjected them to conditions in an attempt to induce a hypermutated state and performed
genomic analysis of the cells as a proof of concept.
To induce a hypermutated state in the MSH6-/--INK4a/ARF-/- x PTEN-/- transformed
astrocytes, we treated them, plus their MSH6-WT counterparts with either vehicle or
O6BG + temozolomide for two months with continuous passaging. This treatment was to
mimic what happens in the GBM patients who recur with hypermutated GBM after
temozolomide treatment. During treatment, growth of the MSH6-/- transformed astrocytes
as well as their wild-type counter parts completely arrested in the extended presence
O6BG + temozolomide. For one additional month, treatments were removed, and the cells
were allowed to recover until they grew continuously and once again needed regular
passaging. We hypothesized that the MSH6-/- astrocyte lines would harbor a
hypermutated state, but only when treated with O6BG and temozolomide. We extracted
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DNA and RNA and performed whole exome sequencing. In addition to the exome
sequencing data, we input the RNA-expression and variant calls into the pVAC-seq
algorithm to assess for neoantigen burden 168.
We also generated DNA polymerase epsilon mutants with the assistance of the Genomic
Engineering and iPSC Center (GEiC) at Washington University. We modeled a mutation
after a GBM patient with a germline DNA polymerase epsilon (POLε) L424V mutation
whose tumor was hypermutated. This particular patient was treated by Drs. Dunn and
Johanns with checkpoint blockade, which conferred objective radiographic response 109.
Additionally, there was histologic evidence of increased numbers of CD4+ and CD8+ T
cells infiltrating the tumor following treatment with pembrolizumab 109. The patient’s POLε
L424V mutation occurred in DNA polymerase epsilon’s proofreading exonuclease region,
which caused this patient’s primary tumor to have over 10000 mutations. This mutation
is also associated with a high penetrance of colorectal cancer is families who carry the
mutation 169. We generated a second mutant: POLε D272A E274A, which has been used
before to generate spontaneous tumors, as well as to cause defects in DNA proofreading
in mice with the germline mutation

170

. We hypothesized that in contrast to the MSH6-/-

mutants, the POLε mutants would become hypermutated simply through the act of cell
division and continuous passaging, and that they would not require additional treatment
from temozolomide or another such agent to cause DNA damage, in contrast to the
MSH6-/- mutants. After the GEiC had provided single cell clones that were homozygous
for either POLε L424V or POLε D272A E274A, we extracted DNA and RNA from lowpassage cells, continuously passaged these cell lines for two months and then extracted
DNA and RNA from high-passage cells for comparison.
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Using the exome sequencing data, we generated a list of variants (total as well as nonsynonymous) and used the pVAC-seq algorithm to identify potential neoantigens in both
the POLε and MSH6-/- mutants. We determined that high passage polymerase epsilon
mutants harbored more total mutations, more non-synonymous mutations, and more
predicted neoantigens than parental transformed astrocytes (which were also
continuously passaged), or the matched low passage POLε mutants (Figure 3-2G, 3-2H).
Furthermore, MSH6-/- mutants which were treated with O6BG + temozolomide harbored
more total mutations, more non-synonymous mutations, and more predicted neoantigens
than the untreated MSH6-/- mutants, or their MSH6-WT O6BG + temozolomide-treated
counter parts (Figure 3-2G, 3-2H). Notably, the MSH6-/- untreated mutants harbored
considerably more mutations and non-synonymous variants than either the treated or
untreated MSH6-WT counterparts, and more predicted neoantigens than any of the cell
lines analyzed (Figure 3-2G, 3-2H). We had hypothesized that MSH6 would not be
required to maintain DNA fidelity during normal cell culture passaging in the absence of
O6BG + temozolomide induced DNA damage, which stood in contrast to our findings.
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Figure 3-2. MSH6/POLε disruption leads to hypermutation. A. MSH6-deletion western blot. B and C.
GL261 or transformed astrocytes sensitivity/resistance to temozolomide, measured by cell-cycle PI assay.
D. MGMT western blot in various cell lines. E. Temozolomide/O6BG growth arrest in transformed astrocytes
as a function of MSH6 status. F. Extracranial tumor formation following intracranial astrocyte injection. G
and H. Tumor mutational burden or predicted neoantigens in transformed astrocytes subject to various
genetic permutations, treatments, and passage durations. Statistics by student’s t-test. *p <.05, **p<.01.
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3.3 Conclusion and Discussion
To generate an isogenic model of recurrent, hypermutated GBM, we isolated astrocytes
from C57BL/6 INK4a/ARFfl/fl x PTENfl/fl P0 pups. We transduced them with Cre/mPDGFβ
expressing lentivirus and validated that they retained astrocyte characteristics, were
transformed into malignant cells, and possessed the intrinsic ability to provoke an immune
response. We demonstrated evidence of this immune response by observing growth and
subsequent regression of OS-bearing tumors, as well as by isolating SIINFEKL-specific
CD8+ T cells from the spleens and draining lymph nodes of mice that had been challenged
with OS-bearing tumors.
We disrupted MSH6 and generated DNA polymerase epsilon mutants to induce a state
of hypermutation in the transformed astrocytes. We demonstrated that MSH6 disruption
conferred additional resistance to temozolomide, but we found that the transformed
astrocytes were temozolomide resistant at baseline, likely due to MGMT expression. This
stood in contrast to the GL261 murine glioma line, which was temozolomide sensitive and
did not express MGMT at baseline. When we inhibited MGMT in the transformed
astrocytes by treating them with O6 benzylguanine, they became sensitive to
temozolomide treatment as assessed by growth curves. Furthermore, O6BG +
temozolomide treatment induced a state of hypermutation in the transformed astrocytes,
as did continuous passaging (without temozolomide treatment) in the POLε mutants. The
hypermutated cell lines harbored more mutations, more non-synonymous mutations, and
had more predicted neoantigens than the control cell lines, which were untreated MSH6WT or POLε-WT cells. Collectively, these data indicate that we successfully modeled
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particular aspects of recurrent-hypermutated GBM, including temozolomide-induced
hypermutation after MSH6 disruption.
Although the MSH6-/- mutants harbored more mutations following treatment with
temozolomide and the MGMT inhibitor O6 benzylguanine, it was notable that even the
treatment-naïve MSH6-/- mutants harbored more mutations than both the high-passage
and low passage POLε mutants. We had originally hypothesized that the activity of the
mismatch repair pathway would be low at baseline due to the absence of a DNAdamaging agent. However, our data suggest that normal passaging of our cell lines
requires intact mismatch repair machinery to maintain genome fidelity. MSH6 is
canonically understood to be part of the mismatch repair pathway and required to detect
and correct mispairings between DNA bases, which would ordinarily be caused by a DNAdamaging agent. Our data suggest that in our particular case normal passaging without
temozolomide and O6 benzylguanine treatment was sufficient to cause the mispairings
that mismatch repair machinery would ordinarily correct.
Although we generated an isogenic transformed astrocyte line and successfully induced
hypermutation in the cells by multiple approaches, unfortunately the transformed cells did
not appear to have tropism for the brain parenchyma when transplanted there. They
instead grew in extracranial subcutaneous regions, even after intracranial transplantation.
We believe this resulted from a combination of subcutaneous tropism and either reflux of
malignant cells outside the burr hole in the skull or deposition of malignant cells as we
withdrew the needle following transplantation of tumor cells into the brain parenchyma.
While this same process likely happens during the transplantation of other established
glioma cell lines into the mouse brain, the tropism of those malignant cells is for brain
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parenchyma, which makes their growth more favorable in the brain. This permits brain
tumors, rather than subcutaneous tumors, to form.
We transformed astrocytes and disrupted either the mismatch repair pathway or the DNA
proofreading machinery and identified that either mutation was sufficient to induce
hypermutation; however, our model is limited in that transplantation of transformed
astrocytes into the brain did not result in brain tumor formation. Further work is needed to
address whether using different oncogenes such as EGFRvIII would be sufficient to
confer brain-specific tropism upon the transformed astrocytes. Alternatively, other tumor
suppressors could be targeted. Additionally, other cell types could be used as the
originating cell for the tumor model, such as neural stem cells, which we have begun
isolating and transforming. Nevertheless, once we do identify factors that confer our
model with brain-tumor forming capacity, we can correctly address the original hypothesis
that higher tumor mutational burden leads to greater immunogenicity and higher likelihood
of response to checkpoint blockade in the brain. We can also assess heterogeneity of the
tumors and determine whether greater heterogeneity would portend for lower
immunogenicity, as Wolf and colleagues identified in the B2905 melanoma model 95.
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CHAPTER FOUR
cDC1 are required for CNS antitumor immunity
4.1 Introduction
Numerous studies have established that the conventional dendritic cell 1 subset (cDC1)
is essential for antitumor immunity across a range of types 20-23, 27, 28, 30, 31, however their
role in the CNS remains undefined. The lack of studies defining the role of cDC1 in CNS
antitumor immunity could be for several reasons, among them that cDC1 (as well as other
dendritic cell subsets) are absent in the steady state brain parenchyma 49, or that the CNS
lacks conventional lymphatics

171

which would presumably be required for cDC to traffic

from the periphery (or brain in this case) to a lymph node to prime a T cell response. In
addition to the ostensible lack of cDC infiltrating the steady state brain and lack of
conventional lymphatics, glioblastoma is associated with a range of immunologic defects,
including GBM-induced lymphopenia

71, 72

, a multitude of immunosuppressive factors

secreted by the tumor itself or by infiltrating immune cells
of checkpoint molecules such as PD-L1

86,

87,

77, 80-82, 172, 173
174

microenvironment with abundant tumor associated MDSCs
circulating levels of MDSCs compared to healthy controls

, overexpression

, an immunosuppressive
89

90

, as well as high levels of

. The combination of these

immunosuppressive elements associated with GBM have led many to describe GBM as
an immunologically “cold” tumor. The premise of GBM being an “immunologically cold”
tumor, when combined with the absence of steady state dendritic cells in the brain
parenchyma, has perhaps led many investigators to focus instead on the innate cell types
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that are present in the brain parenchyma, or on the immunosuppressive aspects of GBM
in the context of innate immunity and antigen presentation, rather than on the anatomic
and cellular basis for endogenous antigen presentation and T cell priming in CNS
antitumor immunity.
The anatomic location of dendritic cells in the steady state brain is restricted to the
meninges and the choroid plexus

49, 51

. The only leukocytes in the steady state brain

parenchyma are microglia, a specialized phagocytic cell unique to the brain and derived
from the embryonic yolk sac

49

. Microglia are involved in maintenance of homeostasis,

elimination of microbes, removal of dead cells and debris, and are a source of proinflammatory cytokines during inflammation 49, 175. A second phagocytic cell type that has
received some attention is the border associated macrophage (BAM), a specialized
macrophage that exists along the basement membranes of blood vessels throughout the
brain parenchyma 49. Given their abundance in the steady state brain, these two cell types
have garnered interest as the putative T cell-priming antigen presenting cell in the brain.
However, even though they can phagocytize and present antigen, they are not known to
be able to migrate outside the CNS to draining lymph nodes. In contrast, cDC have been
demonstrated to possess the machinery required to cross the network of specialized
endothelial cells which comprise the blood brain barrier in an in vitro system 53 as well as
the capability of migrating to cervical lymph nodes in the neck under certain experimental
conditions 23, 176. However, cDC are largely absent from the steady state brain 51. Despite
these observations, an abundance of dendritic cells have been demonstrated to infiltrate
the brain parenchyma during certain inflammatory conditions

51

, and it is further

conceivable that the inflammation and dysregulated blood-brain barrier present in GBM
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would permit additional opportunity for entry of circulating dendritic cells from the blood.
Needless to say, it remains an open question whether cDC, microglia, or BAM perform
immune surveillance to prime T cell responses against CNS tumors.
Some of the most compelling experiments implicating the role of dendritic cells in CNS
immune surveillance and T cell priming are those which involve CNS autoimmunity. A
clever study by Mundt and colleagues measured the effect of temporal and conditional
deletion of MHCII from different APC subsets in the brain during EAE

55

. They used a

microglial specific Cre strain and crossed it to a MHCIIfl/fl mouse to hinder antigen
presenting capability of microglia. They determined that they could still induce EAE in
these mice, which suggests that microglia were dispensable. They also crossed the
MHCIIfl/fl mouse to a Cx3cr1 Cre-ER strain in order to target all three APC subsets in the
brain. This cross also allowed for temporal deletion of MHCII so that APC with different
developmental origins and lifespans could be differentially targeted. Whereas chronic
tamoxifen treatment deleted MHCII from all APC subsets, acute tamoxifen treatment
followed by a recovery period completely deleted MHCII from slowly cycling microglia and
BAMs but allowed nascent MHCII-intact cDC which had developed after tamoxifen
clearance, to repopulate the CNS during inflammatory conditions. In contrast to acute
treatment, which permitted cDC but not microglia or BAMs to express MHCII, only chronic
treatment, which deleted MHCII from all APC subsets, ameliorated EAE. MHCII on cDC
was sufficient for EAE progression. This set of experiments demonstrated that cDC are
the critical APC required for disease progression in the EAE model.
A second compelling study by Giles and colleagues showed in an EAE model that during
the inflammatory conditions of EAE, CNS cDC accumulated in considerably greater
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numbers compared to during the steady state. Additionally, cDC possessed superior
ability to prime MOG-specific CD4 T cells compared to endogenously arising monocytederived dendritic cells (moDC) and were additionally more pro-inflammatory than moDC.
Furthermore, they showed that depletion of cDC using a ZBTB46-DTR mouse resulted in
attenuated disease compared to non-depleted control mice 56.
While the steady state brain is relatively devoid of conventional dendritic cells, these
studies highlight the importance of cDC for disease progression in EAE models. Notably,
these studies did not distinguish between cDC1 and cDC2 subsets (their Cre strains and
diphtheria-toxin cDC-depletion model targeted all cDC), and they additionally did not
address the role of cDC in antitumor immunity of the CNS.
Given the open questions regarding identity of the antigen presenting cell responsible for
T cell priming in the brain, the lack of studies regarding endogenous T cell priming for
CNS tumors, the implication of cDC in other immunologic responses in the brain, and the
established role of cDC1 in antitumor immunity of other tumor types, we set out to define
the role of cDC1 in CNS antitumor immunity. Herein we demonstrate that while cDC1 are
absent in the steady state brain, that cDC1 infiltrate the brain parenchyma when a brain
tumor is present. We also demonstrate that cDC1 are required both to mount neoantigenspecific CD8+ T cell responses and to confer benefit from checkpoint blockade in a
preclinical model of GBM. Together, our findings demonstrate the critical role that cDC1
play in mounting antitumor immunity in the brain.
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4.2 Results
4.2.1 cDC1 infiltrate brain tumors and mediate checkpoint blockade-conferred protection
During steady state conditions, the primary locations for dendritic cells in the CNS are the
choroid plexus and the surrounding meninges (consisting of the dura, arachnoid, and pia
mater)

49, 51, 177

. The parenchyma itself is largely devoid of conventional dendritic cells,

including cDC1. Despite the low amount of apparent surveillance by cDC in the steady
state brain parenchyma, cDC play pivotal roles for a variety of immunologic responses in
the CNS 53, 55, 56, 178-181. Therefore, we investigated their role in CNS antitumor immunity.
We first determined whether dendritic cells infiltrate the brain tumor microenvironment in
two different murine orthotopic glioma lines derived from the C57BL/6 mouse strain:
GL261, and CT2A. We transplanted GL261 or CT2A tumor cells into the striata of wildtype mice and analyzed the immune infiltrate two weeks following transplantation. Using
flow cytometry, we identified that all dendritic cell subsets (defined as CD45+, F4/80-, IAb+, CD11c+), including cDC1 (defined as dendritic cells which are XCR1+, SIRPα-, Ly6C-), infiltrated brain tumors and accumulated in numbers that were orders of magnitude
greater than the number present in the cerebral hemisphere of sham-injected mice
(Figure 4-1A). In order to validate the presence of cDC1 in tumors, we used a novel cDC1
reporter mouse to examine this population using 2-photon microscopy as well as by flow
cytometry. In this mouse strain, GFP is knocked into one allele of the sorting nexin 22
locus (SNX22GFP/GFP), and the XCR1+ cDC1 specifically and constitutively express GFP
182

. For experiments, we used heterozygotes (Snx22GFP/+), which have normally

functioning cDC1 that still express GFP 182.
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Figure 4-1. cDC1 infiltrate mouse glioma. A. cDC1, cDC2, MoDC and pDC quantification in brains of
sham treated vs. GL261 or CT2A injected mice analyzed by flow cytometry at day 14 following tumor
transplantation. B. cDC1/cDC2 profile and GFP expression of SNX22GFP/+ mice. C-E. 2-photon microscopy
of sham injected brain, or GL261-OFP injected brain at various regions in tumor. Data are represented as
mean +/- SEM of at least three independent experiments. Statistics by student’s t-test. **** p <.0001.
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We transplanted GL261 tumors into the brains of Snx22GFP/+ mice. Using flow cytometry,
we identified that both cDC1 and cDC2 subsets infiltrated the brain tumors of both wildtype (WT) and Snx22GFP/+ mice, but that GFP-expression was restricted to the cDC1
subset of the Snx22GFP/+ mice (Figure 4-1B). To determine the localization of cDC1 in
brain tumors, we used 2-photon microscopy to image OFP-transduced GL261 tumors that
had been transplanted into the brains of Snx22GFP/+ mice. In sham injected Snx22GFP/+
mice, cDC1 were completely absent from the brain parenchyma (Figure 4-1C, 4-1D). In
contrast, cDC1 infiltrated extravascular spaces of tumors and peri-tumor regions of
Snx22GFP/+ mice which bore GL261-OFP brain tumors (Figure 4-1C, 4-1E). Collectively,
these data show that despite a scarcity in the steady state brain, dendritic cells, including
the cDC1, abundantly infiltrate brain tumors in multiple orthotopic preclinical models of
GBM.
Having identified that cDC1 are recruited to the brain tumor microenvironment, we
investigated the immunologic consequences that result from their deficiency. To address
this question, we used the IRF8+32kb-/- mouse, which harbors a 0.5kB deletion at
IRF8/BATF3 binding site within the IRF8 super-enhancer, which falls 32kb downstream
of the transcription start site. This mutation results in IRF8 levels in pre-cDC1 that are
insufficient for cDC1 development 183. We transplanted GL261 cells into the brains of wildtype or IRF8+32kb-/- mice and investigated the immune infiltrate by flow cytometry.
Whereas wild-type mice with intracranial GL261 harbored abundant cDC1 in their brain
tumors, IRF8+32kb-/- mice completely lacked cDC1 in their brain tumors (Figure 4-2A).
Having confirmed that cDC1 were selectively deficient in IRF8+32kb-/- mice, we
investigated the immunologic consequences of their deficiency. Although GL261 grows
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progressively in immune competent mice, PD-1/PD-L1 blockade improves survival 124, 126.
We determined whether cDC1 are required to mediate this benefit. Whereas WT mice
experienced improved median and overall survival following intracranial implantation of
GL261 followed by αPD-L1 treatment, cDC1-deficient IRF8+32kb-/- mice subjected to the
same treatment experienced no benefit (Figure 4-2B). Notably, we observed no survival
difference between WT and IRF8+32kb-/- in vehicle-only treated mice which bore GL261
brain tumors (Figure 4-2B). Collectively, these data demonstrate that dendritic cells
(including the cDC1) are recruited to brain tumors in numbers much greater than found in
the steady state brain parenchyma, and that cDC1 in particular are required to mediate
survival benefit from αPD-L1 in the setting of orthotopic GL261 brain tumors.
4.2.2 cDC1 prime CD8+ T cell responses against glioblastoma
Because cDC1 can cross present antigen to prime CD8 T cell responses

25

, we

investigated the effect of cDC1-deficiency on brain tumor T cell composition. We
transplanted GL261 into the brains of wild-type or IRF8+32kb-/- mice and examined the
infiltrating immune cells by flow cytometry. Compared to wild-type mice, IRF8+32kb-/mice had fewer infiltrating T cells, non-Treg CD4+ T cells, and CD8+ T cells as a percentage
of total CD45+ cells infiltrating their brain tumors. In contrast, both wild-type mice and
IRF8+32kb-/- had equal numbers of Tregs infiltrating their brain tumors (Figure 4-2C). Both
mouse strains had equal numbers of CD45+ cells infiltrating brain tumors (data not
shown). In addition to IRF8+32kb-/- mice having fewer brain-tumor infiltrating CD8+ T cells
compared to wild-type mice, a smaller fraction of the infiltrating CD8+ T cells present
expressed granzyme B or PD-1 compared to wild-type mice (Figure 4-2D). These data
demonstrate that in brain tumors, the T cell defect resulting from cDC1-deficiency spans
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CD4+ T cells and CD8+ T cells, that cDC1-deficiency results in a smaller number of CD8+
T cells infiltrating the tumor, and that of the CD8+ T cells that do manage to infiltrate the
tumor when cDC1 are absent, a smaller fraction of them possess effector function.
Although numerous studies have demonstrated that cDC1 cross present antigen to prime
CD8+ T cells in a variety of tumor types

20-23, 27, 28, 30, 31

, it remains unclear whether they

prime CD8+ T cell responses in CNS tumors. Therefore, we tested the hypothesis that
cDC1 are required to prime neoantigen-specific CD8+ T cells in the GL261 preclinical
model. We previously used a cancer immunogenomics approach to identify mutant Imp3
(mImp3) as a GL261-specific, H-2Db restricted neoantigen

123

. Mice that harbor either

intracranial or subcutaneous GL261 spontaneously prime a CD8+ T cell response against
mImp3. To test the hypothesis that cDC1 are required to prime neoantigen-specific T cells
in CNS tumors, we transplanted GL261 into the brains of wild-type or IRF8+32kb-/- mice
and performed assays to assess presence and function of mImp3-specific CD8+ T cells.
We determined that tumor infiltrating lymphocytes (TIL) isolated from WT mice contained
mImp3-specific CD8+ T cells, whereas TIL isolated from IRF8+32kb-/- did not as measured
by tetramer (Figure 4-2E). We performed an orthogonal approach to assess neoantigenspecific CD8+ T cell function. Whereas CD8+ TIL isolated from wild-type mice produced
interferon gamma in response to stimulation with mImp3 peptide, equal numbers of CD8+
TIL isolated from IRF8+32kb-/- mice did not as measured by ELISPOT (Figure 4-2F).
These data demonstrate that cDC1 are required to prime functional neoantigen-specific
CD8+ T cells which can produce interferon gamma. More broadly, these data suggest that
cDC1 are required for effector T cell function in CNS tumors.
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Figure 4-2. cDC1 prime effector CD8+ T cell responses against mouse glioma. A. cDC1-quantification
in WT vs. IRF8+32-/- brain tumors. B. Survival fractions of vehicle or αPD-L1 treated WT or IRF8+32-/- mice.
C-D Average T cell composition/activation status of WT vs. IRF8+32-/- GL261 brain tumors as assessed by
flow cytometry. E-F. mImp3 neoantigen-specific CD8+ T cell response analyzed with mImp3 tetramer (E)
or IFNγ ELISPOT (F). Data are represented as mean +/- SEM of at least three independent experiments.
Survival differences in A assessed by log-rank test, C-F: student’s t-test. *** p <.001, **** p <.0001.
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4.3 Conclusion and Discussion
Here we demonstrated that cDC1 are required for CNS antitumor immunity in a preclinical
model of glioblastoma. We identified that cDC, including cDC1 are recruited to the brain
tumor microenvironment in numbers significantly greater than in the steady state. We
determined that cDC1 are required for benefit from αPD-L1 checkpoint blockade, to prime
functional CD8+ T cells, and to prime neoantigen-specific CD8+ T cell responses in GBM.
Notably, although cDC1 are essential for shaping the antitumor immune response in the
brain, the steady state brain parenchyma is largely devoid of cDC1 (and all other dendritic
cell subsets). cDC1 and other DC subsets are recruited in vast numbers into the tumor
microenvironment when mice harbor a brain tumor. It is not presently known how exactly
dendritic cells are recruited to the tumor microenvironment in the brain. Previous studies
have shown that dendritic cells are recruited to the brain during inflammation 51, 55, 56, 178181

, but these studies fall short of describing the precise mechanism by which dendritic

cells are attracted to and enter the inflamed parenchyma. Microglia are known to be a
source of pro-inflammatory cytokines 175, however it is not clear whether they function as
the sentinel immune cells responsible for instigating inflammation and secreting
chemokines to trigger recruitment dendritic cells into the tumor microenvironment, or
whether dendritic cells are able to detect the disturbance caused from brain tumors by
some other means to initiate their extravasation from the blood into the tumor
parenchyma. Future studies should distinguish if microglia are required to recruit dendritic
cells into the tumor microenvironment and should additionally identify intrinsic factors
harbored by dendritic cells required for their recruitment to the tumor microenvironment
in the CNS.
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In a clever and interesting study, Harris and colleagues showed that antigen sampling still
takes place in the steady state brain using Cre driven expression of oligodendrocyte
specific OVA, which restricted the antigen’s expression to the CNS 52. In this mouse, they
observed OVA-driven proliferation of adoptively transferred OTI T cells in the periphery,
despite OVA-expression being restricted to the CNS and despite there being no
detectable inflammation in the brain. Notably these adoptively transferred OTI T cells did
not enter the CNS in the steady state, nor did they cause disease progression when
inflammatory conditions were triggered. Although this clever study showed steady state
CNS antigen sampling takes place, these researchers did not show that dendritic cells
are required for this process to occur. Given the previous studies showing the requirement
of dendritic cells for EAE progression, and our work describing the pivotal role of cDC1 in
the CNS antitumor immune response, future experiments should determine if dendritic
cells are required for steady state antigen sampling. It is certainly conceivable that
dendritic cells still may infiltrate the parenchyma and perform immune surveillance in the
CNS in numbers too small to be appreciated by conventional experimental techniques.
Numerous studies have demonstrated that cDC1 cross present antigen to prime CD8+ T
cells in a variety of tumor types, in addition to performing other essential functions in
antitumor immunity

20-23, 27, 28, 30, 31

. Herein we demonstrate the importance of cDC1 and

show that they are absolutely required to mediate checkpoint blockade benefit and are
additionally required to prime neoantigen-specific CD8+ T cells (and effector T cells more
broadly) against CNS tumors in a preclinical model of glioma. Importantly, our studies did
not address the role of cDC2 in CNS antitumor immunity, nor did they determine if cDC1
were required for priming neoantigen-specific CD4+ T cells. Our lab is currently screening
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candidates for CD4+ T cell specific neoantigens in GL261, and we are eager to test
whether dendritic cells are required to prime neoantigen-specific CD4+ T cell cells in this
setting. Our data does suggest that cDC1 might be important for CD4+ function in brain
tumors. Although the majority of our studies focused on CD8+ T cell function given the
available tools to study neoantigen-specific T cell responses in CD8+ T cells, it was
notable that there were also fewer non-Treg CD4+ T cells infiltrating the brain tumors of
cDC1-defecient mice. It is not clear whether there were fewer CD4+ T cells as a
downstream effect of fewer CD8+ T cells having been primed by cDC1, or whether cDC1
were directly priming CD4+ T cells. A potential experiment to address this would be to
deplete CD8+ T cells in cDC1-deficient mice, and to determine whether there were still
non-Treg CD4+ T cell deficiencies. Important studies by Ferris and colleagues have
recently demonstrated that cDC1 prime CD4+ T cells when the tumor antigen is
membrane associated

26

. Thus, whether cDC1 prime CD4+ T cells in brain tumors may

depend on the origin of the antigen. Indeed, cDC2 infiltrated brain tumors in numbers that
were orders of magnitude greater than in the steady brain, however it is not clear whether
they are bystanders, merely recruited because of the increased inflammation, or whether
they additionally performed important functions there. No clean cDC2-deficient mouse
exists—the IRF4-/- mouse has additional defects beyond cDC2 deficiency, and thus the
hypothesis regarding whether cDC2 are important in CNS antitumor immunity (or
antitumor immunity more broadly) is difficult to test. Studies have shown that cDC2 can
help prime effector CD4+ T cells in antitumor immunity 24, although it was notable that the
ovalbumin antigen they used in their experiments was cytosolic, rather than membraneassociated. Furthermore, the most robust survival effects that they observed in their
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model resulted from Treg depletion. They showed that the survival benefits from Treg
depletion were reversed when they depleted CD4+ but not CD8+ T cells. They suggested
this process was cDC2-mediated given that cDC2 have been shown to prime CD4+ T
cells, and that cDC2 associated with the ovalbumin-expressing tumor could exogenously
drive OTII proliferation in their model. However, they did not actually show that cDC2 were
required to mediate survival benefit following Treg depletion. Nevertheless, important work
remains to discern the role of cDC1 in priming CD4+ T cells in brain tumors, as well as
the potential role of cDC2 in mounting CNS antitumor immunity.
Important work also remains to establish the role of cDC1 in antitumor immunity in
humans. GBM is an immune-suppressive tumor which employs a variety of mechanisms
to suppress the immune system. It is certainly conceivable that if cDC1 ordinarily bolster
CNS antitumor immunity in humans, and additionally that immune-suppressive
mechanisms of the tumor might include driving cDC1 dysregulation, exclusion, or
subversion. Nevertheless, important studies remain to answer these questions.
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CHAPTER FIVE
Lymphatic drainage, T cell priming, and durainvolvement in CNS antitumor immunity
5.1 Introduction
The cellular basis for mounting a CNS antitumor immune response is incompletely
understood. In chapter 4 we demonstrated that cDC1 play a key role in mounting CNS
antitumor immunity, however there exists a dearth of knowledge regarding the
intersection between the cellular and the anatomic basis of antitumor immunity in the
brain. The CNS does not harbor conventional lymphatics, nor does it harbor secondary
lymphoid structures

33, 49, 177, 184, 185

. This unique anatomic feature might lead one to

conclude that the CNS is therefore hermetically sealed from the immune system that
surveils the rest of the body; however, this conclusion would be incorrect. Although the
CNS does not contain conventional lymphatics, investigators have known for quite some
time that there exist mechanisms to clear debris and solutes from the brain

57, 59, 60

.

Furthermore, experiments have demonstrated that the superficial and deep cervical
lymph nodes in the neck play a supportive role both in the lymphatic drainage process
and in priming CNS immune responses (primarily in EAE models)

61-63

. However, the

complete anatomic basis for the connection between the CNS and the deep cervical
lymph nodes remained incompletely described until recently.
Two landmark studies published in 2015 (from Louveau and colleagues in Kipnis’ lab and
Aspleund and colleagues in Alitalo’s lab) described the existence bona fide lymphatic
vessels harbored by the dura and which drain the CNS in mice 64, 65. They identified that
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these lymphatic vessels traverse along the superior sagittal sinus and the venous sinuses
as they exit the skull and converge along the deep cervical lymph nodes in the neck which
rest along the internal jugular vein. Louveau and colleagues described that
intraventricular injection of liquid tracer (in the form of Evans Blue dye) led to accumulation
of tracer in both the deep cervical lymph nodes, as well as in a second lymph node chain
which lies more superficially in the neck, known as the superficial cervical lymph nodes,
but that the route to the latter lymph node chain was unclear. They also stated that tracer
reached the superficial cervical lymph nodes at later time points compared to the deep
cervical lymph nodes. Complimenting these findings, Aspleund described that brain
parenchyma-injected fluorescently labeled ovalbumin drained to the deep, but not the
superficial cervical lymph nodes, that this process required intact dura lymphatics, and
furthermore, that ligation of the lymphatic vessels along the internal jugular vein upstream
of the deep cervical lymph nodes prevented drainage of tracer to the lymph node.
In 2018 Da Mesquita and colleagues (also from Kipnis’s group) extended these findings.
They demonstrated that dura lymphatic ablation diminished solute clearance and
accelerated Alzheimer’s disease progression in a preclinical mouse model. They also
showed that conversely, administering VEGF-C to expand dura lymphatics and improve
drainage function caused greater antigen clearance from the CNS and ameliorated
cognitive deficits compared to control mice 66. A second study by Louveau and colleagues
demonstrated that ablation of dura lymphatics blunted disease severity in EAE and
prevented chemokine receptor 7 (CCR7)-dependent trafficking of CNS-originating T cells
to cervical lymph nodes. They showed this was the case when T cells had either been
injected into the cisterna magma or had originated from the dura. They also demonstrated
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that ablation of lymphatics along the cribriform plate prevented T cells from migrating from
the CNS specifically to the superficial cervical lymph nodes 67.
A clever study by Absinta and colleagues in 2017 underscored the relevance of the 2015
mouse dura studies by demonstrating the existence of dura lymphatics in primates and
humans using advanced MRI techniques. They verified the presence of lymphatic vessels
by discerning differential MRI signals in blood vessels and lymphatic vessels by
administering two different contrast agents: one that freely extravasated across
permeable endothelial barriers within capillaries, and one that did not and was confined
to the blood

68

. This allowed them to discern between blood vessels and lymphatic

vessels, which function to collect waste products that have extravasated from the blood.
They demonstrated that similar to their anatomic basis in mice, lymphatic vessels
harbored by the dura in both humans and marmosets traverse along the superior sagittal
sinus and lie in close proximity to the cribriform plate.
Relevant to our work in CNS cancer immunology, a landmark study by Song and
colleagues (of Akiko Iwasaki’s lab) published recently in 2020 described the relevance of
dura lymphatics in CNS antitumor immunity. They demonstrated that VEGF-C agonism
could expand the dura lymphatics to strengthen the CNS antitumor immune response,
and that in this scenario the CD8+ T cell response against the tumor was more potent
than in control mice with unexpanded dura lymphatics. Additionally, they demonstrated
that VEGF-C agonism could improve survival following orthotopic transplantation of
glioma cells compared to control mice that had normal unexpanded dura lymphatics.
Importantly, they determined that ligating the lymphatic vessels that drained to the deep
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cervical lymph nodes could abrogate the antitumor immunity benefit conferred by VEGFC agonism 69.
Adjacent to the studies describing the anatomic basis and immunologic importance of
CNS lymphatic drainage, important studies by Fabry’s group have demonstrated
evidence for antigen presenting cell migration from the CNS to cervical lymph nodes.
They made the important discovery that under certain conditions dendritic cells injected
into the brain parenchyma migrate to the cervical lymph nodes in a CCR7-dependent
manner 54, 179, 186. These findings hinted at the cellular basis for lymphatic drainage of the
CNS, however they were limited in that they introduced exogenously cultured monocytederived dendritic cells into the brain parenchyma and fell short of describing process as
it occurs endogenously. Moreover, these studies did not implicate any particular dendritic
cell subset known to arise naturally in mice—they used GM-CSF/IL-4 cultured monocytederived dendritic cells rather than Flt3L cultured dendritic cells, which much more closely
approximate conventional dendritic cells as they occur in vivo 25, 187-190.
Taken together, these fundamental discoveries highlight the critical role of dura
lymphatics in priming immunity in the CNS, and thus provide a framework for our
understanding of the anatomic basis for lymphatic drainage of the CNS. The studies
originating from Fabry’s lab, which provide the strongest evidence for a possible cellular
mechanism of priming immunity in the CNS, fall short of describing the endogenous
cellular basis for the connection that exists between the brain, the dura lymphatic system,
and the cervical lymph nodes. Thus, there remains an incomplete understanding of the
cellular basis for lymphatic drainage in the context of CNS-antitumor immunity, and how
dendritic cells might or might not be involved.
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Given the incomplete understanding regarding the cellular basis for lymphatic drainage
of the CNS, we set out to determine the relevance of endogenously arising dendritic cells
in lymphatic drainage in the setting of CNS tumors. Herein we demonstrate that
endogenously arising tumor antigen-containing dendritic cells can be isolated from the
tumor, the dura, and the cervical lymph nodes. Moreover, we show that dendritic cells in
the dura undergo dynamic changes in responses to CNS tumors, and that cDC1
specifically appear in the dura lymphatic vessels in both the tumor-bearing and the steady
state settings. Finally, we describe that CD8+ T cell priming and clonal expansion for CNS
antitumor immune responses occurs in the cervical lymph nodes, rather than in the dura
or any other secondary or tertiary lymphoid organ, which takes place before terminally
divided effector CD8+ T cells home to the brain tumor. Together, our findings unravel
clues about the mechanism of lymphatic drainage and T cell priming in antitumor
immunity of the brain.

5.2 Results
5.2.1 Endogenously arising tumor antigen-containing cDC1 appear in the tumor and
cervical lymph nodes
Our current model of cDC1 function is that they phagocytize antigen at the periphery,
activate, upregulate chemokine receptor 7 (CCR7) as well as MHCII, migrate to
secondary lymphoid tissues, and present phagocytosed and processed antigen to prime
naïve T cells. While the brain parenchyma lacks secondary lymphoid tissue and
conventional lymphatics, compelling data have strongly suggested that the extracranial
cervical lymph nodes are critical to prime CNS antigen-specific T cells

54, 65, 69, 178-180

. To

determine if tumor antigen-containing cDC1 appeared in the brain or in these secondary
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lymphoid structures, we exploited the property that conventional dendritic cells
phagocytize target material, activate, and migrate to draining lymph nodes. To this end,
we hypothesized (a) that fluorescent protein overexpressed by the tumor would be
ingested by infiltrating dendritic cells as phagocytized tumor cells or tumor-associated
debris, and (b) that this transferred tumor-derived fluorescent protein could be retained
by and detected within dendritic cells using a flow cytometer, similar to the techniques
used by Merad and Krummel in preclinical melanoma models 22-24.
We generated two fluorescent orthotopic glioma lines: GL261-zsGreen and CT2AzsGreen. The premise of the experiment relies on the principle that when transplanted
into mice, the tumor-derived zsGreen is ingested by infiltrating antigen presenting cells
and can be used as a detectable surrogate for tumor antigen phagocytosis (Figure 5-1A).
Because CT2A-zsGreen tumors most consistently and robustly retained zsGreen
expression at the time of harvest, we used this model for most of the dendritic cell/tumor
antigen tracking experiments we performed. To test the hypothesis that cDC1 which
infiltrate the brain tumor uptake tumor-derived antigen, we transplanted CT2A-zsGreen
tumor cells into the brains of mice and monitored for the presence of zsGreen-containing
cDC1 (and other endogenously arising dendritic cell subsets) by flow cytometry at two
weeks post-transplantation. In CT2A-zsGreen tumors, we identified zsGreen not only
within tumor-infiltrating cDC1, but additionally within cDC2, monocyte-derived dendritic
cells (MoDC), and plasmacytoid dendritic cells (pDC) (Figure 5-1B). These data suggest
that all of these dendritic cell populations share the ability to ingest tumor-derived antigen
in vivo. Importantly, we did not detect zsGreen-containing dendritic cells within the nontransduced, non-fluorescent CT2A control mice, which suggests that the phenomenon
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we observed was specific to the presence of tumor-derived zsGreen protein. In addition
to the tumor itself, we examined the ipsilateral superficial and deep cervical lymph nodes
(cLN) to determine whether tumor antigen containing dendritic cells could be observed
extracranially. We identified zsGreen+ cDC1 (both migratory CD103+CD8α- and resident
CD8a+CD103- subsets) in the superficial cLN, and zsGreen+ migratory cDC1 in the deep
cLN (Figure 5-1C, 5-1D). Notably a larger percentage of migratory cDC1, which
presumably migrated from the tumor itself, were zsGreen+ compared to resident cDC1 in
both lymph node sets. We also identified zsGreen+ cDC2, MoDC and pDC in the
superficial cLNs, and zsGreen+ MoDC in the deep cLNs (Figure 5-1C, 5-1D). Notably, the
presence of zsGreen within dendritic cells was not restricted to the cDC1 subset, which
suggests that while cDC1 are essential to prime an effective CNS antitumor immune
response, other dendritic cell subsets are capable of ingesting and trafficking tumorassociated protein to cervical lymph nodes.
5.2.2 CCR7 is required for dendritic cells to traffic tumor antigen from the brain to
cervical lymph nodes
Having determined that tumor antigen containing cDC1, cDC2, MoDC and pDC infiltrated
the tumor and appeared in the cervical lymph nodes within the neck, we considered the
possibilities by which tumor antigen containing cDC might appear within the cervical
lymph nodes. We envisaged two potential mechanisms for trafficking tumor antigen to
draining lymph nodes. As the first possibility, we considered that dendritic cells might
infiltrate the tumor, activate, upregulate CCR7, and migrate down a chemokine ligand
19/21 gradient to carry the antigen that they had ingested to a draining lymph node via
CCR7-mediated chemotaxis
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(in short, active migration). Second, we that considered
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the alternative possibility that tumor antigen would be expelled or lost from the tumor as
debris, make its way into a lymphatic vessel, and flow down a pressure gradient toward
an awaiting dendritic cell native to the lymph node, without being carried there by a
migrating dendritic cell trafficking from tumor to the draining lymph node (in short, passive
migration). Moreover, we considered that both processes could take place
simultaneously. Because there was a predominance of zsGreen within migratory rather
than resident cDC1 subsets, we hypothesized that active, cell-mediated antigen
trafficking is the predominant mechanism by which zsGreen+ tumor antigen containing
dendritic cells appear within draining cervical lymph nodes.
To address this question, we tested the hypothesis that CCR7 is required for zsGreen+
dendritic cells to appear within the cervical lymph nodes. CCR7-/- mice lack migratory
dendritic cell subsets, therefore we did not distinguish between migratory cDC1 and
resident cDC1 in our analysis of lymph nodes, and instead included all cDC1 together as
XCR1+ cDC in our analysis. To test our hypothesis, we transplanted CT2A zsGreen
glioma cells into the brains of wild-type (WT) or CCR7-/- mice and monitored the zsGreen
signal within dendritic cells isolated from the tumors and from the cervical lymph nodes.
We first investigated the tumor microenvironment itself. Importantly, we identified equal
proportions of tumor-infiltrating zsGreen+ cDC1 (as well as other DC subsets) in both WT
and CCR7-/- mice (Figure 5-1E). This suggested that dendritic cells which arose in either
WT or CCR7-/- mice were capable of infiltrating the tumor and ingesting tumor antigen,
and that any potential defect we might observe in CCR7-/- mice was downstream (in terms
of lymphatic drainage) from the tumor microenvironment itself. We next investigated the
CNS-draining cervical lymph nodes. In contrast to WT mice, CCR7-/- mice which bore
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CT2A-zsGreen brain tumors had a significantly diminished zsGreen signal in cDC1
isolated from both the superficial and the deep cervical lymph nodes (Figure 5-1E). This
observation of a diminished zsGreen signal in CCR7-/- mice compared to WT mice also
held true for pDC from both the deep and superficial cLN, as well as MoDC from the
superficial cLN (Figure 5-1E). Importantly, small but equal fractions of B cells isolated
from cervical lymph nodes from WT or CCR7-/- mice were zsGreen+ (Figure 5-1E), which
suggests that passive migration from the periphery still took place independent of CCR7
expression since B cells are not known to migrate from the periphery to draining lymph
nodes in contrast to dendritic cells.
Notably, the zsGreen signal was incompletely extinguished from dendritic cells isolated
from lymph nodes of CCR7-/- mice. This phenomenon was not uniform across replicates—
most of the CCR7-/- mice with a zsGreen signal had only a small percentage of dendritic
cells which were zsGreen+ within the cLN. However, a select few CCR7-/- mice harbored
cLN zsGreen+ dendritic cell percentages comparable to WT counterparts. This suggests
that under certain conditions, there exist cell-migration independent mechanisms to traffic
tumor antigen from the brain to cLN, but that active, cell-mediated trafficking
predominates. Together with our observation that cDC1 are required to mount effective
antitumor immune responses in the CNS, these data collectively suggest that cDC1 do
so in part by infiltrating the brain tumor, phagocytizing tumor antigen, and migrating with
that phagocytosed tumor antigen to the cervical lymph nodes in a CCR7/cell migrationdependent fashion.
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Figure 5-1. cDC1 isolated from TIL and CNS-draining cervical lymph nodes retain tumor antigen. A.
Fluorescence transfer conceptual outline. B. zsGreen retention by DC infiltrating the tumor. C. zsGreen
retention in deep cLN and D. superficial cLN dendritic cells. E. zsGreen retention by DC harbored by the
tumor, the deep cLN, and the superficial cLN of WT vs. CCR7-/- mice. Data are represented as mean +/SEM of at least three independent experiments, student’s t-test to determine significance. * p<0.05,
**p<0.01, ****p<0.0001. Grubbs outlier test was used to eliminate both a WT and a CCR7-/- outlier in E.
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5.2.3 Dura-associated cDC1 undergo dynamic changes in response to GBM
Having determined that cDC1 are critical for mounting neoantigen-specific CD8+ T cell
responses against brain tumors as well as for priming CNS antitumor immunity more
broadly, and also having determined that cDC1 perform their role in part by ingesting
tumor antigen at the site of the tumor and trafficking that antigen to the cervical lymph
nodes, we next investigated their function in the dura, which consists of the fibrous sheath
covering the brain and lies just beneath the periosteum on the inner surface of the skull.
The dura has been increasingly recognized as an immunologically dynamic location that
in the steady state harbors a diverse composition of leukocytes, including all dendritic cell
subsets, as well as macrophages, T cells, and B cells among other cell types. In contrast,
the only steady state brain parenchymal leukocytes are microglia

49, 55

. In addition to

harboring immune cells in the steady state, the dura also contains lymphatic vessels
which traverse alongside the venous sinuses and drain to the deep cervical lymph nodes
64, 65, 69, 191

. More recently, studies have demonstrated that VEGF-C induced hyperplasia

of dura lymphatics strengthened the CNS antitumor immune response

69

. Given these

features, and the growing recognition of the importance of the dura for immune responses
in the CNS, we investigated if there were any immunologic changes in the dura which
were associated with the CNS antitumor immune response.
We determined the presence and location of dura-associated cDC1 using 2-photon
microscopy and the same SNX22GFP/+ mouse we had used previously. We first began by
examining the dura with 2-photon microscopy in both the tumor-bearing and sham-treated
control state. In both mice that harbored GL261-OFP brain tumors or were sham-injected,
the dura harbored extravascular cDC1 near the superior sagittal sinus (Figure 5-2A). We
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hypothesized that the number of cDC1 harbored by the dura would increase in mice that
harbored intracranial GL261. To address this question, we used flow cytometry due to its
capability regarding quantifying the total number of a particular cell type within a tissue.
Compared to sham-injected control mice, mice bearing GL261 brain tumors harbored
increased numbers of cDC, cDC1, cDC2, MoDC and pDC within their dura when
measured quantitatively by flow cytometry (Figure 5-2B).
We next examined whether the growth factor responsible for dendritic cell development,
Flt3L, could also expand the population of dura-associated cDC1. Previous work
identified that Flt3L could drive expansion of CD11c+, I-Ab+ cells within the dura

177

, and

a second study identified that Flt3L administration could specifically expand both cDC1
and cDC2 subsets harbored by the whole brain and surrounding meninges, which
includes the dura

49

. We expanded on these findings and included specifically in our

analysis measurement of the effects of Flt3L on dura-associated cDC1. Compared to
control-treated mice, mice treated by Flt3L had a significantly expanded cDC1 population
(as well as other DC subsets) within their dura as measured by flow cytometry (Figure 52C). Consistent with our observations using flow cytometry, we also observed expanded
dura-associated cDC1 in the SNX22GFP/+ mouse using 2-photon microscopy. Compared
to control-treated mice, Flt3L-treated mice harbored dramatically more cDC1 within their
dura near the lambda region of the skull (Figure 5-2D), which primarily localized to the
dura adjacent to the superior sagittal sinus when we examined a larger field (Figure 52E). Notably, although both brain tumors and systemic Flt3L administration were both
sufficient to drive expansion of dura-associated cDC1 (as well as all other DC subsets we
examined), the magnitude of expansion was much greater from Flt3L administration.
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Figure 5-2. Mouse dura harbors Flt3L-sensitive tumor-responsive dendritic cells. A. 2-photon
microscopy of SNX22GFP/+ mouse dura along the superior sagittal sinus depicting sham vs. GL261 OFP
intracranially injected mice. B. Dura DC quantified by flow cytometry from sham vs. GL261 injected brains
at d14 post-tumor injection, and C. Dura DC quantified by flow cytometry from -Ctrl vs. Flt3L treated mice.
D. Near Lambda or E. Full view 2-photon microscopy of SNX22GFP/+ mouse dura of -Ctrl vs. Flt3L treated
mice. For both samples in E, superior sagittal sinus runs horizontally from rostral to caudal in the middle of
each image. Data are represented as mean +/- SEM of at least three independent experiments. Student’s
t-test used to determine significance, * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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These data suggest that while both stimuli (brain tumors an Flt3L overexpression)
expanded the dendritic cell populations harbored within the dura, that the mechanism of
and precise factors driving expansion may have differed between each stimulus.
5.2.4 Dura-associated cDC1 reside in lymphatic vessels and contain tumor antigen
In addition to harboring a diverse population of immune cells, the dura is vested with
lymphatic vessels which traverse parallel and immediately adjacent to the superior
sagittal sinus, and which deliver lymph to the deep cervical lymph nodes in the neck 64, 65,
69, 191

. Lymphatic vessels associated with the dura also drain to the superficial lymph

nodes via a separate route that traverses through the cribriform plate, parallel to the
olfactory nerve roots

67

, although the complete pathway for this route is less well

characterized. To examine the spatial relationship between dura and cDC1, we crossed
the SNX22GFP/GFP cDC1 reporter mouse with the Prox1-Cre-tdTomato+/+ lymphatic vessel
reporter mouse, which expresses the tdTomato fluorophore in lymphatic vessels after
tamoxifen administration 192. The resultant F1 mice have both GFP+ cDC1 and tdTomato+
lymphatic vessels post-tamoxifen administration. Using these mice and 2-photon
microscopy, we confirmed that the dura harbors lymphatic vessels which run parallel to
the superior sagittal sinuses and along venous sinuses as they diverge from the superior
sagittal sinus (Figure 5-3A), consistent with previous reports 64, 65, 69, 191. Within the dura,
we also identified several instances of tomato/GFP signal overlap in all 3 dimensions,
indicative of cDC1-lymphatic vessel spatial overlap. This suggests that the dura lymphatic
vessels contained cDC1. This was true both when mice harbored intracranial GL261-OFP
(Figure 5-3B) or were instead sham injected (Figure 5-3C). These data suggest that dura-
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associated lymphatic vessels support cDC1 migration from the CNS to draining lymph
nodes both in the tumor-bearing state as well as in the steady state.
Given our observations that the dura harbors cDC1, some of which can be localized to
within lymphatic vessels, and given our observations that tumor antigen-retaining
dendritic cells appeared in cervical lymph nodes in a CCR7/cell migration-dependent
manner, we hypothesized that a small fraction of dura-associated cDC1 might also harbor
tumor antigen in the setting of brain tumors. Because CT2A-zsGreen retained highest
levels of zsGreen expression at the time of harvest compared to GL261-zsGreen, we
used the CT2A-zsGreen model to assess for presence of tumor antigen within duraassociated cDC1. To test the hypothesis that a subset of dura-associated cDC1 contain
tumor antigen in the brain tumor setting, we transplanted CT2A-zsGreen tumor cells
intracranially and monitored for zsGreen within cDC1, as well as other DC subsets, by
flow cytometry. We selected an early time point to ensure that tumors were small and
confined to within the brain parenchyma. We also resected the dura that surrounded the
injection site to avoid potential contamination of the dura samples by tumor which may
have engrafted near the cerebral surface apposed to the dura. This phenomenon
sometimes happens because of reflux or from leaving behind trace amounts of tumor
cells along the needle trajectory during tumor cell transplantation. Using flow cytometry,
we simultaneously observed zsGreen+ migratory cDC1 in the tumor itself, the dura, the
superficial cervical lymph nodes, and the deep cervical lymph nodes (Figure 5-3D).
Importantly, we did not observe CD45-/zsGreen+ cells within the dura, which indicates
that our dura samples were not contaminated by tumor infiltrate, and that the zsGreen+
cDC1 observed in dura samples were truly dura-associated rather than tumor-infiltrating.
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Figure 5-3. Mouse dura lymphatic vessels harbor cDC1 and dura-associated cDC1 retain tumor
antigen. A. Dura from intracranial GL261 OFP-bearing, tamoxifen treated SNX22GFP/+ x Prox1-CretdTomato+/- mice. Superior sagittal sinus running horizontally across the page from rostral to caudal. B.
Same sample as in A rotated 90º counterclockwise, near lambda: cDC1 visualized in lymphatic vessels. C.
cDC1 visualized in a lymphatic vessel in Sham-injected mice with dura in same orientation in B. D. Tumor,
dura, deep and superficial cLN-associated migratory cDC1 zsGreen retention. E. zsGreen retention
quantified across all dendritic cell subsets. Dura samples with CD45-/zsGreen+ cells were excluded from
analysis. Data represent as mean +/- SEM of at least three independent experiments, student’s t-test to
determine significance, * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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While our work has demonstrated the importance of cDC1 specifically in priming the CNS
antitumor immune response, notably the phenomenon of tumor antigen retention by
dendritic cells was not restricted to cDC1; we observed detectable levels of zsGreen
within cDC2, MoDC and pDC that had been isolated from the tumor, the dura, the deep
cervical lymph nodes, and the superficial cervical lymph nodes (Figure 5-3E). The
dynamic changes of the dura when mice have brain tumors, including the expanded
population of Flt3L-sensitive cDC1, the presence of cDC1 within lymphatic vessels, and
the evidence for cell-mediated tumor antigen trafficking collectively suggest that the dura
plays a supportive role in mounting CNS antitumor immune responses.
5.2.5 CD8+ T cell priming and clonal expansion occurs in cervical lymph nodes
Where in the body a CNS antitumor immune response is primed remains an open
question. We have demonstrated evidence for the essential role of cDC1 in this process,
as well as evidence for cell-mediated tumor antigen trafficking by cDC1 from the tumor to
the superficial and deep cervical lymph nodes, with the dura likely playing a supportive
role in this process. However, these observations do not address the nature of T cell
priming and clonal expansion, which lie downstream of antigen uptake and trafficking by
dendritic cells. Multiple previous observations implicate the role of cervical lymph nodes
in CNS immune responses. First, lymphadenectomy of cervical lymph nodes decreased
EAE disease burden in rodents

61-63

. Second, ablation of dura lymphatics lessened

disease incidence in an EAE model and was shown in the same set of experiments to
decrease the CD11c+-T cell interactions in cervical lymph nodes compared to control
mice 67. Third, expansion of dura lymphatics using VEGF-C agonism has been shown to
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bolster CNS-antitumor immunity and could be reversed by ligating the lymphatic vessels
which drain to the deep cervical lymph nodes 69.
Because we identified tumor antigen-harboring dendritic cells in the tumor, the dura, and
the CNS-draining cervical lymph nodes, we considered the possibilities of where CD8+ T
cell priming might occur in the setting of CNS antitumor immunity, and included in our
analyses the tumor itself, the dura, the cervical lymph nodes, and the spleen. We also
included in our analysis the presumably non-CNS-draining inguinal lymph node as an
additional control. To address the question of where CD8+ T cell priming occurs in this
setting, we tracked the cell division of adoptively transferred OT-I CD8+ T cells in vivo in
mice that harbored intracranial GL261 transduced with full length cytosolic ovalbumin
(GL261-OVA). In addition to an I-Ad/MHCII-restricted antigen, ovalbumin also contains in
its amino acid sequence the H-2Kb/MHCI-restricted antigen SIINFEKL, which engages
the OT-I T cell receptor of an adoptively transferred (or endogenously arising) OT-I T cell
receptor when presented on the H-2Kb/MHCI protein

193

. Engagement of this T cell

receptor and priming by a dendritic cell can cause the OT-I T cells to activate, divide, and
clonally expand. The adoptively transferred OT-I T cells can themselves be tracked by
congenic expression of unique CD45 alleles whose identity differ between the host and
the adoptively transferred cells. Division can be measured by labeling the adoptively
transferred OT-I T cells with the protein-binding fluorophore carboxyfluorescin
succinimidyl ester (CFSE). CFSE cannot be expelled from the OT-I T cells and can only
be proportionally divided between daughter cells. This dilution, which results only from
cell division, can be detected on a flow cytometer as a weaker fluorescent signal
compared to parental un-divided adoptively transferred CFSE-high OT-I T cells. The
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CFSE dilution can be treated as a surrogate for antigen presentation to OT-I T cells. We
crossed a C57BL/6 CD45.1+/+ mouse with a C57BL/6 CD45.2+/+OT-I mouse and used the
resultant F1 mouse to purify CD45.1+CD45.2+ OT-I CD8+ T cells for adoptive transfer
experiments.
We transplanted GL261-OVA tumor cells into the brains of CD45.2+/+ C57BL/6 WT mice
and adoptively transferred CFSE labeled CD45.1+CD45.2+ OT-I T cells 4 days after tumor
transplantation. At both 3 and 6 days after the adoptive transfer (days 7 and 10 posttumor transplantation), we harvested the region of brain where the tumor cells had been
transplanted, the dura, the ipsilateral superficial and deep cervical lymph nodes, the
spleen, and the non-CNS-draining contralateral inguinal lymph node. In each of these
tissues we determined the degree of OT-I cell division with flow cytometry by measuring
CFSE dilution in the congenically labeled OT-I T cells (Figure 5-4A).
We envisaged the different concentrations of CFSE (low, mid, and high) harbored by OTI T cells to reflect how much cell division a parent cell had undergone as a result of being
activated by cognate antigen presentation. We imagined CFSE-high to reflect un-divided
naïve OT-I T cells, CFSE-mid to reflect early primed OT-I T cells (which might
preferentially localize to a draining lymph node), and CFSE-low to reflect terminally
divided OT-I T cells (which might preferentially localize to the effector site).
At 3 days post-adoptive transfer of OT-I T cells (seven days total after tumor implantation),
we observed the greatest fraction (as a percentage of CD45+/live cells) of undivided/naïve
CFSE-high OT-I T cells in the lymph nodes, with no difference between any of the lymph
nodes taken from different regions in the body. We observed the next highest fraction in
the spleen, but there were significantly fewer than in the lymph nodes We observed a
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near complete absence of CFSE-high OT-I T cells in both the dura and the tumor region,
when compared to the spleen or the lymph nodes (Figure 5-4B). CFSE-mid, initially
divided OT-I T cells occupied the greatest percentage of the CD45+/live compartment in
the CNS-draining superficial and deep cervical lymph nodes, with significantly more there
than in any of the other organs (Figure 5-4B). CFSE-low terminally divided OT-I T cells
were rare but occurred in greatest frequency in the deep cervical lymph node compared
to the dura or the inguinal lymph node, with no differences between any of the other
organs (Figure 5-4B). Collectively, this demonstrated that OT-I T cell priming and clonal
expansion preferentially took place in the CNS-draining cervical lymph nodes when
compared to other lymphoid organs, the dura, or the tumor itself. This early time point
captured the first stages of clonal expansion, which was also reflected by a paucity of
terminally divided OT-I cells within the tumor, the presumed effector site.
At 6 days post-adoptive transfer, we observed a similar pattern as at 3 days post-adoptive
transfer with a few notable distinctions. CFSE-high naïve OT-I T cells persisted in the
lymph nodes and spleen when compared to other organs similar to 3 days post-adoptive
transfer. (Figure 5-4C). We also observed a similar pattern compared to 3 days postadoptive transfer with CFSE-mid early divided OT-I T cells: predominance in the CNSdraining superficial and deep cervical lymph nodes, although the fraction of CFSE-mid
OT-I T cells in the cervical lymph nodes had decreased when compared to day 3 postadoptive transfer. The notable contrast between day 3 and day 6 post-adoptive transfer
occurred in the CFSE-low terminally divided OT-I T cells. In contrast to day 3 postadoptive transfer, when CFSE-low terminally divided OT-I T cells were not prevalent in
any of the tissues analyzed, they predominated in the tumor region and in the dura at day
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6 post-adoptive transfer. They occupied a significantly greater fraction of CD45+/live cells
in the tumor than in any of the lymph nodes (Figure 5-4C). Interestingly by day 6 postadoptive transfer, CFSE low cells had also expanded systemically (beyond just the tumor
region). They also appeared in the spleen and in the non-draining inguinal lymph node
(Figure 5-4A). Interestingly, we did not observe OT-I cells of any CFSE dilution in the
majority of dura samples in our experiments. However, in the isolated samples in which
we did, they were always terminally divided, CFSE-low OT-I cells. The absence of earlydivided CFSE-mid OT-I T cells in the dura indicates that the dura was not a site of T cell
priming, despite being vested with lymphatic vessels and being considered an anatomic
location of dynamic immunologic activity. We also never observed CFSE-mid, early
primed, OT-I cells in organs other than the superficial and deep cervical lymph nodes,
which suggests that the cervical lymph nodes are where T cell priming takes place in the
setting of CNS antitumor immunity. This comports with our understanding that the cervical
lymph nodes form the terminus of lymphatic vessels which drain the CNS. These data
collectively suggest that in this setting, CD8+ T cells are primed in the cervical lymph
nodes to mount a CNS antitumor immune response, and that the dura or the tumor itself
are sites of effector function rather than of CD8+ T cell priming.
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Figure 5-4. Clonal expansion of OT-I CD8+ T cells occurs in CNS-draining cervical lymph nodes. A.
CD44 expression and CFSE dilution of OT-I CD8+ T cells assessed by flow cytometry at day 3 and day 6
post-adoptive transfer of ipsilateral superficial cLN, ipsilateral deep cLN, cerebral hemisphere region
encompassing tumor, dura (with tumor abutting region resected), spleen, and non-draining contralateral
inguinal LN. Cells gated on Live, CD45.1+, CD45.2+, CD4-, Dump- (CD19, CD11b, CD11c, F4/80, Nk1.1),
CD3ε+, CD8α+, TCR-Vα2+/Vβ5+. B-C. Quantitation of CFSE-high, mid, and low OT-I CD8+ T cells at 3 (B)
and 6 (C) days post-adoptive transfer. Data represented as mean +/- SEM of at least three independent
experiments, single comparisons using students t-test, * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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5.2.6 cDC1 and CCR7 are required for early CD8+ T cell clonal expansion
Given our observations that cDC1 are required to endogenously prime neoantigenspecific CD8+ T cell responses against CNS tumors, and that CCR7 is required to traffic
tumor antigen from brain tumors to CNS-draining cervical lymph nodes, we investigated
whether absence of cDC1 or deletion of CCR7 affected clonal expansion of adoptively
transferred OT-I T cells in mice that harbored GL261-OVA brain tumors. We used the
same method as in the previous experiment described and harvested tissues at the same
time points as previous adoptive transfer experiments, but did the experiment in WT,
CCR7-/-, or IRF8+32kb-/- mice. However, we did not discern between CFSE-low, CFSEmid, and CFSE-high OT-I CD8+ T cells, we simply characterized OT-I CD8+ T cells as
“divided” if they had diminished CFSE expression due to cell division.
We hypothesized that absence of CCR7 or cDC1-deficiency would lead to defective
clonal expansion of OT-I CD8+ T cells, given the requirement of CCR7 for trafficking tumor
antigen from brain tumor to cervical lymph nodes, and also given the requirement of cDC1
in priming neoantigen-specific CD8+ T cell responses as demonstrated by our previous
experiments. We transplanted GL261-OVA into brains of WT, CCR7-/-, or IRF8+32kb-/mice, adoptively transferred OT-I T cells 4 days after tumor induction, and measured
CFSE dilution of OT-I CD8+ T cells at days 3 and 6 post-adoptive transfer of the OT-I
CD8+ cells. Compared to WT mice, CCR7-/- and IRF8+32kb-/- mice had decreased clonal
expansion of OT-I CD8+ T cells in the superficial cervical lymph nodes, the deep cervical
lymph nodes, and the spleen, but not the tumor, the dura, or the inguinal lymph node at
3 days post-adoptive transfer (Figure 5-5A).
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Notably, in contrast to day 3, we observed minimal differences in clonal expansion
between WT, CCR7-/-, and IRF8+32kb-/- mice in the organs examined at 6 days postadoptive transfer (Figure 5-5B). Interestingly there were more congenically marked,
expanded OT-I CD8+ T cells in the superficial cervical LNs of CCR7-/- compared to WT
mice at day 6 post-transfer. At the same timepoint in the spleen, there were modestly but
not significantly fewer expanded OT-I CD8+ T cells in CCR7-/- compared to WT mice.
Moreover, at day 6 post-adoptive transfer there significantly fewer expanded OT-I CD8+
T cells in the spleens of IRF8+32kb-/- compared to WT mice.
These data collectively demonstrate that absence of intact cell migration to lymph nodes
(reflected in CCR7-/- mice), and deficiency of cDC1 (reflected in IRF8+32kb-/- mice) both
lead to delayed clonal expansion of adoptively transferred OT-I CD8+ T cells against
tumor-specific antigens expressed by brain tumors. However, it was notable that clonal
expansion of OT-I CD8+ T cells still occurred with varying degrees at the later day 6 postadoptive transfer time point in mice with these defects. This suggests two things: first, if
given enough time in CCR7-/- mice, tumor antigen can still passively drain to the cervical
lymph nodes in amounts great enough to drive clonal expansion of adoptively transferred
OT-I CD8+ T cells without being carried there by dendritic cells. Second, that cell types
other the cDC1 can drive clonal expansion of adoptively transferred CD8+ T cells, albeit
they carry out this task less efficiently as evidenced by clonal expansion being delayed in
most organs until day 6 post-adoptive transfer our experiments. However, these data still
underscore the importance of cell migration and the cDC1 subset in priming an effective
CD8+ T cell response against CNS tumors that develops and expands with normal
kinetics.
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Figure 5-5. cDC1 and CCR7 are required for early clonal expansion of adoptively transferred OT-I
CD8+ T cells. A-B. CD44 x CFSE of OT-I CD8+ T cells analyzed by flow cytometry at day 3 (A) and day 6
(B) post-adoptive transfer, in ipsilateral superficial cLN, ipsilateral deep cLN, cerebral hemisphere region
encompassing tumor, dura (with tumor abutting region resected), spleen, and non-draining contralateral
inguinal LN. Cells gated on Live, CD45.1+,CD45.2+, CD4-, Dump- (CD19, CD11b, CD11c, F4/80, Nk1.1),
CD3ε+, CD8α+, TCR-Vα2+/Vβ5+. Data represented as mean +/- SEM of at least three independent
experiments, single comparisons using students t-test, * p<0.05, **p<0.01, ***p<0.001.
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5.3 Conclusion and Discussion
Here we show that cDC1 (along with other dendritic cell subsets) infiltrate the tumor and
acquire tumor antigen there. We also show that tumor antigen bearing dendritic cells can
be isolated from the dura, and that they traffic tumor antigen to the lymph nodes in a
CCR7-dependent manner. We determined that dura-associated Flt3L-sensitive cDC1
(along with other dendritic cell subsets) additionally expand their population in response
to the stimulus of an intraparenchymal tumor within the brain, and that some cDC1
harbored by the dura specifically localize to the dura lymphatic vessels. Further, we show
that CD8+ T cell priming and clonal expansion of adoptively transferred CD8+ T cells that
recognize CNS tumors takes place in the CNS-draining cervical lymph nodes rather than
in the spleen, non-draining lymph nodes, the tumor, or the dura. Moreover, we show that
clonal expansion of adoptively transferred OT-I CD8+ T cells requires CCR7 expression
and intact cDC1 in order to take place with normal kinetics.
Previous work in EAE models demonstrated that the cervical lymph nodes play a role in
CNS immune responses: resection of cervical lymph nodes was shown to dampen
severity of EAE disease in mice and rats

61-63

. Studies by Kipnis and Alitalo also

highlighted the role of the cervical lymph nodes in lymphatic drainage of the CNS

64, 65

.

Moreover, studies by the Iwasaki lab showed that VEGF-C administration in the brain
tumor setting expanded dura lymphatics, which both drove expansion of the neoantigenspecific CD8+ T population in the deep cervical lymph nodes and improved survival
compared to control mice with brain tumors 69. Importantly, they also identified that ligation
of the CNS draining lymphatic vessels in the neck could reverse the beneficial effect of
VEGF-C on CNS antitumor immunity 69. Given the importance of cervical lymph nodes in
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lymphatic drainage of the CNS, and given our experiments demonstrating the importance
of cDC1 in priming CNS antitumor immunity, we investigated how endogenously arising
cDC1 might play a role in lymphatic drainage and tumor antigen trafficking from the CNS.
We utilized the traceable fluorophore zsGreen in our experiments as a surrogate for tumor
antigen uptake, trafficking, and presentation. A similar approach was used by Krummel’s
and Merad’s labs: each group determined that dendritic cells in draining lymph nodes
contained tumor-derived fluorescent protein

21-24

. This experiment is only possible with

fluorophores which fluoresce brightly, fluoresce at a low pH, and resist degradation in
lysosomes. Conventional fluorophores like GFP do not meet those criteria and are
degraded too rapidly to be observed in draining lymph node dendritic cells, although GFP+
dendritic cells could be observed within the tumor in our preliminary experiments with
GL261-GFP tumors. zsGreen fulfills those criteria and fluoresces extremely brightly,
fluoresces at low pH, and resists degradation in lysosomes. These features make it an
ideal candidate for study of antigen trafficking.
Interestingly, Krummel’s group determined that the cDC1 was the primary dendritic cell
subset in the lymph nodes which contained tumor-associated fluorophore when they used
mCherry to label their tumors; however, when they instead used zsGreen, they found that
zsGreen was distributed across both cDC1 and cDC2 subsets, as well as monocytes and
macrophages in the lymph node

23

. They reasoned that this was because zsGreen was

a more robust fluorophore and persisted for long enough to be “handed off” from the cDC1
to other dendritic cell subsets. In a more recent report, Krummel’s group underscored the
importance of cDC2 of priming the CD4+ T cell response against soluble ovalbuminexpressing B16 melanoma tumors. In that report, they identified highest levels of
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trafficking of zsGreen to lymph nodes by cDC2 and monocyte-derived DC, although
significant zsGreen trafficking by cDC1 occurred as well 24. In our experiments, zsGreencontaining antigen presenting cells across all subsets: cDC1 (predominantly migratory),
cDC2, MoDC, and pDC appeared in both the superficial and deep cervical lymph nodes
at multiple time points following tumor induction. It was impossible in our experiments to
discern whether the surrogate tumor antigen was carried to the lymph node by cDC1 and
then passed off to other dendritic cell subsets, or whether that antigen was carried to the
lymph node by a non-cDC1 dendritic cell in the first place. Our results as well as the
results described by Krummel’s group suggest that multiple dendritic cell subsets within
draining lymph nodes harbor tumor antigen and potentially carry tumor antigen there.
However, our experiments showed that the cDC1 are absolutely required to prime an
endogenous neoantigen-specific CD8+ T cell response in mice, and further, that mice
harboring intracranial checkpoint-responsive GL261 glioblastoma require cDC1 to derive
benefit from αPD-L1 therapy.
An important caveat of the transfer of fluorescence observations is that they still leave
open the question regarding the precise behavior of dendritic cells when they phagocytize
target material. When a dendritic cell phagocytizes tumor-associated zsGreen, it is
possible that (a) the dendritic cell phagocytizes an apoptotic or necrotic tumor cell, (b)
that it phagocytizes debris that was leached by a dead or dying tumor cell, or (c) that it
ingests a zsGreen containing exosome expelled by the tumor. The zsGreen we employed
in our model was cytosolic and could presumably be phagocytized by a dendritic cell in
any one of those three scenarios. One approach to determining the mechanism of antigen
transfer would be to engineer a tumor that transgenically expressed different fluorophores
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engineered to be anchored in different organelles within the cell. By examining the
potentially multiple and disparate colors of tumor-associated fluorophores individually or
simultaneously present within tumor-infiltrating dendritic cells, one could determine if the
dendritic cells had phagocytized cytosolic contents commonly found in exosomes or
debris, in a fraction of a cell, or in a whole cell. If the predominant fluorescing dendritic
cell population simultaneously fluoresced brightly for all tumor-associated fluorophores
that had been anchored to different organelles within the tumor cell, one could conclude
that the dendritic cells primarily functioned by engulfing entire tumor cells instead of
leached debris. Moreover, additional investigation of this question using high resolution
imaging such as electron microscopy could help resolve what parts of the cancer cell a
dendritic cell phagocytizes when it captures antigen to prime a T cell response.
We consistently observed that both the superficial and the deep cervical lymph nodes
harbored

zsGreen-positive

conventional

dendritic

cells

following

intracranial

transplantation with CT2A-zsGreen. Important studies by Kipnis’s group found that when
Evan’s Blue Dye was injected into the ventricles of mice, the deep cervical lymph nodes
contained Evan’s Blue within 30 minutes of injection. They also remarked that the
superficial cervical lymph nodes contained Evan’s Blue at later time points 64. In contrast
to those findings, Alitalo’s group reported that molecular tracers injected into the brain
parenchyma drained only to the deep cervical lymph nodes

65

. In our experiments, we

observed that 7 days post-injection of zsGreen-expressing tumors, a relatively larger
fraction of cDC1 (and other dendritic cell subsets) were zsGreen+ when isolated from the
deep cervical lymph nodes compared to those isolated matched subsets isolated from
the superficial cervical lymph nodes at the same time point, although all dendritic cell

112

subsets still were zsGreen+ in both superficial and deep cervical lymph nodes at the early
7 day timepoint (Figure 5-3D, Figure 5-3E). In contrast, at 14 days post-induction, there
were percentages of zsGreen+ migratory cDC1 that were roughly equivalent between
superficial and deep cervical lymph nodes. Additionally, at the day 14 harvest timepoint,
all of the dendritic cell subsets were positive for zsGreen compared to control mice in the
superficial cervical lymph nodes, whereas at this time point in the deep cervical lymph
nodes, only the migratory cDC1 and MoDC were positive for zsGreen. This suggested to
us that the deep cervical lymph nodes might be the predominant (but not exclusive) site
of tumor antigen trafficking earlier in the CNS antitumor immune response, whereas the
superficial cervical lymph nodes might be the predominant (but not exclusive) site of
tumor antigen trafficking later in the CNS antitumor immune response.
Although the kinetics of the process of trafficking Evan’s Blue dye from the ventricles to
cervical lymph nodes in Kipnis’ experiments differ greatly from the process of trafficking
tumor antigen from brain parenchyma to cervical lymph node (they observed solute
drainage to cervical lymph nodes within minutes to hours following intraventricular
injection of dye; we observed tumor antigen trafficking to lymph nodes within days to
weeks following intraparenchymal injection of tumor cells), our findings somewhat mirror
Kipnis’ findings in which the deep cervical lymph nodes are the predominant site of early
lymphatic drainage, and that the superficial cervical lymph nodes also drain the CNS at
later timepoints

64, 194

. Furthermore, the apparent absence of drainage of molecular

tracers from brain parenchyma to superficial cervical lymph nodes in Alitalo’s studies
could be due to the inherent acellular nature of these substrates, or perhaps the location
of the injection site 65. In contrast, we transplanted into the brain parenchyma an expansile
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and rapidly growing tumor that created increasingly more traceable fluorophore with each
passing day. It is also important to note that the drainage route to the deep cervical lymph
nodes compared to the superficial cervical lymph nodes is much better characterized.
The drainage pathway to the former consists of lymphatic vessels that traverse along the
venous sinuses and converge upon the deep cervical lymph nodes resting upon the
internal jugular vein deep in the neck. In contrast, less is known about the drainage route
to the superficial cervical lymph nodes.
The CNS drainage pathway to the superficial cervical lymph nodes is known to involve
the cribriform plate. Work by Kipnis’s group clarified the drainage route when they ablated
lymphatics that traverse the cribriform plate using a clever visudyne system to destroy
lymphatic vessels in specific anatomic locations around the CNS—they identified that
ablation of cribriform lymphatics prevented trafficking of T cells originating from the dura
or from the ventricles to the superficial cervical lymph nodes

67

. However, they did not

examine dendritic cell trafficking, nor did they comment on the specifics of the drainage
route between the cribriform plate and the superficial cervical lymph nodes. Notably, they
did identify that this drainage route occurred independently of drainage route to the deep
cervical lymph nodes.
Additionally, experiments involving the superficial cervical lymph nodes are further
cofounded by the fact that these lymph nodes are also known to perform lymphatic
drainage of superficial non-CNS structures on the face. Given all these observations, our
experiments with zsGreen strongly suggest that both the deep cervical lymph nodes and
the superficial cervical lymph nodes are involved in CNS lymphatic drainage in the context
of brain tumors. In the context of experiments regarding dura and antitumor immunity by
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other groups, Iwasaki’s group identified that expansion of dura lymphatics improved CNS
antitumor immunity, and that ligation of the lymphatic vessels which enter the deep
cervical lymph node negated that effect

69

. This suggests that the deep cervical lymph

nodes are indispensable for CNS antitumor immunity. Our observations of tumor antigen
trafficking to and CD8+ T cell clonal expansion within both sets of cervical lymph nodes
suggest that both locations might play a role. Future experiments should specifically
abrogate either superficial cervical lymph node function or deep cervical lymph node
function and compare the possible disparate resulting defects in CNS antitumor immunity.
Lymphatic drainage consists of both migrating cells and bulk solute flow from periphery
to lymph node, via lymphatic vessels. The Evan’s blue findings by Kipnis underlie the
importance of bulk-solute flow in the context of lymphatic drainage of the CNS. In contrast,
cellular trafficking requires CCR7. In this process, activated dendritic cells from the
periphery use CCR7 to chemotactically migrate into a lymphatic vessel and down a
CCL19/CCL21 gradient toward a draining lymph node where the highest concentrations
of CCL19 and CCL21 exist

176

. We used the CCR7-/- mouse to discern the predominant

mechanism of lymphatic drainage in the context of CNS antitumor immunity: active, cellmediated drainage, or passive, bulk-solute flow. We consistently observed that a much
larger fraction of cDC1 isolated from cervical lymph nodes were zsGreen+ in the wild-type
compared to the CCR7-/- mice. This suggests that tumor antigen trafficking by dendritic
cells is predominantly an active process in which dendritic cells phagocytize tumor
antigen from within the tumor and carry that tumor antigen to draining lymph nodes, rather
than a passive process in which dendritic cells residing in the lymph node “catch” tumor
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antigen that wasn’t carried to the lymph node by a migrating cell and instead passively
flowed there through the draining lymphatic vessel down a pressure gradient.
We used B cells as a control to examine for passive drainage—they are not known to
migrate from the periphery to lymph nodes and instead enter lymph nodes via high
endothelial venules originating from blood vessels

195

. Our thoughts were that if tumor-

derived zsGreen drains passively, B cells in the lymph node would hypothetically
phagocytize and retain zsGreen, which we could detect with a flow cytometer. Both the
wild-type and CCR7-/- mice had small but equal fractions of zsGreen+ B cells within the
cervical lymph nodes, which suggests that passive drainage is also a potential, albeit
minor mechanism of trafficking tumor-associated material to lymph nodes. In the same
vein, the dendritic cell zsGreen signal was diminished, but not completely extinguished in
the CCR7-/- mice, (and was particularly strong in a few of the CCR7-/- replicates, which
suggests that passive flow can still be sufficient to traffic at least some tumor antigen from
CNS to dendritic cells residing in the draining lymph node). Given our observations of
intact passive drainage of tumor antigen to draining lymph nodes in various capacities
when CCR7 was deficient, it is important underscore that the zsGreen signal was
significantly amplified and considerably more robust when active cell migration was intact.
Similar to our findings, previous work by Krummel identified that CCR7 deletion led to a
diminished, but not extinguished zsGreen signal in draining lymph nodes in a preclinical
melanoma model 23.
An important caveat of using lymph node zsGreen+ B cells as a control to measure
passive lymphatic drainage is that we additionally observed zsGreen+ B cells within the
brain tumors of both wild-type and CCR7-/- mice. These B cells may have extravasated
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from the blood into the brain tumor via leaky capillaries, which are known to permeate a
brain tumor’s parenchyma. We do not know the function of B cells in the tumor—whether
they were bystanders or performing an important function remains unknown. Nor can we
completely exclude the possibility that B cells migrated from the brain tumor to cervical
lymph nodes. However, migration from the periphery to lymph nodes in this setting is not
a known B cell function. Additionally, if B cells did migrate from the brain tumor to cervical
lymph nodes, we presume that this process would require CCR7, as is the case with
dendritic cells and T cells. Our observation was that small but equal fractions of zsGreen+
B cells could be isolated from the cervical lymph nodes of both wild-type and CCR7-/mice. If B cells phagocytized tumor antigen in the tumor and migrated from the brain tumor
to cervical lymph nodes (presumably in a CCR7 dependent fashion), we would expect
wild-type mice to have much larger fractions of lymph node zsGreen+ B cells compared
to CCR7-/- mice. The fractions of zsGreen+ cervical lymph node B cells were both small
but also equal between wild-type and CCR7-/- mice, which suggests that zsGreen+ B cells
are an appropriate control for passive drainage in our experiments.
Previous work has identified the meninges as an immunologically dynamic structure that
harbors cDC1, cDC2, and pDC

49, 55

, and furthermore, that conventional dendritic cells

within the dura could expand in response to Flt3L as a stimulus 177. In addition to harboring
these dendritic cell subsets, the dura is vested with lymphatic vessels 64, 65, 191 which drain
CSF and as well as antigens from the CNS to the deep cervical lymph nodes in the neck.
The dura lymphatic vessels have been shown to expand in response to VEGF-C
stimulation to bolster the CNS antitumor immune response

69

. Our work extends these

findings—we identified that all dendritic cell subsets within the dura expanded in response
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to the stimulus of a brain tumor, and that we could additionally expand all dendritic cell
subsets, including the cDC1 subset, by systemic administration of Flt3L. Furthermore, we
observed cDC1 in dura lymphatic vessels by 2-photon microscopy, and additionally
observed tumor-derived zsGreen within dendritic cells harbored by the dura when mice
bore zsGreen-expressing brain tumors. Our collective observations could represent
dendritic cells phagocytizing tumor antigen from within the tumor and trafficking the tumor
antigen to the deep cervical lymph node, via dura-lymphatics. The transit point and the
mechanism by which antigen enters the dura-lymphatic vessels remains an open
question, and further work is needed to investigate this phenomenon.
After characterizing the dynamics of lymphatic drainage, tumor antigen trafficking, and
dura involvement in the CNS antitumor immune response, we next investigated the
downstream steps of this process, in particular the location of T cell priming in CNS
antitumor immunity. Given our observations that zsGreen-containing dendritic cells could
be isolated from both groups of cervical lymph nodes, from the tumor, and from the dura,
we considered the possibility that any of those anatomic locations could be a potential
site for a tumor antigen-containing dendritic cell to encounter a cognate T cell and initiate
T cell priming. We also considered other locations, such as the spleen, as a location of
priming the CNS antitumor immune response. To investigate this phenomenon, we
employed an ovalbumin-expressing tumor and monitored for expansion of adoptively
transferred CFSE-labeled OT-I CD8+ T cells in the different previously mentioned
anatomic locations. We envisaged that locations of naïve T cell priming in the setting of
the CNS antitumor immune response would display the earliest evidence of clonal
expansion of OT-I T cells, and thus would harbor the bulk of early-primed CFSE-mid, OT-
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I CD8+ T cells. Accordingly, we observed earliest expansion of OT-I CD8+ T cells in both
the superficial and deep cervical lymph nodes. They consistently harbored the bulk of
CFSE-mid, early primed, OT-I CD8+ T cells among the organs we examined. Moreover,
we primarily observed the CFSE-low, terminally divided OT-I CD8+ T cells at the later day
6 post-transfer timepoint, and the majority of them localized to the tumor. While expanded
OT-I cells sometimes appeared in the tumor and dura by the early time point, they were
always terminally expanded, CFSE low, which suggests that they had been primed
elsewhere, in particular the cervical lymph nodes, as suggested by our observations.
Notably, neither the spleen, the dura, nor the non-CNS draining inguinal lymph node
appeared to be the site of clonal expansion of adoptively transferred OT-I cells. Our
observations extend previous work done with EAE models in which investigators showed
that cervical lymph node resection dampened disease burden

61-63

, and expand the

known role of cervical lymph nodes to include priming a CNS antitumor immune response.
Additional experiments should include abrogating cervical lymph node function and
monitoring for T cell response, and alternatively preventing T cell egress from lymph
nodes with a sphingosine-1-phosphate receptor antagonist and examining for downstream effects on CNS antitumor immunity.
We expanded our findings to define the role of cDC1 and CCR7 in this process of T cell
priming in antitumor immunity. In CCR7-deficient and cDC1-deficient mice, we
determined that both of these defects led to delayed, but not completely defective clonal
expansion of adoptively transferred OT-I T cells. This could be for a variety of reasons.
We know from our previous experiments that cDC1 are required for endogenous priming
of neoantigen-specific CD8+ T cells, and that cDC1 are additionally required to mediate
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survival benefit conferred by checkpoint blockade in a preclinical model of glioblastoma.
However, these two different scenarios of T cell expansion are quite different. The
ovalbumin brain tumor/OT-I adoptive transfer experiments involved initiating a T cell
response with several hundred thousand adoptively transferred naïve T cells against a
tumor that overexpresses a particular antigen recognized by those T cells. In contrast,
the unmodified GL261 brain tumor experiments involved allowing 1-100 naïve T cells
comprising the precursor population of a particular T cell clone to be spontaneously
primed and to clonally expand on their own. The former scenario in which both tumor
antigen expression and precursor T cell frequency are artificially high might be a sufficient
catalyst to overcome some of the defect created by absence of cDC1. Moreover, the
ovalbumin construct we used is not entirely cell-associated—there is no sequence or
structure anchoring it to the cell membrane. In addition to specializing in cross
presentation, cDC1 are specifically equipped to handle cell membrane-associated
antigen

26

. Soluble ovalbumin, which these tumors make, could potentially be cross-

presented by other dendritic cell subsets in small but non-zero amounts sufficient drive
OT-I CD8+ T cell expansion (albeit less efficiently), even in the absence of cDC1

26, 29

.

This was reflected by our observations: given enough time in cDC1-deficient mice, OT-I
CD8+ T cells still expanded when mice harbored GL261-OVA brain tumors.
Interestingly, we also observed delayed but not absent OT-I CD8+ T cell expansion in
CCR7-/- mice compared to wild-type mice. At day 3 post-adoptive transfer, OT-I CD8+ T
cells had failed to expand in CCR7-/- mice whereas at the same time point they had
expanded robustly in cervical lymph nodes of wild-type mice. In contrast, at day 6 postadoptive transfer, OT-I CD8+ T cells expanded in proportions comparable between both
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CCR7-/- and wild-type mice in all the tissues we analyzed. This suggests that there exist
cell migration-independent mechanisms of trafficking tumor antigen from the CNS to
draining lymph nodes. An important caveat that warrants mention is that we could not
determine where initial priming and OT-I CD8+ T cell expansion initially commenced in
CCR7-/- mice—it was as if in these mice there was negligible OT-I clonal expansion in the
cervical lymph nodes by day 3 post-adoptive transfer, and by day 6 post-adoptive transfer
we observed expanded OT-I CD8+ T cells in every anatomic location we examined.
Additional experiments should examine the nature of expansion at different time points
that fall between days 3 and 6 post-adoptive transfer, and specifically, to determine where
the first site of clonal expansion of adoptively transferred OT-I cells occurs in CCR7-/mice.
One additional caveat of our observations regarding the relationship between host CCR7deficiency and clonal expansion of adoptively transferred T cells is that we used an
artificial system of T cell priming by performing experiments that involved adoptive
transfer of large numbers of T cells and overexpression by the tumor of the cognate
antigen that the T cells recognized. Moreover, CCR7-deficiency in mice leads to broad
immunologic defects. We know from our experiments that that precise deficiency of a
single cell type, the cDC1, leads to defective neoantigen-specific T cell priming and
incompetent immune responses against CNS tumors. The same precise experiment
which isolates and implicates a single cell type is not possible in CCR7-/- mice. The goal
of our experiments with the CCR7-/- mice was to determine the immunologic defects
caused by deficient dendritic cell trafficking of tumor antigen from brain tumors to draining
lymph nodes. However, CCR7-/- mice harbor additional defects in the immune response:
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they have defective T cells in addition to all dendritic cell subsets. This is because both T
cells and dendritic cells require CCR7 to migrate to the proper location in a lymph node’s
paracortex to commence T cell priming and clonal expansion through antigen
presentation and co-stimulation by activated dendritic cells. We attempted to circumvent
this problem by adoptively transferring CCR7WT/WT OT-I CD8+ T cells into CCR7-/- hosts,
however our adoptive transfer experiments involved a precursor frequency of several
hundred thousand adoptively transferred T cells clonally expanding in response to an
overexpressed tumor-associated antigen, which is somewhat unrealistic. The proper way
to address the requirement of cell migration from periphery to lymph nodes by cDC1 in
mounting CNS antitumor immunity would be to selectively restrict CCR7-deficiency to the
cDC1 subset and monitor for endogenous T cell priming in that setting. This could be
achieved by using a CCR7-/- + IRF8+32kb-/- mixed bone marrow chimera, or by crossing
an XCR1-Cre mouse (cDC1-specific Cre) to a CCR7fl/fl mouse.
Important work remains to establish the role and importance (or lack thereof) of cDC1
migration in antitumor immunity of the CNS, and to further characterize the complete
pathway of cDC1 migration from tumor parenchyma in the CNS to the dura lymphatic
vessel, and from the dura lymphatic vessel to the cervical lymph nodes, in particular,
superficial cervical lymph nodes given their less well-characterized drainage route
compared to deep cervical lymph nodes.
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CHAPTER SIX
Dendritic cells and antigen presentation in human GBM
6.1 Introduction
In mouse preclinical models of GBM we demonstrated that cDC1 play a critical role in
mounting an effective antitumor immune response in the CNS—they are required to both
prime neoantigen-specific CD8+ T cell responses as well as to mediate survival benefit
conferred by checkpoint blockade in the setting of malignant glioma. We also
demonstrated evidence which suggests that cDC1 carry out their role in part by
phagocytizing tumor antigen from within the tumor, migrating via dura lymphatics, and
appearing with phagocytized tumor antigen in the deep and the superficial cervical lymph
nodes, where they prime CD8+ T cells to drive clonal expansion to mount antitumor
immunity against the tumor residing in the CNS. We also showed that these processes
of brain tumor antigen trafficking and clonal expansion of adoptively transferred CD8+ T
cells depend on both presence of cDC1 and intact CCR7-mediated cell migration to occur
with normal kinetics. Despite the results from these experiments, as well as other rodent
studies which clarified the role of dendritic cells in the progression of the CNS immune
response in other disease processes or which demonstrated the importance of dura
lymphatics in CNS immunity (including CNS anti-tumor immunity), little is known about
whether or how dendritic cells play a role in human brain tumors, or in the human central
nervous system more broadly.
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To date there have been a few isolated reports regarding dendritic cells in the human
brain. Researchers have identified dendritic cells in human choroid plexus by cellular
expression of HLA-DR

196

. A second report described in greater detail dendritic cells

embedded among epithelial cells in the choroid plexus. Observers described cells in the
choroid plexus which both expressed HLA-DR, possessed long dendrites extending in all
directions, and lacked tight junction proteins expressed by their epithelial cell neighbors
197

. Dendritic cells have also been isolated from human CSF and characterized as cDC

by their expression of HLA-DR, CD11c and variable expression of CD123 to discern pDC
from cDC (human pDC are CD123+, human cDC are CD123-) 198. Investigators have also
identified CD209-expressing cells (an established human dendritic cell marker) in
extravascular spaces in the brain that lie beyond the glia-limitans and well into the brain
parenchyma

199

. An interesting study of human stroke patients identified transient

decreases in circulating dendritic cells and increased infiltrate of dendritic cells over
background into the diseased area in both ischemic and hemorrhagic strokes, which
reflected a potential recruitment of dendritic cells into the brain from the blood into injured
tissue

200

. In another stroke study, researchers identified that APC (including CD1c+

dendritic cells) in the cervical lymph nodes and palatine tonsils harbored neuronal-derived
and oligodendrocyte-derived antigens in levels greater than in healthy control patients 201.
They did not explore cDC in the brain directly, but this study’s implications hint toward the
relationship between the brain and extracranial immune responses in humans, which
would be consistent with similar observations from mice. Despite these discoveries, little
is known about the potential role of dendritic cells in antitumor immunity of human brain
tumors.
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Most studies that have examined innate immunity in human GBM have not focused on
dendritic cells and instead have investigated the immune-suppressive mechanisms of the
tumor itself, as well as how the infiltrating innate immune cells engage in immunesuppressive behavior. Previous work has identified that the microenvironment of human
GBM tumors could induce PD-L1 expression on monocytes/macrophages isolated from
healthy donors
89

88

. Studies have also shown that human GBMs are infiltrated by MDSCs

, and that GBM patients tend to have high levels of circulating MDSCs compared to

healthy controls

90

. Moreover, experiments have shown that tumor associated

macrophages and microglia express high levels of the immune-suppressive cytokine IL10

83, 84

. Although these researchers demonstrated the immune-suppressive functions

which APC and innate immune cells can perform within the tumor microenvironment, they
fall short of explaining whether or how cDC infiltrate the tumor and perform their function
of antigen presentation to prime T cell responses. Perhaps similar to in mice, human cDC
have been underappreciated and understudied in brain tumors due to their low
background prevalence in the brain parenchyma.
Most of the work on dendritic cells in human brain tumors has centered around developing
dendritic cell vaccines for glioma. These efforts originate from rodent studies performed
in the late 1990s/early 2000s, in which researchers identified that pulsing exogenously
cultured monocyte-derived dendritic cells with peptides derived from glioma tumors
followed by subsequent vaccination with those antigen-loaded monocyte-derived
dendritic cells led to greater infiltration of CD4+ and CD8+ T cells into the rodent brain
tumors compared to control mice

202

. These researchers also determined that the

monocyte-derived dendritic cell vaccination strategy led to improved survival in these
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rodent models as well 203. The findings spurred investigators in 2001 to design a phase 1
clinical trial in which peptide derived from the patient’s brain tumor was combined with
autologous cultured monocyte-derived dendritic cells to create a personalized vaccine.
Vaccination was demonstrated to lead to increased CD8+ T cell and memory T cell
infiltrate into the tumors in 2/7 of the vaccinated patients, with evidence of systemic
response in 4/7 vaccinated patients

204

. More recently, Northwest Biotherapeutics has

enrolled patients in a phase III clinical trial called DCVax, which uses a similar formulation
of dendritic cell vaccines. To administer this dendritic cell vaccine, researchers expose a
patient’s own autologous monocyte-derived DC to their brain tumor lysate and inject these
tumor lysate-exposed DC intradermally 121. This trial is currently underway and reports a
median survival of 23.1 months and a subset of long-term survivors in their intent-to-treat
cohort compared to the placebo group 122. Despite early promise, the trial is ongoing and
DCVax has not proven to change the standard of care for GBM.
Although there might be some early hints of benefit from these vaccines, they have not
radically changed GBM treatment strategies at present. Notably (and perhaps for
apparent historical reasons), these DC-vaccine studies and trials have employed
exogenously derived cultured dendritic cells known as monocyte-derived dendritic cells,
which were first developed in 1992 in mice, and which require culturing hematopoietic
stem cells (HSCs) with GM-CSF and IL-4 205, 206. Just two years after the rodent studies,
researchers successfully differentiated human HSCs into equivalent monocyte-derived
dendritic cells using a similar technique

207

. Monocyte-derived dendritic cells may have

been selected for cancer vaccines for a variety of reasons. First, researchers have how
to differentiate them successfully since the mid 1990s. Second, they can present soluble
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antigen efficiently in vitro. Third, additional characterization suggests they are a functional
dendritic cell beyond sheer antigen presentation capability: they lack expression of the
monocyte marker CD14, they express costimulatory molecules required for priming T
cells, and can actually stimulate naïve T cell proliferation in vitro

207

. Researchers have

also demonstrated that monocyte-derived dendritic cells can induce demonstrable benefit
with respect to antitumor immune responses—dendritic cell vaccines were demonstrated
to broaden the neoantigen-specific T cell repertoire in melanoma patients

208

. Despite

these potential benefits from vaccination with monocyte-derived dendritic cells, these
cells are not true dendritic cells that arise endogenously in vivo.
In contrast to exogenously cultured monocyte-derived dendritic cells, endogenously
arising conventional dendritic cells require Flt3L for development, and have been
demonstrated to expand in both mice

209

and in humans

210

following systemic

administration of Flt3L. Conversely, experiments in mice have demonstrated that
administration of GM-CSF and IL-4, the same factors used to generate monocyte-derived
dendritic cells in vitro, causes no such expansion conventional dendritic cell populations
or monocyte-derived dendritic cell populations in vivo

209

. Moreover, conventional

dendritic cells are transcriptionally distinct from exogenously cultured monocyte-derived
dendritic cells

190

. Additionally, monocyte-derived dendritic cells and are comprised of a

heterogeneous population of monocyte-derived macrophages and cDC-like cells with
unique and disparate functions

211

. Researchers have sorted the cell populations

comprising cultured monocyte-derived the dendritic cells and identified that the cDC-like
fraction is much more capable of stimulating CD4+ and CD8+ T cell proliferation compared
to macrophage-like population in vitro 211.
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Beyond in vitro differences demonstrated between conventional dendritic cells and
monocyte-derived dendritic cells, of the conventional dendritic cell subsets, true cDC1 are
the only dendritic cells that arise endogenously and cross present antigen in vivo

25, 212

.

Critically, cDC1 are the only cell type that has been repeatedly demonstrated to elicit
potent CD8+ T cell responses and to be required for antitumor immunity in vivo 20-23, 25-31.
cDC1 are also the only dendritic cells that can process cell-associated antigen in vivo 26,
as is the case for many neoantigens derived from tumor cells. Despite these potential
advantages of using true dendritic cells for a vaccine, GM-CSF/IL-4 cultured monocytederived dendritic cells have had such a strong foothold in vaccine studies of GBM and
other tumors likely because researchers did not know how to culture human HSCs into
bona fide cDC until recently, and the issue still stands regarding how to generate sufficient
numbers of human cDC to generate a vaccine from exogenously cultured dendritic cells.
Flt3L exposure alone is sufficient to culture dendritic cells from mouse bone marroworiginating HSCs

213, 214

. In contrast, human dendritic cells are much more difficult to

generate exogenously. Culturing human HSCs with Flt3L results in few dendritic cells,
unlike with mice. Only recently in 2018 did researchers develop a method to generate
somewhat appreciable numbers of functional human cDC1 and cDC2 from HSCs 215. This
technique requires co-culturing HSCs with adherent OP9-DL1 feeder cells to induce notch
signaling, and requires adding to the media Flt3L, stem cell factor, and GM-CSF in order
to differentiate a large fraction of HSCs into cDC 215. This complex protocol still might fall
short of generating a sufficient number of cDC for a dendritic cell vaccine. The delay of
the development of this protocol until much more recently, combined with the lingering
issue of insufficient dendritic cell numbers resulting from this culture method, have
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contributed to the significant delay in using conventional dendritic cells instead of
monocyte-derived dendritic cells for dendritic cell vaccines.
In addition to the difficulty regarding culturing human dendritic cells, studies to determine
which dendritic cell subsets in mice correlate to their human counter parts have not been
published since the last decade or so. Poulin and colleagues identified a subpopulation
of human blood dendritic cells analogous to the mouse cDC1 which also express the
mouse cDC1-specific cell surface marker Clec9A, express high levels of IRF8 and BATF3
transcription factors (required for mouse cDC1 development), respond to TLR agonists,
produce IL-12 (also mouse cDC1-spefic), and which have been shown to present
exogenous proteins derived from internalized dead cells to prime CD8+ T cells in vitro (in
which mouse cDC1 specialize)

216

. Notably, this study also showed that CD8α+ human

DC possessed superior ability to phagocytize dead cells, and to cross present antigen,
when compared to monocyte-derived dendritic cells in vitro 216. This equivalence between
the mouse and human cDC1 counterparts was further underscored by a case report of a
patient with biallelic IRF8 mutations, which caused severe immunodeficiency

217

. IRF8-/-

mice have completely defective cDC1 development 183. The patient with the biallelic IRF8
mutations had a complete loss of circulating pDC (CD123+ DC) and cDC1 (CD141+ cDC),
as well as a monocyte deficiency, underscoring the parallel between the human
CD141+Clec9A+ cDC and the mouse cDC1 subset.
Given the dearth of knowledge regarding the role of dendritic cells in human brain tumors,
the lack of understanding regarding endogenously arising CNS antitumor immunity, and
the focus on monocyte-derived dendritic cell vaccines as a form of immunotherapy to treat
brain tumors (which for reasons described above may not be the most appropriate cell
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type), we set out to determine the role of endogenously arising dendritic cells in human
brain tumors and to describe the characteristics of cDC1 within anatomic locations inside
and adjacent to the tumor. We also devised an assay that like our mouse models,
leverages a tumor-specific fluorophore as a surrogate for tumor antigen. We again
leveraged the transfer of fluorescence principle to measure tumor-antigen uptake by
tumor-infiltrating dendritic cells, including the human cDC1 equivalent CD141+ cDC.

6.2 Results
6.2.1 The human equivalent of the cDC1 is detectable in dura and brain tumors
Having demonstrated that mouse dura and brain tumors harbored orders of magnitude
more dendritic cells than the same anatomic locations in the steady state, and also having
demonstrated the important role of the cDC1 in mounting CNS antitumor immunity in
mice, we investigated the infiltrate of human dura and brain tumors for the presence of
the human cDC1-equivalent: the CD141+ cDC. In both mice and humans, the cDC1 can
produce IL-12 216, cross present exogenous proteins derived from internalized dead cells
to CD8+ T cells

216

, and expresses high levels of IRF8

188

, a critical regulatory factor

required for cDC1 development in mice 183 and in humans 217.
We explored the immune cell populations comprising the cellular infiltrate of tumor and
matched dura specimens from patients undergoing craniotomies for tumor resection for
whom there was, in addition to an indication to resect the tumor, a clinical indication to
resect the tumor-adjacent dura as well (Figure 6-1A). We disaggregated several patients’
tumor and matched dura specimens from five meningiomas and a GBM. We analyzed an
additional twelve GBM tumor specimens in which no dura was resected. We performed
flow cytometry to characterize the immune infiltrate of these samples, with particular focus
130

on dendritic cells. In both GBM tumors as well as meningiomas, we detected the presence
multiple human dendritic cell equivalents, in addition to other APC subsets, within the
cellular infiltrate of the patients’ respective tumor and dura specimens. We observed the
cDC1 (CD141+ cDC) and cDC2 (CD1c+ cDC) subsets, CD14+ classical monocytes, as
well as CD16+ non-classical monocytes, in dura and tumor samples (Figure 6-1B, 6-1C,
6-1D). Additionally, we also observed CD4+ T cells as well as CD8+ T cells in most of the
thirteen total GBM specimens that we analyzed (Figure 6-1C). Moreover, between the
GBM and meningioma dura specimens, the tissue harbored similar fractions of CD141+
cDC, CD1c+ cDC, CD14+ classical monocytes, and CD16+ non-classical monocytes
(Figure 6-1E), although our analysis was limited to a single GBM sample in which dura
was additionally resected. These findings collectively demonstrate that human
conventional dendritic cell subsets are abundant in dura and tumors and across different
brain tumor types, which suggests they play a role in human CNS antitumor immunity.
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Figure 6-1. Dendritic cells infiltrate human dura and brain tumors. Representative sketch of
meningioma/associated dura or GBM/associated dura. B. Flow cytometry of immune infiltrate of GBM tumor
and dura. C. GBM immune infiltrate quantified as a fraction of CD45+/live cells from twelve GBM specimens
(ten primary and two recurrent). D. Flow cytometry of immune infiltrate of meningioma tumor and dura. E.
Quantification of APC subsets from one GBM and five meningioma dura samples.
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6.2.2 The CD141+ cDC phagocytizes a tumor specific marker in GBM
Having identified in mice that a fluorophore transgenically expressed by the brain tumor
could be detected within cDC1 (and other dendritic cell subsets) isolated from the tumor,
the dura, and the cervical lymph nodes, we next investigated whether this phenomenon
of tumor antigen transfer occurred in dendritic cells isolated from human GBM. During
GBM resection, the FDA-approved drug 5-aminolevulinic acid (5-ALA) can be used to
fluorescently label the tumor to distinguish it from normal brain

218-221

. 5-ALA is

administered systemically during the preoperative period, extravasates from the leaky
blood vessels that permeate the tumor, and is imported and converted by target tumor
cells to the fluorescent metabolite, protoporphyrin IX (PPIX)

222

. PPIX is selectively

retained by, and highly specific to tumor cells 222, 223. During resection, the neurosurgeon
can illuminate the tumor with blue light, and the PPIX harbored by the tumor selectively
fluoresces pink, which allows the surgeon to discern fluorescent pink tumor-tissue from
dark blue normal brain to safely and maximally resect the tumor without disturbing normal
brain (Figure 6-2A). We leveraged the same principle we had employed previously with
fluorescent mouse GBM tumors to investigate human GBM. This principle relies on the
premise that fluorescent material specific to the tumor could potentially be transferred to,
and detectable within tumor-infiltrating dendritic cell subsets (Figure 6-2B).
When incorporated into cells, PPIX fluoresces across the wavelengths that span the
brilliant violet channels on a conventional flow cytometer. To test whether we could detect
PPIX+ cells by FACS, we first disaggregated a GBM tumor which was resected using 5ALA and subjected the resulting purified single cell suspension to flow cytometry. We
determined that the PPIX signal was strongest in the BV650 channel and were able to
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observe clearly defined PPIX- and PPIX+ populations within the sample (Figure 6-2C, left).
In an orthogonal approach we additionally exposed the U343 GBM cell line to 5-ALA in
vitro. Compared to untreated U343 cells, 5-ALA-exposed U343 cells fluoresced brightly
in the BV650 channel (Figure 6-2C, right).
We designed a panel that could stain for conventional dendritic cell subsets, monocytes,
and T cells, while leaving open the brilliant violet channels that span the PPIX
fluorescence spectrum, including BV650, to avoid potential compensation conflicts.
Whereas with preclinical models, we could use a non-fluorescent brain tumor as a
negative control for a fluorescing brain tumor to determine that a fluorescent signal in
dendritic cells was specific to the transgenic expression of a tumor-specific fluorophore,
and to additionally discern the fluorescence intensity cutoff between positive and negative
fluorophore expression, no such control exists for human brain tumors resected using 5ALA/PPIX. To try to identify a PPIX+/PPIX- fluorescence intensity, we devised two internal
controls with two questions in mind. First would PPIX fluorescence depend on immune
cell identity, with only phagocytic cells acquiring PPIX? Second, would PPIX fluorescence
depend on cell location, with only tumor-infiltrating immune cells acquiring PPIX?
We surmised that a brightly fluorescing PPIX+ tumor would harbor high levels of PPIX in
the microenvironment, and that any cells that had infiltrated the environment would be
universally exposed to PPIX. However, if a unique cell population, such as CD3- cells
(which includes phagocytic cells) was the only PPIX+ cell population, PPIX fluorescence
could be attributed to the specific identity of the infiltrating immune cell rather than solely
because that cell had been exposed to a high concentration of PPIX. This was the basis
for our first control to identify a PPIX+/PPIX- fluorescence cutoff.
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As our second control, we harvested, stained with the same antibody panel, and
performed flow cytometry on patients’ intraoperative peripheral blood mononuclear cells.
This controlled for systemic exposure of APC to 5-ALA and allowed us to identify a PPIXcutoff through a second means by analyzing matched peripheral cells, which were
presumably exposed to lower concentrations of 5-ALA/PPIX, against tumor-infiltrating
cells where PPIX was most concentrated. If circulating dendritic cells systemically
exposed to 5-ALA did not fluoresce with PPIX, any potential PPIX signal observed in
dendritic cells infiltrating the tumor would be attributable to them having infiltrated the
tumor, rather than having been systemically exposed to 5-ALA. By using these controls
and identifying a range of cellular PPIX fluorescence intensities, we were able to discern
a fluorescence intensity cutoff PPIX+ vs. PPIX- cell populations, akin to the fluorescence
intensity cutoff we identified between zsGreen+ and zsGreen- populations by comparing
a zsGreen-transduced tumor against a non-transduced control.
We hypothesized that PPIX would be detectable specifically in tumor-infiltrating rather
than peripheral immune cells, and further, that only phagocytic cells would fluoresce with
PPIX. To test these hypotheses, we performed flow cytometry on intraoperatively taken
PBMC along with a patient’s disaggregated GBM tumor which had been resected using
5-ALA/PPIX. Of a patient’s CD45+/Live PBMCs, neither the CD3ε+ fraction, nor the CD3εfraction fluoresced with PPIX (Figure 6-2D, left, figure 6-2E). In contrast, of a patient’s
CD45+/Live tumor-infiltrating immune cells, only a miniscule fraction of CD3ε+ cells were
PPIX-positive, whereas a significantly larger fraction of the CD3ε- cells were PPIX-positive
(Figure 6-2D, right, Figure 6-2E). These observations demonstrate that the phenomenon
of PPIX-fluorescence within CD45+ cells was attributable to their cell identity (tumor
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infiltrating CD3ε- cells, but not CD3ε+ cells were PPIX-positive), and specific to a cell’s
anatomic localization to the tumor (Peripheral CD3ε- cells where largely PPIX-negative,
whereas a significant fraction tumor infiltrating CD3ε- cells were PPIX-positive).
We next investigated whether different tumor infiltrating APC subsets had detectable
levels of PPIX in six primary and two recurrent GBM specimens that had been resected
using 5-ALA. We used peripheral intraoperative PBMCs to determine where to set the
negative/positive threshold for PPIX-positivity by comparing PPIX-fluorescence between
corresponding antigen presenting cell populations isolated from the tumor against
matched cells from the periphery. We identified that compared to their matched controls,
majorities of tumor-infiltrating CD141+ cDC1, CD1c+ cDC2, CD14+ classical monocytes,
and CD16+ non-classical monocytes contained PPIX (Figure 6-2F, Figure 6-2G).
Moreover, across all tumor samples the PPIX-signal was absent from T cells and instead
specific to antigen presenting cells that had infiltrated the tumor (Figure 6-2H).
The fraction of a particular APC population that was PPIX-positive varied between APC
identities as well as patients, similar to our observations in mice with zsGreen. However,
our observations suggest that multiple distinct APC subsets infiltrating the tumor
possessed the required machinery to home to the tumor and to phagocytize tumorderived material after arriving, similar to our observations in mice. Collectively, these data
demonstrate that the phenomenon of acquiring tumor-derived material by immune cells
was specific to cell identity (phagocytic but not CD3ε+ immune cells within the tumor were
PPIX+) as well as cell location (tumor-infiltrating but not peripheral phagocytic cells of the
same identity were PPIX+). These data also underscore the similar behavior shared
between mouse and human phagocytic cells in the setting of brain tumors.
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Figure 6-2. Dendritic cells infiltrate human GBM and retain the tumor-specific reporter PPIX. A.
Photograph of GBM after 5-ALA administration illuminated by white (top) or blue (bottom) light. B.
Schematic describing experimental concepts. C. 5-ALA/PPIX+ tumor single cell suspension without
antibodies (left) or PPIX+ U343 cells on the BV650 channel (right). D. CD3ε expression by PPIX
fluorescence gated on CD45+/Live PBMC (left) or CD45+/Live tumor (right) cells. E. PPIX fluorescence
quantified in CD3ε+ vs. CD3ε- fractions in either PBMC or tumor. F. PPIX expression in APC subsets across
3 representative tumors compared to peripheral PBMCs harvested at the time of surgery, quantified in G
across 8 specimens. H. PPIX fluorescence quantification in tumor APC vs. tumor T cells.
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6.3 Conclusion and Discussion
Here we demonstrate that human brain tumors and adjacent matched dura harbor
conventional dendritic cells in meningiomas and GBM. Furthermore, in a surrogate assay
for tumor antigen uptake and presentation, we also demonstrate that GBM infiltrating
cDC1, cDC2, and monocytes are positive for the tumor antigen-surrogate PPIX, which is
used to in 5-ALA fluorescence-guided surgery to resect GBM. We determined that this
signal was specific to cells that had infiltrated the tumor, and was unique to non-T cells
(i.e., phagocytic cells) within the tumor. The PPIX fluorescence intensities which varied
between cell type and were dependent on cell location comport with our understanding
that the highest concentration of PPIX lies within the tumor and that phagocytic cells within
the tumor preferentially acquire tumor-derived material compared to non-phagocytic cells
within the tumor. These observations fit with our understanding regarding the
mechanisms of fluorescence transfer. They suggest that the results from our experiments
designed to observe a surrogate for antigen uptake represent a naturally occurring
biologic phenomenon that arises endogenously in the tumor. Moreover, we observed
similar findings in 8 different GBM specimens, which further corroborates the conclusions
we drew from the data. These experiments demonstrate that across multiple patients,
dendritic cells and monocytes infiltrate GBM and phagocytize tumor-associated material
once they arrive, a function that dendritic cells were known to perform, but which has yet
to be directly observed in human tumors to our knowledge.
The majority of studies regarding dendritic cells in the CNS have focused on preclinical
models in rodents, and for obvious reasons—acquiring human brain tissue is only
possible in unique cases. Most human dendritic cell studies have been restricted to the
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study of blood, due to the limited availability of donors and the limited ability to collect
tissue without compromising patients’ health. With the advancement of cancer
immunology as a field, human brain tumor specimens have been probed for neoantigenspecific T cells, which have been observed in the vaccine setting 224-226. In the non-tumor
setting, lymphatic vessels have been observed with non-invasive techniques in human
and non-human primates using clever MRI imaging sequences 68. However, to date there
are a paucity of studies which describe the role or presence of dendritic cells in human
brain tumors. Most previous work has identified dendritic cells in isolated locations, like
the choroid plexus

196, 197

, the CSF198, just beyond the glia limitans,

199

, or as having

relevance in stroke 200, 201. Despite these discoveries, little is known about dendritic cells
in human brain tumors.
Most studies that have examined innate immunity in human brain tumors have instead
focused on the immune-suppressive mechanisms in GBM, or on dendritic cell vaccines,
instead of on the endogenously arising conventional dendritic cells that home to the tumor
without an exogenous stimulus. While the immune suppression mechanisms of GBM are
extensive

83, 84, 88-90

, we set out to instead study endogenously arising dendritic cells as

well as their potential role in antigen capture within the tumor, with a focus on conventional
dendritic cells. We identified the CD141+ cDC1 human equivalent, along the CD1c+ cDC2
human equivalent in human dura and tumor samples across different tumor types,
including GBM specimens as well as meningiomas. We analyzed both meningiomas and
a GBM tumor in which associated matched dura was also resected. We additionally
analyzed eleven GBM tumor specimens (nine primary, two recurrent) which did not have
matched dura. These findings extend our observations in mice, in which we observed that
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brain tumors are infiltrated with dendritic cells far above the normal background for steady
state brain. Additional studies remain to characterize more samples and to delve into
dendritic cell subsets with increased granularity and characterization of their specific
migration patterns and additional functions.
Finally, to our knowledge, the phenomenon of direct tumor antigen uptake by dendritic
cells has yet to be observed in human cancer. The use of 5-ALA (and the associated
fluorescent tumor-specific PPIX metabolite) allows the neurosurgeon to discern
fluorescing malignant glioma tissue from normal brain more easily than otherwise, and
accordingly, to achieve better safe and total resection of the tumor

218-222

. Systemically

administered 5-ALA is selectively imported, metabolized, and retained by the GBM tumor
cells

222, 223

. We leveraged this phenomenon of tumor-specific fluorescence and

integrated it with conventional flow cytometry to probe for the fluorescent 5-ALA
metabolite PPIX in various dendritic cell and antigen presenting cell subsets that infiltrated
the tumor. According to our model, a fluorescent dendritic cell would indicate that the
dendritic cell had phagocytized part of or a whole tumor cell, or debris leached or expelled
from a tumor cell. Importantly we observed this phenomenon uniquely in antigen
presenting cells (T cells in the tumor were PPIX-) which were specifically isolated from
the tumor (the same dendritic cell subsets isolated from intraoperatively collected patient
PBMCs were PPIX-). These were important controls to establish first, that PPIX retention
was dependent on immune cell identity, and second to establish that any PPIX signal in
a tumor-infiltrating APC was due to presence within the tumor, rather than systemic
exposure to 5-ALA/PPIX. As with mice, transfer of fluorescence from tumor to infiltrating
APC could have occurred because the infiltrating APC phagocytized a whole tumor cell,
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phagocytized debris leached from a dead or dying tumor cell, or phagocytized exosomes
expelled by the tumor. Our observational techniques preclude us from discerning the
means by which a dendritic cell phagocytosed tumor-derived material. Determining this
would require a technique such as high-resolution electron microscopy to discern what
takes place at the cellular and sub-cellular levels. Nevertheless, these findings extend our
observations of tumor antigen uptake by dendritic cells from mice to humans.
Our work also has important implications for the field of dendritic cell vaccines. Dendritic
cell vaccines were based on a few studies that showed more robust T cell responses and
survival benefit from exogenously cultured monocyte-derived dendritic cell vaccines in
rodent GBM models 202, 203 in the late 1990s. These observations led to a phase I trial that
showed some efficacy and demonstrated safety with this vaccination strategy in GBM 204.
More recently, an ongoing phase III trial by Northwest Biotherapeutics has enrolled
patients to determine whether there is benefit from exogenously cultured monocytederived dendritic cell vaccines in GBM 121. Although trial is currently underway and reports
a median survival of 23.1 months as well as a subset of long term survivors in their intentto-treat cohort compared to the placebo group

122

, DC-Vax has not proven to be a silver

bullet and probably won’t change the standard of care.
There are a few reasons that the investigators might not be conducting a trial destined for
success. Notably these DC-vaccine studies and trials have employed exogenously
cultured monocyte-derived dendritic cells, which were first developed in 1992 in mice, and
in 1994 in humans. These vaccines require culturing hematopoietic stem cells (HSCs)
with GM-CSF and IL-4, along with different additional cytokines such as TNF-α depending
on the formulation

205-207

. Monocyte-derived dendritic cells may have been selected for
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cancer vaccines because researchers have known how to differentiate them for nearly 30
years, and because these cells share some characteristics with conventional dendritic
cells such as the capacity to uptake antigen and present it to T cells to stimulate their
proliferation in vitro 207. Exogenously cultured monocyte-derived dendritic cells have also
induced demonstrable antitumor immune responses by expanding the neoantigenspecific T cell repertoire in melanoma patients

208

. These results notwithstanding,

monocyte-derived dendritic cell vaccines have not changed the standard of care
appreciably. It could be because T cell priming by monocyte-derived dendritic cells isn’t
optimal. It could additionally be because monocyte-derived dendritic cells don’t have the
same capability (beyond T cell priming) as true dendritic cells that arise endogenously in
vivo. Exogenously cultured monocyte-derived dendritic cells are comprised of a
heterogeneous population of monocyte-derived macrophages and dendritic cell-like cells
that each have unique functions and differential ability to stimulate T cells

211

conventional dendritic cells require Flt3L rather than GM-CSF for development

. True

209, 210

.

Moreover, of the conventional dendritic cell subsets, true cDC1 are the only dendritic cells
that arise endogenously and perform the functions of CD8+ T cell-priming through crosspresentation, cell-associated antigen processing/presentation, and TH1 polarization in
vivo 20-23, 25-31, 212, all functions which have been demonstrated to be important in eliciting
potent antitumor immunity in countless experiments.
In addition to work demonstrating that exogenously monocyte-derived dendritic cells differ
in function and potential utility from true cDC1, a recent report by Maier and colleagues
of the Merad lab also calls into question the utility of IL-4, which is used to culture
monocyte-derived dendritic cells from human or mouse HSCs. Maier and colleagues used
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a GFP-expressing non-small cell lung cancer (NSCLC) preclinical model to examine the
function of tumor antigen-containing dendritic cells under various perturbations

227, 228

.

They demonstrated that IL-4 negatively impacted the ability of GFP+ dendritic cells, which
had acquired tumor antigen, to produce IL-12. IL-12 is normally required to polarize naïve
CD4+ T cells into IFNγ-secreting TH1 CD4+ T cells 229, 230. They further demonstrated that
tumor-infiltrating GFP+ dendritic cells isolated from mice treated with anti-IL-4 antibodies
to globally restrain IL-4 signaling had greater capacity to stimulate tumor antigen-specific
T cell division, as well as greater T cell production of IFNγ and TNFα, when compared to
the same GFP+ dendritic cells isolated from untreated tumor-bearing mice. Importantly,
they also showed that IL-4 inhibition led to greater tumor control compared with untreated
mice. Collectively, this study demonstrated that IL-4 signaling negatively impacted
dendritic cell function in a manner that had negative downstream consequences for T cell
activation and tumor control. While this study did not investigate potential deleterious
effects of IL-4 signaling on anti-tumor immunity in humans, its implications should be
cause for further investigation regarding human monocyte-derived dendritic cell
vaccination, which require culturing in IL-4 for their derivation. It is conceivable that
monocyte-derived dendritic cells arise from the beginning with functional impairments and
less capacity to stimulate potent TH1 CD4+ or cytotoxic CD8+ T cell responses when
compared to true cDC1 which are not differentiated using IL-4. Nevertheless, the potential
deleterious effects of IL-4 signaling on a dendritic cell’s capacity (whether endogenously
arising or exogenously cultured monocyte-derived) to stimulate antitumor immunity
should be further investigated in human tumors.
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In addition to the reasons discussed above, the limited use of true cDC1 in vaccines might
be because suitable techniques to differentiate appreciable numbers of bona fide human
cDC1 were not developed until just recently in 2018, and even so, the number of dendritic
cells which result from that culturing method may still be insufficient to make an effective
dendritic cell vaccine 215. Future work should include developing techniques to efficiently
culture large numbers of bona fide human cDC1 so that they can be used instead of
monocyte-derived dendritic cells, in order to give dendritic cell-based vaccines the
greatest chance of bolstering strong antitumor immunity and improving patient outcomes.
From previous experiments by our lab and others, we know that cDC1-deficient mice have
severe deficits with respect to antitumor immunity. These defects cannot be rescued by
adoptive transfer of exogenously cultured monocyte-derived dendritic cells.
The Northwest Biotherapeutics DC-Vax in phase III trials involves injecting tumor lysateexposed exogenously cultured monocyte-derived dendritic cells intradermally

121

. Our

data demonstrates that endogenously arising cDC1 appear in the tumor and uptake
antigen upon arrival in both mice and humans. In mice we show that tumor antigencontaining cDC1 can be additionally isolated from the dura and the CNS-draining cervical
lymph nodes. Dendritic cell vaccines should introduce true cDC1 instead of monocytederived dendritic cells (for reasons enumerated above) and would take care to consider
where CNS immune responses are normally primed in order to stimulate the most potent
response and introduce them there instead of intradermally. There exists an axiom in
vaccinology which holds that vaccines generate the most effective immunity when the
vaccine itself is administered at the same anatomic location as the portal of entry of the
pathogen against which they vaccinate

231

. The reason for this is that T cells are more
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likely to be polarized correctly and to more efficiently home back to the site where antigen
was first introduced, and furthermore, antibody of the most effective isotype is more likely
to be generated. Moreover, given the demonstrated clinical benefit of neoadjuvant
checkpoint blockade in GBM, which derives its clinical benefit from pre-operative rather
than post-operative administration

112

, perhaps a similar approach should be employed

with cDC1 vaccination, in which cDC1 are introduced pre-operatively into the tumor mass
so that they have a chance to phagocytose tumor antigen, activate, and prime
neoantigen-specific T cell responses.
Nevertheless, many additional experiments are required to elucidate human dendritic cell
function, and to develop more effective dendritic cell-based therapies. Our experiments
revealed the presence of dendritic cells in GBM, which upon entry into the tumor acquire
tumor-derived material in both mice in humans. Our additional experiments in mice
demonstrated that dendritic cells additionally traffic the tumor-derived antigen from the
brain tumor itself to the cervical lymph nodes, likely via the dura lymphatics, to prime CNS
antitumor immunity. We also showed in mice that cDC1 in particular are indispensable
for CNS antitumor immunity. Our findings collectively portend that correctly designed
dendritic cell-based therapies have the potential to improve the standard of care and
extend survival in GBM patients. We hope that our work in describing the importance and
function of dendritic cells in human and mouse brain tumors demonstrates the need to
study them further.
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CHAPTER SEVEN
Conclusion, discussion, and future directions
In summary, while there are certainly unique traits of immune surveillance in the central
nervous system, our data suggest that the antitumor immune response in the CNS shares
many commonalities with the immune response elsewhere in the body: in both settings
the cDC1 is required to mount an effective antitumor immune response, the
consequences of cDC1-deficiency are distinct and severe, and the cDC1 subset (along
with other dendritic cell subsets) traffics tumor antigen from the tumor to draining lymph
nodes, where cDC1 prime neoantigen-specific CD8+ T cells. Importantly, many questions
remain. The mechanism by which dendritic cells extravasate from the blood to infiltrate
the tumor remains unknown, particularly regarding whether the tumor somehow serves
as a stimulus for dendritic cell entry, or whether their entry is merely a stochastic event
made all the more likely by the leaky vasculature that permeates the tumor. Furthermore,
it remains unknown whether additional cell types already present in the steady state brain
parenchyma (such as microglia) act as sentinels and by some means detect the
disturbance caused by a growing tumor, secrete chemokines, and recruit dendritic cells
from the blood into the tumor to trigger an adaptive immune response.
The exact migration path of dendritic cells from the brain tumor parenchyma to the cervical
lymph nodes (particularly to the superficial cervical lymph nodes) also requires further
investigation in mice. In both mice and humans, the transit path by which dendritic cells
exit the tumor parenchyma and enter the dura lymphatic vessels is also unknown. The
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dura lymphatic vessels in mice and humans follow the venous sinuses as they traverse
out of the skull and become internal jugular veins, where experiments (only in mice thus
far) have demonstrated that the lymphatic vessels converge upon the deep cervical lymph
nodes. This pathway is well characterized in mice (at least regarding drainage to the deep
cervical lymph nodes), however the complete pathway of CNS lymphatic drainage in
humans remains unknown.
Moreover, the question regarding whether human cDC even migrate extracranially
remains incompletely understood. There have been a few limited experiments in humans
which have demonstrated supportive evidence for extracranial dendritic cell migration.
Investigators demonstrated that APC (including that CD1c+ cDC2 equivalent) isolated
from the cervical lymph nodes and palatine tonsils harbored CNS-derived antigens in the
setting of stroke at levels greater than in healthy control patients

201

. While this clever

study suggested that cervical lymph nodes perform CNS lymphatic drainage functions in
humans, their evidence was indirectly supportive. Their experiments fell short of tracing
the migration path of a dendritic cell which arose in the CNS to an extracranial location
such as a cervical lymph node. Moreover, an additional confounding factor complicating
future studies is that human CNS lymphatic drainage is much more complex than in mice.
Humans typically have hundreds of cervical lymph nodes instead of 5 per side, as is the
case in mice.
We are currently engaging in experiments to determine whether extracranial dendritic cell
migration occurs in the setting of human GBM. To investigate this phenomenon, we are
using LYMPHOSEEK®, which consists of a mannose analogue conjugated with
Techetium-99m isotope. This γ-emitting macromolecule binds CD206 (also known as
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mannose receptor), which is expressed by macrophages and immature dendritic cells 232234

, and is ordinarily used by surgeons resecting tumors with metastatic potential to trace

dendritic cell migration from the tumor to lymph nodes to determine which lymph nodes
might harbor metastases

235, 236

. We have just been granted IRB approval for a protocol

in which Dr. Dunn and his colleagues will administer LYMPHOSEEK® to the GBM tumor
cavity following resection. After administration, we will use a gamma camera to determine
whether the γ-radiation signal localizes preferentially to the neck, which harbors cervical
lymph nodes in humans (as well as mice). A detectable γ-signal that localized to the neck
and not to other anatomic locations would suggest that CD206-expressing cells had
migrated extracranially to cervical lymph nodes.
Despite our discoveries underscoring the importance of dendritic cells in CNS antitumor
immunity, GBM itself is an immune-suppressive tumor that employs multifaceted tactics
of immune escape. It is conceivable that one of the immune-suppressive mechanisms
employed by GBM is to subvert antigen presentation and dendritic cell function either
within the tumor, or at downstream steps. Important work by Gajewski has shown that
excessive WNT signaling by the tumor excluded dendritic cells from the tumor
environment in a melanoma model

30, 31

. While we have detected cDC in most human

brain tumors, there have been isolated GBM specimens in which we observed a paucity
of conventional dendritic cells infiltrating the tumor. Notably, we analyzed one GBM
specimen in which we observed that the dendritic cell infiltrate was polarized toward
CD1c+ cDC, which are presumably less capable of priming potent CD8+ and/or CD4+ TH1
antitumor immune responses. Moreover, there are additional steps downstream of
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dendritic cells infiltrating the tumor and phagocytizing tumor antigen that could be subject
to subversion by the tumor.
Incidentally, we identified possible evidence of suppression of antigen presentation and/or
T cell activation downstream of tumor antigen trafficking to lymph nodes in preliminary
studies which were not discussed in this thesis. Among murine preclinical models of GBM,
CT2A is a less immunogenic brain tumor that cannot be treated successfully with
checkpoint blockade alone unlike its GL261 counterpart. CT2A instead requires
combination adjuvant checkpoint blockade and neoantigen-specific therapeutic
vaccination

126

. This is despite the two models harboring thousands of mutations and

having neoantigen burdens of roughly the same magnitude

126

. These differences

regarding immunogenicity between the two models were notable considering
experiments that we additionally performed comparing GL261-zsGreen to CT2A-zsGreen
tumor antigen trafficking. Our preliminary data demonstrated that despite CT2A being
less immunogenic than GL261, and despite CT2A-zsGreen being an objectively less
brightly fluorescent tumor than GL261-zsGreen when measured by both fluorescence
microscopy and flow cytometry, CT2A-zsGreen showed a stronger signal than GL261zsGreen did of tumor antigen trafficking by dendritic cells to the CNS-draining cervical
lymph nodes, which suggests that the immune suppression resulting from CT2A falls
downstream of tumor antigen trafficking to draining lymph nodes.
Moreover, we performed additional preliminary experiments pertinent to this line of inquiry
(also not discussed in this thesis) in which we transduced CT2A with a lentivirus that
enforced expression of the same mImp3 antigen which when natively expressed by
GL261, causes a neoantigen-specific CD8+ T cell response to be spontaneously primed
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against GL261 brain tumors. Compared to the CT2A-WT-Imp3-transduced control
tumors, we detected no mImp3-specific CD8+ T cell responses above background in mice
that had been transplanted with CT2A-mImp3-transduced tumors despite multiple
attempts using multiple screening platforms and investigating multiple organs. These
results showed us that despite evidence of more robust tumor antigen trafficking from the
CNS in CT2A brain tumors compared to GL261 brain tumors, neoantigen-specific CD8+
T cell responses don’t typically arise spontaneously in CT2A, even if the tumor itself overexpresses a neoantigen capable of priming neoantigen-specific CD8+ T cell responses in
different settings. To have detectable neoantigen-specific CD8+ T cell responses in the
setting of CT2A brain tumors requires bolstering the immune response with therapeutic
vaccination in combination with adjuvant checkpoint blockade therapy 126.
This set of preliminary experiments suggests that in the setting of CT2A brain tumors,
subversion of antitumor immunity occurred at some point downstream of the step of tumor
antigen trafficking by dendritic cells from the CNS to the draining lymph nodes. Several
mechanisms could be responsible for this, including (a) subversion by the CT2A brain
tumor of dendritic cells in their T cell priming function, or alternatively (b) suppression of
T cell activation and clonal expansion, or otherwise (c) enforced sequestration of T cells
at an anatomic location distant from the tumor, such as the bone marrow, as has been
suggested by work performed by Fecci’s group

71, 72

. Our preliminary experiments could

not determine at which step downstream of tumor antigen trafficking to lymph nodes that
immune suppression occurred in the setting of CT2A brain tumors. Nevertheless, future
studies should examine all potential mechanisms that GBM might employ to blunt antigen
presentation and dendritic cell function, and additionally should compare the unique and
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disparate methods by which individual GBM tumors differentially suppress immune
responses against the tumor.
In course of developing this thesis, we generated a GEMM preclinical model of glioma,
which for unknown reasons, resulted in tumors that were histologically distinct from GBM;
their histologic characteristics were instead those of gliosarcoma, which is a considerably
less common form of malignant glioma. Moreover, the isogenic recurrent hypermutator
model also had characteristics that made it unsuitable for testing the relationship between
checkpoint blockade and mutational burden: the transformed astrocytes, also for
unknown reasons, did not form brain tumors and instead had a predilection to form
extracranial tumors, despite being transplanted directly into the brain parenchyma. The
easiest next step in both models would be to try a different oncogene. Our model used
murine rather than human PDGFβ as the oncogene to drive transformation. We selected
murine PDGFβ to avoid the potential pitfall of creating artificial neoantigens under the
assumption that murine immune systems are not tolerant to human PDGFβ. To our
knowledge, our model is one of the first such models to use mouse rather than human
PDGFβ. Other GEMM GBM models have used human PDGFβ expression to drive
transformation, which has resulted in successful transformation and tumors with the
correct GBM histology

129, 135, 140

. However, we set out to generate a model in which

potential neoantigens harbored by the tumor resulted from mutations that spontaneously
arose through the act of cell division, rather than from mutations engendered from the
transforming factors themselves. The next rational oncogene to employ is EGFRvIII,
which incidentally, is more commonly a driver than aberrant PDGFβ signaling 6, and which
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has been used in combination with PTEN and INK4a/ARF gene deletion in autochthonous
GEMMs before to generate tumors with GBM histology 237.
We originally set out to generate a GEMM that could simulate the entire evolution of GBM
from near-spontaneous nascence, in which the malignant cells arose from cells already
present in the host. We did so in part to avoid the issues with orthotopic models, in which
thousands of cells syngeneic to the host, but still a foreign entity, are transplanted into the
brain to initiate tumor formation. This initiating event does not recapitulate GBM as it
occurs in humans where one or a few cells become mutated and transform into malignant
cells, all while under constant selective pressure from the immune system. Moreover, the
GL261 and CT2A preclinical orthotopic glioma lines we used each harbor thousands of
mutations 123, whereas human GBM harbors 50-100 mutations 6.
The pinnacle of convergence of the disparate aims in this thesis would be to combine the
dendritic cell and GEMM projects. A combination of these projects could result if future
work optimized the GEMM model to result in GBM with the correct histology. The GEMM
could be combined with either a genetic model of cDC1-deficiency or with zsGreen
expression by the tumor. By generating these tools, one could determine the role of cDC1
in a model that more closely aligns with both the immunologic, genomic, and evolutionary
characteristics of human GBM.
Despite having fallen short regarding some of the aims in this thesis, we did make
interesting and important discoveries about cDC1 in preclinical brain tumor models—first,
that they are indispensable for CNS antitumor immunity. Second, that they capture
antigen in the tumor and traffic it to cervical lymph nodes in a CCR7/cell-migrationdependent manner to drive clonal expansion of CD8+ T cells that recognize the tumor.

152

Third, that the dura plays a supportive role in CNS-antitumor immunity, including likely
functioning as a transit point by which dendritic cells traffic tumor antigen from the tumor
parenchyma to draining lymph nodes via dura lymphatic vessels. Fourth, and perhaps
most importantly, we extended our observations from preclinical models to human
disease. We identified cDC1 as well as other APC subsets within human GBM and
meningioma tumor and dura specimens. We also identified that GBM-infiltrating antigen
presenting cells (including the cDC1) uniquely phagocytize tumor-associated material.
Future work on this project should employ single cell RNA sequencing to examine the
granular characteristics of antigen presenting cells in human GBM that have acquired
tumor antigen. Tumor antigen-harboring cDC could be compared against cDC that lacked
tumor antigen to determine whether changes in gene-expression were attributable to
dendritic cell antigen acquisition and activation. Similar experiments have been performed
in mouse tumors by the Merad lab, which revealed that both cDC1 and cDC2 dendritic
cell subsets harbored a gene signature associated with convergence of identity upon
acquiring tumor antigen that was associated with upregulation of both common activation
genes, as well as immunoregulatory genes

227, 228

. We need to study the same question

in human dendritic cells.
Here we report several important novel findings which underscore the role and
significance of antigen presentation and cDC1 (as well as other dendritic cell subsets) in
CNS antitumor immunity in mice and humans. Our hope is that better understanding how
the antitumor immune response is endogenously primed against brain tumors could
ultimately lead to therapeutic advances which improve disease outcomes for the patients
who have the misfortune of being diagnosed with glioblastoma.
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CHAPTER EIGHT
Methods
Mice
All animal experiments were approved by the Washington University Animal Studies
Committee. For survival studies, mice were euthanized upon first sign of neurologic deficit
and/or neurologic deficits. Male and female mice 6-16 weeks of age were used for all
experiments. Wild-type C57BL/6 mice were purchased from Taconic Biosciences
(Hudson, NY).
For autochthonous tumor model experiments, INK4a/ARFfl/fl mice were maintained on a
C57BL/6 background. These mice harbor a loxP insertions upstream of exon 2 and
downstream of exon 3 (common to INK4a/ARF alternative splice products), and are
susceptible to both p19ARF and p16INK4a deletion in any Cre-expressing cell
PTENfl/fl mice, which harbor loxP sites flanking exon 5

239

238

.

, were obtained on a

BALB/cAnNTac background. They were backcrossed to C57BL/6 using speed congenics
to obtain a pure C57BL/6 PTENfl/fl mouse line. INK4a/ARFfl/fl mice were crossed with
PTENfl/fl mice and F1s were intercrossed until mice were homozygous for loxP insertions
at both alleles in both respective loci.
Unless otherwise specified, mice on C57BL/6 backgrounds were used for all experiments
concerning dendritic cells. IRF8+32kb-/- were used for experiments regarding cDC1deficiency, shared generously by Kenneth Murphy. For experiments in which cDC1 were
GFP-expressing, SNX22GFP/WT mice were used, shared generously by Kenneth Murphy
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as well. We bred these mice by crossing a SNX22GFP/GFP mouse on either a 129/SvEv
background, or a C57BL/6 background to a wild-type C57BL/6 mouse and used the
resultant SNX22GFP/WT F1 mice for experiments. For experiments with GFP-expressing
cDC1 and Tomato-labeled lymphatics, we crossed SNX22GFP/GFP mice with Prox1CreER-tdTomato+/+ mice, which were generously shared with us by Gwendalyn Randolph.
We used resulting F1 mice for experiments. After genotyping, we injected mice 3x/week
for two weeks (six total doses) of tamoxifen (10mg/mL) in corn oil (Sigma) at a dose of
50mg/kg intraperitoneally. We allowed two subsequent weeks to elapse before
experiments, so that lymphatic vessels would be sufficiently labeled with tomato
fluorophore. CCR7-/- mice

240

, OT-I mice

193

, and CD45.1 mice

241

were purchased from

Jackson. All mice were housed and handled humanely in accordance with IACUC
standards.
Cell lines
Astrocytes were isolated with the assistance of Najla Kfoury of the Josh Rubin Lab as
described

242

. INK4a/ARFfl/fl x PTENfl/fl P0 pups were decapitated, and brains were

dissected from the encasing skull. Under a stereomicroscope (all Najla’s hands), the
meninges was removed and mouse cortices were separated from the rest of the brain.
Isolated brain cortices were mechanically disaggregated and incubated with trypsin until
the mixture had become a single cell suspension. Cells were spun, the trypsin
supernatant was decanted, and the remaining pellet was resuspended in media (DMEM,
high glucose + 10% heat-inactivated fetal bovine serum + 1% Penicillin/Streptomycin).
Resuspended cells were plated on a poly-D-Lysine coated flask and allowed to adhere.
After cells (including astrocytes) had adhered, flasks were topped off with media, and
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placed on an orbital shaker at max speed at 37ºC overnight to disrupt less adherent cells,
which left behind only the strongly-adhering astrocytes after 24-hours. Astrocytes were
cultured in Corning® Primaria™ Culture Plates or poly-D-lysine coated plates
subsequently.
CT2A (generous gift of Peter Fecci), GL261, 293T, and 3T3 cells were maintained in
culture at 37ºC, 5% CO2 in a culture medium comprised of DMEM with 10% heatinactivated FBS, 1% Penicillin/Streptomycin, 1% minimum essential amino acids, 1% Lglutamine, and 1% Sodium Pyruvate (D10). Cells were harvested at 90% confluency to
inject intracranially.
Lentivirus and retrovirus, stable cell lines
Lentivirus/Retrovirus production for in vitro transductions. For lentivirus production, 293Ts
were transfected with 1µg of lentiviral backbone, 100ng of VSV-G envelope protein
plasmid, 900ng of Δ8.9 transfer plasmid. One day before transfection, 293Ts were plated
at a density of 1x106 cells per T25. Transfections were performed with the FuGENE® HD
Transfection reagent according to the manufacturers protocol. On days 2 and 3 posttransfection, lentiviral supernatant was collected, filtered through a 0.45µM filter, and
combined with polybrene (final concentration of 8µg/mL). Target cells were transduced
by completely removing target cell growth media and exchanging with the filtered
lentivirus-containing polybrene infused supernatant. For retrovirus production, we used
the same protocol, except used the pCL-Eco transfer plasmid along with the retroviral
backbone to transfect 293Ts. For cloning purposes, all lentivirus backbones were grown
by transforming One Shot™ Stbl3™ Chemically Competent (ThermoFisher catalog
#C737303) or NEB® Stable Competent (NEB catalog #C3040H) E. coli strains, and
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retroviral backbones were grown by transforming DH5α (ThermoFisher catalog #EC0112)
or NEB® 5-alpha Competent (NEB catalog #C2987H) E. coli strains.
Lenti PDGFβ, Lenti-PDGFβ-OS, Lenti-Cre-Empty lentiviral backbones: Lenti-PDGFβ and
Lenti-PDGFβ-OS was derived from cloning the murine PDGFβ coding sequence into
Lenti-LucOS

(gift

from

Tyler

Jacks,

Addgene

plasmid

#

22777;

http://n2t.net/addgene:22777; RRID:Addgene_22777) at the NheI and XhoI restriction
sites, just upstream of the OS cassette. The OS cassette encodes for the ovalbumin H2Kb-restricted

antigen

SIINFEKL,

the

ovalbumin

I-Ad-restricted

antigen

ISQAVHAAHAEINEAGR, and the H-2Kb-restricted antigen SIYRYYGL. For LentiPDGFβ, a stop codon was inserted at the end of the mPDGFβ coding sequence just
upstream of the OS cassette to prevent protein expression of the OS antigens. For LentiPDGFβ, the stop codon was removed to allow for translation into the OS cassette. For
experiments in which Cre but neither oncogene nor OS cassette was used to transduce
cells or inject mice, the Luc.Cre empty (termed Lenti-Cre-Empty in figures) was used (gift
from

Tyler

Jacks,

Addgene

plasmid

#

20905;

http://n2t.net/addgene:20905;

RRID:Addgene_20905).
CMV/GFAP/MBP promoter-driven lentiviral constructs. The following plasmids were
obtained from the Washington University Hope Center Viral Vectors Core: pRRLsinCMVGFP (CMV promoter), pRRLsinGFAP-GFP (GFAP promoter), and pRRL-MBP-GFP
(MBP promoter). GFP was removed from each of the plasmids using the BamHI and
EcoRI restriction enzymes and replaced with either Cre (as a single fragment) or CreP2A-mPDGFβ (as two separate but overlapping fragments) using the Gibson Assembly®
cloning system (NEB catalog #E2611S) according to the manufacturer’s protocol.
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INK4a/ARFfl/fl x PTENfl/fl astrocytes were transformed with either Luc.cre Empty, Lenti
PDGFβ, or Lenti-PDGFβ-OS lentiviruses for experiments.
3T3 dsRed Cre reporter. The pMSCV-loxP-dsRed-loxP-eGFP-Puro-WPRE retroviral
plasmid

was

a

gift

from

Hans

Clevers

(Addgene

plasmid

#

32702;

http://n2t.net/addgene:32702; RRID:Addgene_32702), which we used to transduce 3T3
cells in order to generate the Cre reporter cell line.
GL261-OFP. OFP designated our abbreviation for the mOrange2 fluorophore, which was
a gift from Bob Schreiber. We inserted the mOrange2 gene into the pLX304 lentiviral
backbone using the Gateway Cloning protocol according to manufacturer’s instructions
(Invitrogen™ Gateway™ BP Clonase™ II Enzyme mix, catalog #11789020; Invitrogen™
Gateway™ LR Clonase™ II Enzyme mix, catalog #11791020) as described 243, 244.
GL261-zsGreen and CT2A-zsGreen. zsGreen was a gift from David DeNardo. The gene
for zsGreen was inserted into the pLX304 lentiviral backbone using the gateway cloning
protocol as described above.
CT2A-mFlt3L. The coding sequence for murine Flt3L was obtained (SinoBiological
catalog #MG51113-UT) and inserted into the pLX304 lentiviral backbone using the
gateway cloning protocol as described above.
GL261-OVA. Full length cytoplasmic ovalbumin was cloned from pcDNA3-OVA (gift from
Sandra

Diebold

&

Martin

Zenke,

Addgene

plasmid

#

64599;

http://n2t.net/addgene:64599; RRID:Addgene_64599), and inserted into pBabe-puro
retroviral backbone (gift from Hartmut Land & Jay Morgenstern & Bob Weinberg,
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Addgene plasmid # 1764; http://n2t.net/addgene:1764 ; RRID:Addgene_1764), using
EcoRI and SalI restriction enzymes at the multiple cloning site.
Intracranial Injections
Orthotopic lines: cells for injection were trypsinized at 70-90% confluency, trypsin was
neutralized with D10, and cells were washed 1X in PBS before suspending cells in PBS
for injection. Before surgery, mice were anesthetized with ketamine/xylazine mouse
cocktail and administered Buprenorphine SR (1mg/kg) in the nape of the neck for
analgesic. For intracranial injections, 50,000 cells were injected 2mm to the right and
2mm posterior of bregma, at a depth of 3.5mm using a Stoelting stereotactic headframe
that fixed the mouse head in place and allowed for precise injections at a slow and
controlled rate. For most experiments mice were euthanized and tissues were analyzed
two weeks post-injection, except for dura experiments with intracranial CT2A-zsGreen
brain tumors, in which case mice were euthanized one-week post-injection. For CCR7-/intracranial CT2A-zsGreen brain tumor experiments, mice were euthanized 12 days postinjection.
Lentivirus for in vivo injections: Concentrated Lenti-PDGFβ, Lenti-PDGFβ-OS and LentiEmpty (Luc.cre Empty) lentiviruses were obtained from the University of Iowa Lentivirus
core. Concentrated CMV/GFAP/MBP promoter-driven lentiviral constructs were obtained
from the Washington University Hope Center Viral Vectors Core. For experiments, 1x1051.5x106 titered units were injected at the same coordinates as with orthotopic injections
into the striatum using a Stoelting headframe with mice anesthetized as described above.
Health of mice was monitored by weighing weekly, until mice lost weight and became
cachectic, at which point they were euthanized.
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mPDGFβ qPCR
RNA was extracted from 3T3s transduced with Lenti PDGFβ, Lenti-PDGFβ-OS, LentiCre-Empty using an RNA-easy extraction kit (Qiagen), cDNA was amplified using an
Applied Biosystems™ High-Capacity cDNA Reverse Transcription kit and a murine
PDGFβ TaqMan® gene expression assay, with GAPDH as a reference control, according
to manufacturer instructions.
PDGF-BB ELISA
In supernatants and total cell lysates, murine PDGFβ concentration was measured using
Mouse/Rat PDGF-BB Quantikine ELISA Kit (R&D Biosystems) according to
manufacturer’s instructions.
CRISPR-mediated gene disruption
Genetic mutations were made in Lenti-PDGFβ INK4a/ARFfl/fl x PTENfl/fl astrocytes.
MSH6: the first exon of murine MSH6 was targeted using the following guide sequence:
GGCGGTATCCGCCTCGTCGC, and cloned into the pSpCas9(BB)-2A-Puro plasmid
(PX459) (gift from Feng Zhang, Addgene plasmid # 62988; http://n2t.net/addgene:62988;
RRID:Addgene_62988). MSH6 was genetically disrupted as described

245

. Briefly, cells

were transfected with the MSH6-pSpCas9(BB)-2A-Puro plasmid, subjected to puromycin
selection, allowed to recover, and plated in limiting dilution to derive single cell clones.
Clones were screened for genomic biallelic disruption of MSH6, and clones with
disruption were screened for protein loss.
POLε: L424V and D272A E274A mutants were generated by Washington University
GEiC. Single cell clones were screened for biallelic mutant knock-in.
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Long term passage of hypermutated lines
POLε INK4a/ARFfl/fl x PTENfl/fl astrocytes were immediately frozen at low passage, and
subsequent splits were passaged continuously for three months to derive high passage
cells.
MSH6-WT and MSH6-/- Lenti-mPDGFβ-transduced INK4a/ARF-/- x PTEN-/- astrocytes
were subjected to no treatment or treatment with 500µM temozolomide/40µM O6Benzyl
Guanine for two months with passaging as needed. Growth had completely arrested in
all cell lines treated with 500µM temozolomide/40µM O6Benzyl Guanine, regardless of
MSH6 status. At the end of the two months of treatment, cells were allowed to recover in
growth media with no treatment for an additional month, until cell growth had restored to
normal and regular passaging was required.
DNA and RNA were extracted using an AllPrep DNA/RNA Mini Kit (Qiagen). RNA
sequencing and whole exome sequencing was performed by Novagene. Variants were
called and subjected to pVAC-Seq to identify neoantigens 168.
Propidium iodide nuclear analysis
For analysis of temozolomide sensitivity, nuclei were analyzed as described 164, including
cold ethanol fixation of the cells whose nuclei were analyzed.
Survival studies
For survival studies, age matched, sex matched WT or IRF8+32kb-/- C57BL/6 mice were
intracranially injected with 50,000 GL261 cells as described above. At days 3, 5, 7, and
14, mice were administered intraperitoneal injections of either PBS vehicle or αPD-L1
(Clone 10F.9G2, Leinco Technologies, Inc) at a dose of 200µg/mouse in a volume of
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100µL. Mice were euthanized before they became moribund. The day of euthanasia was
considered the day of death for purposes of this study.
ELISPOT
For ELISPOT studies, age matched sex matched WT or IRF8+32kb-/- C57BL/6 mice were
intracranially injected with 50,000 GL261 cells as described above. Mice were euthanized
at two weeks post-injection and tumors were mechanically dissociated between frosted
slides, and further dissociated by incubating in a collagenase A solution (1mg/mL
Collagenase A (Millipore Sigma catalog#11088793001) and 2% heat inactivated FBS in
RPMI) at 37ºC for 20 minutes, with intermittent pipetting. Tumor single cell suspensions
were separated from myelin using a 22.5% Percoll® (GE/Cytivia product #17089101)
solution and subjected to ACK buffer to lyse red blood cells. CD8+ T cells were isolated
with an EasySep™ Mouse CD8a Positive Selection Kit II (Stem Cell), counted and plated
with naïve splenocytes that were isolated that day using a Ficoll® (GE/Cytivia product
#17144003) centrifugation gradient from a naïve sex-matched C57BL/6 mouse. The
ELISPOT antigen presentation assay was performed as follows: 50,000 CD8+ T cells
isolated from the tumor were cultured with 125,000 naïve splenocytes with or without
mImp3 peptide overnight at 37ºC/5% CO2 on a pre-coated murine IFNγ detection plate
according to manufacturer’s instructions (Cellular Technologies Limited). Plates were
developed the following day and analyzed with an Immunospot Plate Reader (Cellular
Technologies Limited).
mImp3 Tetramer
For mImp3 tetramer studies, age matched sex matched WT and IRF8+32kb-/- C57BL/6
mice were intracranially injected with 50,000 GL261 cells as described above. Mice were
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euthanized at two weeks post-injection. Tumors were removed from the brain, cut into
small chunks, and cultured in R10βME media (RPMI, 10% heat inactivated FBS, 1%
sodium bicarbonate, 1% L-glutamine, 1% minimum essential amino acids, 1% sodium
pyruvate, 1% Penicillin/Streptomycin, 55µM β-mercaptoethanol) overnight. The following
morning, the cultures were assessed for lymphocyte egress from tumor chunks. Tumor
chunks were removed, and the remnants containing the remaining lymphocytes were
filtered and separated from myelin using a 22.5% Percoll solution and subjected to ACK
buffer to lyse red blood cells. mImp3 (AALLNKLYA)/H-2Db tetramer stock solutions were
generated by the Washington University Immune Monitoring Lab. Briefly, tetramer was
conjugated with the PE or BV421 fluorophore bound to streptavidin, incubated for 15 mins
at 37ºC. Subsequently, the remaining surface antibodies were added, suspensions were
incubated on ice for 20 additional minutes, washed, and subjected to flow cytometry.
Tissue Harvest
Mice with intracranial tumors were harvested 7-14 days after injection, depending on the
experiment. The brain/tumor, superficial cervical lymph nodes, deep cervical lymph
nodes, inguinal lymph node, dura, and/or spleen were harvested depending on the
experiment. Lymph nodes, dura, and tumor were mechanically dissociated between two
frosted slides and digested in 1mg/mL Collagenase A (Roche), 2%FBS, in RMPI for 20
minutes at 37ºC/5% CO2. Suspensions were washed and red blood cells were lysed with
ACK as necessary. Tumors were separated from myelin using a 22.5% Percoll™ solution
and centrifuged at room temperature for 15 minutes at 500g, (acceleration 9, deceleration
5). Mononuclear cells were separated from spleens by first mechanically dissociating the
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spleens between two frosted slides, and then using a Ficoll™ gradient (GE) to generate
a buffy coat. We retained the cells in the buffy coat for experiments.
OT-I cell division assay
CD45.1 mice were mated to OT-I mice. CD45.1 and CD45.2, as well as CD8+ T cell TCRVα2Vβ5 expression was verified in F1 mice before experiments. For adoptive transfer
experiments, 5x105 GL261-OVA cells were injected intracranially. Four days later, a
spleen from a CD45.1xOT1 F1 mouse >6 weeks of age was subjected to Ficoll gradient,
and CD8+ T cells were isolated using an EasySep™ Mouse CD8a Positive Selection Kit
II (Stem Cell). Immediately after isolation, OT-1 CD8+ T cells were CFSE labeled in PBS
(10 mins at RT, 5µM), and adoptively transferred via tail vein into recipient mice. At days
3 and 6 post-adoptive transfer, mice were harvested, and tissues were dissociated as
described above.
Human dura preparation
Human dura was macerated and incubated in 2mg/mL Collagenase A (Roche) and
2mg/mL Collagenase D (Roche), 10% FBS and IMDM overnight at 37ºC, with pipetting
every few hours throughout the evening before leaving for the night. The next morning,
the single cell suspension was filtered through progressively smaller strainers (100µM
first, then 70µM, then 40µM) and red blood cells were lysed with ACK buffer as needed
to prepare cells for flow cytometry.
Human tumor preparation
Human tumors were macerated and incubated in 2mg/mL Collagenase A (Roche) and
2mg/mL Collagenase D (Roche), 10% FBS and IMDM overnight at 37ºC. The next
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morning, the single cell suspension was filtered through a 100µM filter into a 22.5%
Percoll™ solution and centrifuged as described above. After centrifugation, pellets were
subjected to ACK lysis as necessary, and then filtered through progressively smaller
strainers (70µM then 40µM) to prepare cells for flow cytometry.
Flow cytometry and tissue preparation
Before flow cytometry, single cell suspensions were filtered at least 3 times over the
course of the preparation (usually progressively smaller strainers: 100µM, then 70µM,
then 40µM), subjected to 1/200 Fc block, and then stained with surface antibodies for >20
minutes on ice. Cells were washed once and suspended in MACS buffer (10g/L BSA,
4mM EDTA in PBS). Flow cytometry was performed on a BD LSR Fortessa™ X- 20 flow
cytometer.
2photon images
For harvest, mice were anesthetized and perfused with cold PBS until the liver blanched
and became pale. The skull cap was removed (dura still attached to skull) and skull cap
and brain were fixed in ice cold 4%PFA, with gentle shaking overnight. If blood vessels
were to be labeled, 5 minutes prior to perfusion, mice were injected IV with 100µL of 1:2
PBS-diluted 594-lectin (Lycopersicon Esculentum (Tomato) Lectin (LEL, TL), DyLight®
594, Vector Laboratories). For brain sections, brain was cut with a vibrotome after fixation.
Fixed tissues were glued to a cover slip with superglue and immersed in PBS for imaging.
Images were collected using a custom Leica SP8 two-photon microscope (Leica
Microsystems, Wetzlar, Germany) equipped with a 25x 0.95 NA water immersion
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objective, and two Femtosecond pulsing tunable Ti:Sapphir lasers (Mai Tai HP DeepSee
and InSight DS+), both Spectra-Physics (Mountain View, CA, USA).
GFP, mOrange2/OFP and TdTomato were excited using a wavelength of 925nm whereas
Dylight 594 and Dylight 649 were excited using a wavelength of 830nm.
Fluorescence emission was guided directly to 4 external detectors in dendritic
arrangement (two hybrid and two classical PMTs). For signal separation, three dichroic
beam

splitters

(Semrock,

Rochester,

NY,

USA)

were

used.

To

separate

GFP, mOrange2/OFP, Dylight 594 and the SHG (Second-harmonic generation), the three
cutoff wavelengths were 358nm ,538nm and 593nm. The separation of GFP, tdTomato,
DyLight 649 and the SHG was obtained with cutoff wavelengths of 458nm, 560nm, and
652nm.
Flt3L treatment
To administer Flt3L to mice, mice were injected subcutaneously in the flanks with 1x106
cells of CT2A transduced with Flt3L, such that the tumor drove overexpression of Flt3L
similar to as described 177. As a negative control, mice were injected in the same
manner with untransduced CT2A. Mice were harvested 2-3 weeks post-transplant of
tumor cells into the flank, when tumors had reached 1-2cm in diameter.
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Table 1. Mouse Antibodies
Antigen
4-1BB
B220
CCR7
CD103
CD11b
CD11b
CD11c
CD11c
CD19
CD3
CD4
CD4
CD44
CD44
CD45
CD45
CD45.1
CD45.2
CD62L
CD62L
CD8a
CD8a
CD8α
CD8α
CTLA-4
F4/80
F4/80
FoxP3
granzyme B
I-Ab
Ki-67
Ly-6C
mIFNγ
NK1.1
NK1.1
OX-40
PD-1
PE tetramer
SIRPα
TCR Vα2
TCR Vβ5
XCR1
Zombie
BV421 streptavidin
PE streptavidin

Color
APC
BV510
PE-Cy7
BV421
PE-Cy7
BV650
PE-Cy7
APC
PE-Cy7
PE-Cy5
PerCP Cy5.5
APC
BV785
BV785
AF700
APC-Cy7
BV421
AF700
BV605
BV510
PE-Dazzle
BV711
FITC
PE-Cy7
BV605
PE-Cy7
BV711
PE
AF700
AF700
FITC
BV785
BV421
PE-Cy7
BV650
PE-CF594
PE-Cy7
PE
PE-CF594
APC
PE
PE
APC-Cy7
BV421
PE

Vendor
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
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Product no.
106109
103248
120123
121421
101216
101239
117318
117310
123113
100310
100433
100412
103041
103041
103128
103116
110731
109822
104441
104441
100762
100747
100706
100722
106323
115519
123147
126403
372221
107622
652409
128041
505830
108713
108735
119417
135215
405204
144016
127809
139503
148204
423106
405225
405204

Clone
17B5
RA3-6B2
4B12
2E7
M1/70
M1/70
N418
N418
6D5
145-2C11
GK1.5
GK1.5
IM7
IM7
30-F11
30-F11
A20
104
MEL-14
MEL-14
53-6.7
53-6.7
53-6.7
53-6.7
UC10-4B9
BM8
BM8
MF-14
QA16A02
M4/114.15.2
16A8
HK1.4
XMG1.2
PK136
PK136
OX-86
29F.1A12
streptavidin
P84
B20.1
MR9-4
ZET
n/a
n/a
n/a

Table 2. Human Antibodies
Antigen
CD11c
CD11c
CD14
CD14
CD141
CD16
CD1c
CD3
CD3
CD4
CD45
CD8α
HLA-DR
UV Zombie

Color
PE-Cy5
BV421
APC-Cy7
BV650
APC
PerCP-Cy5.5
PE-CF594
PE-Cy7
BV510
FITC
AF700
BV711
BV785
UV

Vendor
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
BioLegend
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Product no.
301609
301627
367107
301835
344105
302027
331531
371333
371331
357405
368513
301043
307641
423107

Clone
3.9
3.9
63D3
M5E2
M80
3G8
L161
OKT3
OKT3
A161A1
2D1
RPA-T8
L243
n/a

Table 3. Gating Definitions
Mouse
Cell type

Definition

cDC

CD45+, F4/80-, CD11c+, I-Ab+, Ly-6C-

cDC1

cDC plus XCR1+, SIRPα-

migratory cDC1

cDC1 plus CD103+, CD8α-

resident cDC1

cDC1 plus CD103-, CD8α+

cDC2

cDC plus, XCR1-, SIRPα+

pDC

CD45+, F4/80-, CD11c+, I-Ab+, Ly-6C+, CD11b-

MoDC

CD45+, F4/80-, CD11c+, I-Ab+, Ly-6C+, CD11b+

T cells

CD45+, CD3+, NK1.1-

CD8+ T cells

T cell plus CD8α+, CD4-

CD4+ T cells

T cell plus CD8α-, CD4+; plus FOXP3 for T regulatory cells

OT-I CD8+ T cells

CD45.1+, CD45.2+, Dump- (NK1.1, CD19, CD11b, CD11c, F4/80),
CD3+, CD8α+, CD4-, TCRVα2+, TCRVβ5+, CFSE variable.

Human
Cell type

Definition

cDC

CD45+, CD11c+, HLA-DR+, CD14-, CD16-

cDC1/CD141+ cDC

cDC plus CD141+, CD1c-

cDC1/CD1c+ cDC

cDC plus CD141-, CD1c+

CD14+ monocytes

CD45+, CD11c+, HLA-DR+, CD14+, CD16-

CD16+ monocytes

CD45+, CD11c+, HLA-DR+, CD14-, CD16+

T cells

CD45+, CD3+

CD8+ T cells

CD45+, CD3+, CD8α+, CD4-

CD4+ T cells

CD45+, CD3+, CD8α-, CD4+
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